Investigating the impact of ovarian carcinoma ascites on Toll-like receptor mediated dendritic cell activation by Brencicova, Eva
This electronic thesis or dissertation has been 
downloaded from the King’s Research Portal at  
https://kclpure.kcl.ac.uk/portal/  
 
 
 
 
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 
other rights are in no way affected by the above. 
 
 
 
 
 
 
 
Investigating the impact of ovarian carcinoma ascites on Toll-like receptor mediated
dendritic cell activation
Brencicova, Eva
Awarding institution:
King's College London
Download date: 05. Apr. 2019
  1 
 
 
Investigating the impact of ovarian carcinoma 
ascites on Toll-like receptor mediated dendritic 
cell activation 
 
 
 
Eva Brenčičová 
 
 
 
 
Thesis submitted for the degree of 
Doctor of Philosophy 
at King’s College London 
August 2013 
 
 
 
 
 
 
King’s College London 
Guy’s, King’s and St Thomas’ School of Medicine 
Peter Gorer Department of Immunobiology 
Guy’s Hospital, Borough Wing, 2
nd
 Floor 
London SE1 9RT 
  2 
 
 
 
 
 
 
 
 
 
“Nothing in life is to be feared, it is only to be understood. Now is the 
time to understand more, so we may fear less.” 
 
 
- Marie Curie 
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Abstract 
 
In this study, we investigate the impact of ovarian carcinoma associated ascites on dendritic 
cell (DC) activation by Toll-like receptor (TLR) agonists in vitro. DC have the potential to 
instigate a tumour-specific adaptive immune response, but their ability to induce 
differentiation of naïve lymphocytes into effector cells in lymphoid tissues is dependent on 
their activation status. Here, we examine whether DC activation by TLR agonists is impeded 
by ovarian carcinoma environment and if so, how these effects can be alleviated. 
Our results show that ascites reduces the TLR-mediated up-regulation of the co-stimulatory 
molecule CD86 and partially inhibits the production of the pro-inflammatory cytokines 
interleukin-6 (IL-6), IL-12 and tumour necrosis factor α (TNFα) in monocyte-derived DC from 
healthy donors. We further observe an impaired T cell stimulatory capacity of monocyte-
derived DC upon activation with TLR agonists in the presence of ascites, indicating that their 
function as antigen-presenting cells is affected by the immunosuppressive factors. Selective 
neutralization of IL-10 and prostaglandin E2 (PGE2) in vitro alleviates the suppressive effects 
of ovarian carcinoma associated ascites. However, our results show that autocrine IL-10 
contributes to the observed suppression. The role of autocrine PGE2 is yet unclear, as we have 
no indication that this protein is produced by TLR-activated monocyte-derived DC. We have 
established and present here an elegant method to dissect the relative contributions of ascites-
derived versus autocrine IL-10 and PGE2, and experiments to this effect are ongoing.  
The findings of this study can enhance the understanding of the ovarian carcinoma 
environment and its influence and relevance in the context of DC-based vaccines and other 
immunotherapeutic intervention strategies in ovarian carcinoma. 
 
 
 
 
  4 
Acknowledgements 
 
First and foremost, I would like to thank my wonderful supervisor Sandra Diebold, who gave 
me the opportunity to work with her on this project. You have shown me what it means to be a 
great scientist, you supported and guided me, and all the while you gave me room and time to 
grow and learn, from you and others. Throughout these four years, despite all my faults and 
flaws, I always felt you believed in me. For all this, I will always be grateful. 
 
My gratitude also goes to my second supervisor Leonie Taams for her support, help and 
encouragement throughout my PhD. Your door was always open, and you greeted me with a 
smile on your face whenever I needed advice. 
 
Claudia Kemper, Randy Noelle and Mike Robson have formed a fantastic thesis committee 
who kept me on my toes and contributed invaluable feedback to this project. For all your 
efforts and the time you so readily took out of your busy schedules, a big thank you. 
 
The Departments of Immunobiology and Infectious Diseases provided a fantastic working 
environment, and my thanks goes to all fellow researchers for thought-provoking and inspiring 
discussions and helpful feedback. A special thank you to Valerie Wicksey, your kindness and 
helpfulness are very much appreciated. 
 
A big thanks to The Mermaids for all the fun we’ve had, especially Robin Knight and James 
Reading, who never fail to make me smile, even on bad lab days. 
 
Lolly S. Fraser, you helped me through thick and thin in the last four years, in the lab and more 
importantly, beyond. You are a wonderful person and a precious friend, and I am so happy we 
met at the benchside in DIIID. 
 
Finally, I would like to thank my parents and my sister for their continuous and unconditional 
support. You mean the world to me. 
  
  5 
Table of contents 
 
Abstract….. ................................................................................................ 3 
Acknowledgements .................................................................................... 4 
Figure Index ............................................................................................... 9 
Table Index .............................................................................................. 13 
Abbreviations ........................................................................................... 14 
Chapter 1: Introduction ......................................................................... 18 
1.1  Pattern recognition .................................................................................................... 19 
1.1.1  Toll-like receptors ................................................................................................ 20 
1.2  Innate immune activation ......................................................................................... 23 
1.2.1  Dendritic cells ....................................................................................................... 25 
1.2.1.1  Myeloid DC ......................................................................................................................................... 26 
1.2.1.2  Plasmacytoid DC ............................................................................................................................... 30 
1.3  Adaptive immune activation ..................................................................................... 32 
1.3.1  B lymphocytes ...................................................................................................... 32 
1.3.2  T lymphocytes ...................................................................................................... 33 
1.4  Cancer and the immune system ................................................................................ 37 
1.4.1  Cancer immunoediting ......................................................................................... 38 
1.4.2  Ovarian carcinoma ............................................................................................... 40 
1.4.3  Cancer immunotherapy ........................................................................................ 44 
1.5  Aims of this study ....................................................................................................... 48 
Chapter 2: Material & Methods ............................................................ 49 
2.1 General laboratory equipment ..................................................................................... 49 
  6 
2.2 Tissue culture reagents ................................................................................................. 50 
2.3 Patient specimens .......................................................................................................... 50 
2.4 PBMC isolation .............................................................................................................. 53 
2.5 Enrichment of CD14
+
 monocytes ................................................................................. 54 
2.6 Generation of monocyte-derived DC ........................................................................... 55 
2.7 Activation assay of monocyte-derived DC .................................................................. 56 
2.8 Enrichment of primary DC subsets (panDC) ............................................................. 58 
2.9 FACS sorting of mDC1 from panDC .......................................................................... 59 
2.10 Activation assay of primary mDC1 ........................................................................... 60 
2.11 Depletion of IL-10 or PGE2 from ascites ................................................................... 61 
2.11.1 Depletion of IL-10 using Protein G coated agarose beads .................................... 61 
2.11.2 Depletion of IL-10 using Streptavidin magnetic beads ......................................... 62 
2.11.3 Depletion of IL-10 using Protein G coated magnetic beads .................................. 63 
2.11.4 Depletion of IL-10 or PGE2 using NHS coated magnetic beads ........................... 64 
2.12 Enrichment of naïve T cells ........................................................................................ 66 
2.13 Allogeneic mixed leukocyte reaction ......................................................................... 67 
2.14 Flow Cytometry ........................................................................................................... 68 
2.15 Cytokine analysis of cell culture supernatants ......................................................... 72 
2.15.1 Flow Cytomix ........................................................................................................ 72 
2.15.2 ELISA for detection of TNF-α .............................................................................. 73 
2.15.3 ELISA for detection of IL-6 and IL-12p40 ........................................................... 75 
2.15.4 ELISA for detection of mouse IgG1 and mouse IgG2b ........................................ 77 
2.16 Cytokine analysis of malignant ascites and benign peritoneal fluid samples ........ 78 
2.17 Statistical analysis ....................................................................................................... 79 
Chapter 3: Impact of ovarian carcinoma associated ascites on TLR-
mediated monocyte-derived DC activation ...................... 80 
Introduction ......................................................................................................................... 80 
3.1  In vitro generation of monocyte-derived DC ........................................................... 84 
  7 
3.2  Activation of monocyte-derived DC with TLR agonists ........................................ 86 
3.3  In vitro viability of monocyte-derived DC in presence of ovarian carcinoma 
associated ascites .................................................................................................... 89 
3.4  Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
monocyte-derived DC activation in vitro ............................................................. 91 
3.4.1  Ovarian carcinoma associated ascites partially suppresses TLR-mediated up-
regulation of CD86 but not CD40, HLA-DR or PD-L1 ...................................... 91 
3.4.2  Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
production of IL-6, IL-12p40 and TNFα but not IL-1β or IL-10 ........................ 95 
3.5  Peritoneal fluid from patients with benign ovarian tumours partially suppresses 
TLR-mediated up-regulation of CD86 and induction of IL-6 and IL-12 but not 
TNFα  ...................................................................................................................... 98 
Discussion ........................................................................................................................... 101 
Chapter 4: Investigating components of ovarian carcinoma associated 
ascites that impair TLR-mediated monocyte-derived DC 
activation ............................................................................ 111 
Introduction ....................................................................................................................... 111 
4.1  Composition of ovarian carcinoma associated ascites .......................................... 114 
4.2  Correlation between protein levels in ascites and suppression of TLR-mediated 
monocyte-derived DC activation ........................................................................ 116 
4.3  Neutralization of IL-10 in cell cultures alleviates the ascites-induced suppression 
of R848-mediated activation of monocyte-derived DC .................................... 121 
4.4   Neutralization of IL-10 restores LPS- but not poly I:C-mediated monocyte-
derived DC activation in presence of ovarian carcinoma associated ascites . 127 
4.5  Ovarian carcinoma associated ascites impairs the T cell stimulatory capacity of 
monocyte-derived DC in vitro ............................................................................. 130 
4.6  Factors other than IL-10 in ovarian carcinoma associated ascites contribute to 
suppression of TLR-mediated monocyte-derived DC activation .................... 134 
4.7  PGE2 and IL-10 in ovarian carcinoma associated ascites have an additive effect 
on suppression of TLR-mediated TNFα  induction .......................................... 138 
4.8  TLR-mediated activation of primary myeloid DC in presence of ovarian 
carcinoma associated ascites ............................................................................... 142 
Discussion ........................................................................................................................... 146 
  8 
Chapter 5: Contribution of ascites-derived versus autocrine IL-10 
and PGE2 to suppression of TLR-mediated monocyte-
derived DC activation ....................................................... 154 
Introduction ....................................................................................................................... 154 
5.1  Depletion of IL-10 from ovarian carcinoma associated ascites using αIL-10 
antibody and Protein G agarose beads .............................................................. 157 
5.2  Alternative methods for IL-10 depletion from ovarian carcinoma ascites and 
their drawbacks ................................................................................................... 163 
5.2.1  Depletion of IL-10 from ascites using streptavidin beads and magnetic column 
separation ........................................................................................................... 163 
5.2.2  Depletion of IL-10 from ascites using magnetic Protein G beads pre-coated with 
IL-10 specific neutralizing antibody .................................................................. 167 
5.3  Successful depletion of IL-10 and PGE2 from ascites using neutralizing 
antibodies covalently bound to NHS ester coated magnetic beads ................. 171 
5.4  Initial experiments with IL-10 or PGE2 depleted ovarian carcinoma ascites    
fluid ....................................................................................................................... 175 
Discussion ........................................................................................................................... 177 
Discussion… ........................................................................................... 184 
Bibliography .......................................................................................... 188 
 
 
 
  
  9 
Figure Index 
 
Chapter 3 
 
Figure 3.1 Differentiation of CD14
+
 monocytes into monocyte-derived DC…………...85 
Figure 3.2 Titration of TLR agonists for activation of monocyte-derived DC………….88 
Figure 3.3 Ovarian carcinoma associated ascites does not impair cell viability 
in vitro………………………………………………………………………..90 
Figure 3.4 Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
up-regulation of CD86……………………………………………………….92 
Figure 3.5 Influence of TLR agonists and ovarian carcinoma associated ascites on 
expression levels of cell surface markers PD-L1 and OX-40L………………94 
Figure 3.6 Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
production of IL-6, IL-12 and TNFα………………………………………...96 
Figure 3.7 Peritoneal fluid associated with benign ovarian tumours partially suppresses 
TLR-mediated up-regulation of CD86 and production of IL-6 and IL-12 but 
not TNFα……………………………………………………………………100 
 
Chapter 4 
 
Figure 4.1 Levels of proteins in ovarian carcinoma associated ascites vary considerably 
between individuals………………………………………………..………..115 
Figure 4.2 IL-10 in ovarian carcinoma associated ascites correlates positively with the 
suppression of CD86, IL-6 and IL-12p40, but not TNFα……………..……117 
  10 
Figure 4.3 Correlation of levels of VEGFα, Arg-1 and TNFα in ovarian carcinoma 
associated ascites with the suppression of TLR-mediated CD86 up-regulation 
and/or production of the cytokines IL-6, IL-12p40………………………...120 
Figure 4.4 Titration of specific neutralizing antibodies in cell cultures of R848-activated 
monocyte-derived DC and ovarian carcinoma associated ascites……….….123 
Figure 4.5 Neutralization of IL-10 in cell cultures alleviates the suppression of 
R848-mediated monocyte-derived DC activation…………………………..126 
Figure 4.6 Neutralization of IL-10 in cell cultures alleviates the suppression of LPS- but 
not poly I:C-mediated monocyte-derived DC activation…………………...129 
Figure 4.7 Ovarian carcinoma associated ascites impairs the T cell stimulatory capacity 
of monocyte-derived DC, but functionality can be restored by IL-10 
neutralization………………………………………………………………..131 
Figure 4.8 The CD4
+
 T cell response induced by monocyte-derived DC in MLR reactions 
is not altered towards a regulatory or TH17 phenotype by ovarian carcinoma 
associated ascites…………………………………………………….……...133 
Figure 4.9 Factors other than IL-10 that impair TLR-mediated monocyte-derived DC 
activation are present in ovarian carcinoma ascites but not peritoneal fluid 
from patients with benign ovarian tumours………………………………...135 
Figure 4.10 Arg-1 and BIP levels in malignant ascites versus benign peritoneal fluid 
samples and influence of recombinant BIP on R848-mediated  
DC activation……………………………………………………………….137 
Figure 4.11 Impact of recombinant PGE2 on R848-mediated monocyte-derived DC 
activation……………………………………………………………………139 
 
  11 
Figure 4.12  Neutralization of PGE2 partially restores R848-induced TNFα production and 
enhances TNFα levels beyond those reached by IL-10 neutralization 
  alone……………………………………………………………………..….140 
Figure 4.13 PGE2 levels in ascites from ovarian carcinoma patients or in peritoneal fluid 
from patients suffering from benign tumours of the ovary…………….…...141 
Figure 4.14 Influence of ovarian carcinoma associated ascites on R848-mediated 
activation of primary mDC1………………………………………………..145 
 
Chapter 5 
 
Figure 5.1 Schematic depiction of rationale behind the experimental approach using 
αIL-10 neutralizing antibody and Protein G coated agarose beads for 
depletion of IL-10 from 
ascites………………………………………………………………….……158 
Figure 5.2 Activation assays performed in order to explore effects of ascites-derived 
versus autocrine IL-10 on TLR-mediated DC activation…………………...159 
Figure 5.3 Schematic depiction of pitfalls encountered with the experimental approach 
using αIL-10 neutralizing antibody and Protein G coated agarose beads for 
depletion of IL-10 from ascites………………………………………….….162 
Figure 5.4 Schematic illustration of the experimental approach using streptavidin beads 
and magnetic column separation for depletion of IL-10 from 
ascites……………………………………………………………………….164 
Figure 5.5 Attempted depletion of IL-10 from ascites using streptavidin magnetic beads 
and magnetic columns……………………………………………………....166 
  12 
Figure 5.6 Schematic depiction of the rationale behind the experimental approach using 
magnetic Protein G beads pre-coated with neutralizing IL-10 antibody for 
depletion of IL-10 from ascites……………………………………….…….168 
Figure 5.7 IgG2b levels in ascites samples after attempted depletion of IL-10 using 
magnetic Protein G beads pre-coated with IL-10 neutralizing antibody…...169 
Figure 5.8 Schematic depiction of the experimental approach using magnetic NHS ester 
coated beads with neutralizing IL-10 antibody for depletion of IL-10 from 
ascites……………………………………………………………………….172 
Figure 5.9 IL-10 levels in ascites after depletion using NHS magnetic beads................173 
Figure 5.10 PGE2 levels in ascites after depletion using NHS magnetic beads…………174 
Figure 5.11 Initial activation assays performed with ascites that had been successfully 
depleted of IL-10 in order to explore effects of ascites-derived versus 
autocrine IL-10 on TLR-mediated DC activation…………………..............176 
  
  13 
Table Index 
 
 
Chapter 1 
 
Table 1.1 Human TLR…………………………………………………………………22 
 
 
Chapter 2 
 
Table 2.1 Characteristics of patient specimens recruited for this study………………...52 
Table 2.2 Compilation of antibodies used for flow cytometry…………………………69 
 
 
Chapter 4 
 
Table 4.1 Correlation of cytokine levels in ovarian carcinoma associated ascites with the 
suppressive activity of individual ascites samples as assessed by suppression 
of TLR-mediated CD86 up-regulation and production of the cytokines IL-6, 
IL-12p40 or TNFα……………………………………….…………………119 
 
  
  14 
Abbreviations 
 
AA = arachidonic acid 
APC = antigen presenting cell 
APC = allophycocyanin 
Arg-1 = arginase-1 
Batf3 = Basic leucin zipper transcription factor ATF-like 3 
BCR = B cell receptor 
BDCA = blood dendritic cell antigen 
BIP = binding immunoglobulin protein 
BRCA 1 = breast cancer gene 1 
BRCA 2 = breast cancer gene 2 
CCL = CC chemokine ligand 
CCR = CC chemokine receptor 
CD = cluster of differentiation 
CFSE = carboxyfluorescein succinimidyl ester 
CLR = C-type lectin receptor 
Clec9A = C-type lectin domain family 9 member A 
COX-1 = cyclooxygenase-1 
COX-2 = cyclooxygenase-2 
CpG = Cytosine-phosphate-Guanine 
CRE-AP = cAMP response element adapter protein 
CTL = cytotoxic T lymphocyte 
CTLA-4 = cytotoxic T lymphocyte antigen-4 
DAMP = damage associated molecular patterns 
DC = dendritic cell 
DMSO = dimethyl sulfoxide 
DNA = deoxyribonucleic acid 
  15 
DNGR-1 = dendritic cell natural killer lectin group receptor 1 
dsRNA = double stranded ribonucleic acid 
EDTA = ethylene-diamine-tetraacetic acid 
ELISA = enzyme-linked immunosorbent assay 
FACS = fluorescence activated cell sorting 
FCS = fetal calf serum 
FIGO = Féderation Internationale de Gynécologie et d’Obstétrique 
FITC = fluorescein isothiocyanate 
FoxM1 = forkhead box protein M1 
FoxP3 = forkhead box P3 
GM-CSF = granulocyte-macrophage colony-stimulating factor 
HGSC = high-grade serous carcinoma 
HIV = human immunodeficiency virus 
HMGB1 = high mobility group box 1 
IDO = indoleamine 2,3-dioxydase 
IFN = interferon 
Ig = immunoglobulin 
IL = interleukin 
IRAK = IL-1 receptor associated kinase 
IRF3 = interferon-regulatory factor 3 
IRF7 = interferon-regulatory factor 7 
KO = knock-out 
LIF = leukemia inhibitory factor 
LT = lymphotoxin 
LPS = lipopolysaccharide 
MAP = mitogen-activated protein 
MCP-1 = monocyte chemoattractant protein 1 
mDC = myeloid dendritic cell 
  16 
MDSC = myeloid derived suppressor cells 
MFI = mean fluorescence intensity 
MHC = major histocompatibility complex 
MLR = mixed leukocyte reaction 
MyD88 = myeloid differentiation factor 88 
Necl2 = nectin-like molecule 2 
NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells 
NK cell = natural killer cell 
NOD = nucleotide-binding oligomerisation domain 
NSAID = non-steroidal anti-inflammatory drugs 
OD = optical density 
ODN = oligodeoxynucleotide 
PAMP = pathogen associated molecular pattern 
PBMC = peripheral blood mononuclear cells 
PBS = phosphate-buffered saline 
PD-1 = programmed cell death protein-1 
PD-L1 = programmed cell death 1 ligand 1 
PD-L2 = programmed cell death 1 ligand 2 
pDC = plasmacytoid dendritic cell 
PE = phycoerythrin 
PE-Cy7 = phycoerythrin conjugated with cyanine 7 
Per-CP Cy5.5 = peridin-chlorophyll-protein complex conjugated with cyanine 5.5 
PGE2 = prostaglandin E2 
poly I:C = polyinosinic:polycytidylic acid 
PRR = pattern recognition receptor 
R848 = resiquimod 
RA =  rheumatoid arthritis 
RIG-I = retinoic acid inducible gene I 
  17 
RNA = ribonucleic acid 
ROS = reactive oxygen species 
RT = room temperature 
SLE = systemic lupus erythematosus 
ssRNA = single stranded ribonucleic acid 
STAT3 = signal transducer and activator of transcription 3 
TAA = tumour associated antigen 
TAM = tumour associated macrophages 
TAP = transporter associated with antigen processing 
TCR = T cell receptor 
TGFβ = transforming growth factor β 
TH cell = T helper cell 
TIL = tumour infiltrating lymphocytes 
TIR = Toll/interleukin-1 receptor 
TLR = Toll-like receptor 
TNFα = tumor necrosis factor α 
T reg = regulatory T cell 
TRIF = TIR-domain containing adapter-inducing interferon β 
TRAF = TNFα receptor associated factor 
VEGFα = vascular endothelial growth factor α 
 
 
  
Chapter 1 Introduction 
 18 
Chapter 1 
 
Introduction 
 
While the foremost function of the immune system is the protection of the host from 
infectious pathogens, immune malfunction can bear detrimental consequences for the 
host that stretch beyond the scope of infectious diseases. Challenges lurk not only in 
the environment in the form of invading pathogens, danger can often arise from within 
an organism in form of cancerous cells. The immune system has the ability to 
eliminate tumour cells and this capacity is increasingly gaining relevance and 
importance and is being intensively explored in the field of cancer immunology and 
immunotherapy. 
The immune system constitutes a large number of cells and molecules that act together 
to protect the host from disease. In essence, regardless of the nature of the challenge, a 
functional immune response that leads to host protection requires activation of 
leukocytes, the cellular constituents of the immune system. The first line of defence is 
provided by the innate immune system comprising several cell types with diverse 
functions but the common ability to react to challenges rapidly, together leading to the 
subsequent initiation of the adaptive immune response. Dendritic cells (DC) are 
considered pivotal to the linking of the innate and adaptive immune response, and 
these cells were the primary focus of our study. To appreciate their function in the 
context of an immune response as a whole, an understanding of the processes and 
components of the innate and adaptive immune system is necessary.  
Measures needed for elimination of cancerous cells resemble in many aspects those 
required for the elimination of pathogens. However, important differences between the 
challenge with pathogens versus tumour cells prevail. With an understanding of these 
differences, it becomes apparent that the immune system has primarily evolved to 
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protect the host from infections and at the same time, reasons why it so often fails at 
conquering cancer become evident. 
 
 
1.1 Pattern recognition 
 
In 1989, Charles Janeway first proposed the existence of evolutionarily conserved 
molecules essential to pathogen function which are absent from the host but can be 
recognized by specialized pattern-recognition receptors (PRR) present on host cells 
(Janeway, 1989). The so-called pathogen-associated molecular patterns (PAMP) are 
abundant in bacteria and comprise cell wall components such as lipopolysaccharide 
(LPS), lipoproteins or peptidoglycans, and also bacterial DNA containing 
unmethylated CpG motifs. Yeast and fungal cell walls have PAMP in the form of 
mannans and β-glucans, and viral PAMP include single-stranded (ss) and double-
stranded (ds) ribonucleic acid (RNA) (Reis e Sousa, 2001). 
Upon invasion of the host with pathogens, PAMP act as ‘alarmins’ and can be 
recognized by several classes of PRR which have been identified to date, including 
Toll-like receptors (TLR), C-type lectin receptors (CLR) and cytoplasmic PRR such as 
nucleotide-binding oligomerisation domain (NOD)-like receptors and retinoic acid 
inducible gene (RIG)-I (Meylan et al., 2006;Diebold, 2009). Each PRR recognizes 
only certain PAMP, and the various PRR are differentially expressed on leukocytes 
including monocytes, macrophages and DC which are all components of the innate 
immune system. These cells thereby posess the ability to sense invading pathogens in 
their surroundings.  
In contrast to pathogens, tumour cells constitute the host’s very own cells and do not 
contain PAMP. Hence, although leukocytes may be present in immediate tumour 
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surroundings,  cancerous cells do not trigger their PRR. This is a crucial difference that 
distiguishes an infectious challenge from a challenge posed by a tumour. 
 
 
 1.1.1 Toll-like receptors 
 
The best characterized family of PRR are TLR, which had originally been discovered 
in the drosophila where they were shown to play an important role in the immune 
response against fungal pathogen (Stein et al., 1991;Lemaitre et al., 1996). The first 
human TLR was identified by Ruslan Medzhitov and Charles Janeway, who have also 
demonstrated that the triggering of TLR can induce expression of cytokines and 
co-stimulatory surface molecules (Medzhitov et al., 1997).  
To date, 10 TLR have been described in the human system. TLR1, TLR2, TLR4, 
TLR5, TLR6 and TLR10 are expressed on the cell surface, allowing the cell to directly 
sense surrounding material through these receptors. In contrast, TLR3, TLR7, TLR8 
and TLR9 are located intracellularly, more specifically on the endosomal membrane. 
Consequently, ligands of the TLR found on the cell surface include molecules that are 
frequently found on extracellular pathogens, such as LPS which triggers TLR4 or the 
bacterial protein flagellin which is recognized by TLR5 (Poltorak et al., 1998;Hayashi 
et al., 2001). Endosomal TLR specialize in detection of nucleic acids. TLR3 is 
triggered by dsRNA (Alexopoulou et al., 2001), while ssRNA is a ligand of TLR7 and 
TLR8 (Diebold et al., 2004;Heil et al., 2004;Lund et al., 2004) and TLR9 recognizes 
bacterial (Hemmi et al., 2000) or viral deoxyribonucleic acid (DNA) (Lund et al., 
2003). The access of such nucleic acids to endosomal TLR is provided either by direct 
infection of a cell in case of non-fusogenic viruses and bacteria that enter cells by 
receptor-mediated uptake, or by uptake of pathogen material by phagocytosis. 
Recognition of ligands is mediated by the extracellular or endosomal domain of the 
TLR, and signals are transduced by a number of cytoplasmic molecules. The 
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Toll/interleukin-1 receptor (TIR) domain of the TLR associates with the TIR domain 
of adaptor protein myeloid differentiation factor 88 (MyD88) and via a variety of 
signalling cascades involving, among others, adaptor TNFα receptor associated factor 
(TRAF), IL-1 receptor associated kinase (IRAK) and mitogen-activated protein (MAP) 
kinase, this leads to activation of transcription factor NFκB. This results in production 
of an array of pro-inflammatory proteins (Takeda and Akira, 2004). 
The MyD88 pathway is triggered by all 10 TLR with the exception of TLR3. This 
endosomal TLR signals via a MyD88-independent pathway mediated by TIR-domain 
containing adapter-inducing interferon β (TRIF). The resulting signalling cascade can 
either result in NFκB activation, or in stimulation of interferon-regulatory factor 3 
(IRF3), a transcription factor that promotes transciption of the gene for interferon β 
(IFNβ) (Takeda and Akira, 2004). 
TLR are differentially expressed on many immune cells, and notably on cells of the 
innate immune system including antigen presenting cells (APC). Triggering of TLR 
induces innate immune activation, which is a pre-requisite for the instigation of an 
adaptive immune response. 
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Toll-like receptor Location Key ligands Adapter molecules Signalling 
pathway 
TLR1 Cell surface 
Lipids, 
Peptidoglycan MyD88, TIRAP NF-κB, CRE-AP-1 
TLR2 Cell surface 
Lipids, 
Peptidoglycan MyD88, TIRAP 
NF-κB, ROS, 
CRE-AP-1 
TLR3 Intracellular dsRNA TRIF NF-κB, IRF3, ROS 
TLR4 Cell surface LPS 
MyD88, TRIF, 
TRAM, TIRAP 
NF-κB, IRF3, 
CRE-AP-1 
TLR5 Cell surface Flagellin MyD88 NF-κB, CRE-AP-1 
TLR6 Cell surface 
Lipids, 
Peptidoglycan MyD88, TIRAP NF-κB, CRE-AP-1 
TLR7 Intracellular ssRNA MyD88 
NF-κB, IRF7, 
CRE-AP-1 
TLR8 Intracellular ssRNA MyD88 
NF-κB, IRF7, 
CRE-AP-1 
TLR9 Intracellular CpG-ODN MyD88 
NF-κB, IRF7, 
CRE-AP-1 
TLR10 Cell surface ? MyD88 NF-κB, CRE-AP-1 
Table 1.1 Human TLR 
Overview of human TLRs and their localisation within the cell, key ligands, adapter molecules and 
triggered signalling cascades. 
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1.2 Innate immune activation 
 
The innate immune system comprises several cell types which are either found in 
circulation or distributed throughout tissues of the body. Macrophages are tissue 
resident phagocytes with a prominent ability to take up material from their 
surroundings. They differentiate from monocytes, which are found in circulation, 
constituting approximately 10% of peripheral blood mononuclear cells (PBMC). Upon 
reception of chemotactic signals conveyed by chemokines such as monocyte 
chemoattractant protein 1 (MCP-1) (CCL2), monocytes leave the blood stream by 
extravasation (Matsushima et al., 1989). Their differentiation and polarization into 
macrophages is influenced by their surroundings. Monocytes express TLR and in the 
presence of pathogens and PAMP in the tissue, they differentiate into the ‘classical’ 
M1 type macrophages. These cells are very efficient at engulfing and eliminating 
pathogens and infected cells. M1 equally express a range of PRR, and upon encounter 
and uptake of infectious material, these receptors are triggered, leading to M1 
activation which is characterized by up-regulation of surface molecules such as major 
histocompatibility complex (MHC) class II and co-stimulatory molecules CD80, CD86 
and others. Although macrophages possess the ability to process and present antigen to 
T cells, this function is secondary. Primarily, production and secretion of 
pro-inflammatory cytokines by M1 macrophages upon PAMP recognition via PRR 
contributes to the orchestration of the local immune response, promoting a 
pro-inflammatory environment by activation and recruitment of further leukocyte 
subsets.  
The monocyte attractant MCP-1 is commonly found in tumour tissue, leading to an 
infiltration of tumours with monocytes. However, in absence of infection and presence 
of tumour-derived factors such as IL-10, monocyte differentiation is skewed towards 
the ‘alternative’ M2 macrophage type. These cells differ considerably from M1 
macrophages both in their phenotype and functions (Mantovani et al., 2002). By 
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secretion of prostaglandins and immunosuppressive cytokines IL-10 and transforming 
growth factor β (TGFβ), they heavily contribute to intratumoral immunosuppression 
and impair activation and functionality of surrounding leukocyte subsets. In the 
context of tumours, M2 macrophages are referred to as tumour associated 
macrophages (TAM). TAM have emerged as an important negative prognostic factor 
in many human cancers, and their characterization is therefore of great interest in the 
field of cancer immunology and immunotherapy (Bingle et al., 2002;Sica et al., 
2006;Heusinkveld and van der Burg, 2011). 
In many ways, the tumour environment resembles a site of infection, abundant in 
soluble mediators, with increased vascular permeability and swelling. However, a 
crucial difference is the absence of pathogens. In absence of infection, inflammatory 
responses in tissue are referred to as sterile inflammation. The triggers of sterile 
inflammation in tumours are complex and include mediators produced by tumour cells, 
stroma and infiltrating leukocytes, as well as apoptotic cells (Chen and Nunez, 2010) 
The contrasting roles of M1 and M2 macrophages illustrate that the underlying cause 
of inflammation can gravely influence the immune response. The presence of PAMP at 
a site of infection promotes the differentiation of monocytes into pro-inflammatory M1 
macrophages, while the absence of pathogens during sterile inflammation together 
with presence of tumour-derived factors favours the induction of immunosuppressive 
TAM. 
Differences between sterile and infection-triggered inflammation extend to other cells 
of the innate immune system including neutrophils, natural killer cells (NK cells) and 
circulating monocytes, which all have the ability to sense invading pathogens via PRR. 
Collectively, the processes of the innate immune response shape the nature of the 
successive adaptive immune response. Through their compelling antigen presenting 
ability, DC of the innate immune system have emerged as a pivotal and direct link 
between innate and adaptive immunity and their activation is therefore of paramount 
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importance for the instigation of an antigen-specific adaptive immune response, both 
in infection and cancer. 
 
 
1.2.1 Dendritic cells 
 
The identification of DC by Ralph Steinman and Zanvil Cohn in 1973 was a landmark 
discovery in modern immunology (Steinman and Cohn, 1973). Steinman described DC 
as a sparse population of murine spleen leukocytes with an exceptional ability to 
potently stimulate proliferation of lymphocytes in mixed leukocyte reactions (MLR). 
He coined the name ‘dendritic cell’ due to the tree-like morphology of the cells’ 
cytoplasmic protrusions. After the initial discovery, several publications outlining their 
morphological and functional characteristics followed in short succession (Steinman 
and Cohn, 1974;Steinman et al., 1974;Steinman et al., 1975). Over several years, 
methods to isolate and culture DC were established and optimized, but working with 
this cell type nevertheless proved challenging due to the intricacy of isolation methods 
as well as paucity of DC among leukocytes, further complicated by the complexity of 
DC subsets. In 1982, DC were discovered in human peripheral blood (Van Voorhis et 
al., 1982), but their study was hindered by the same technical and methodical 
difficulties as previously encountered in the murine system. DC comprise 
approximately 1% of PBMC, and hence the numbers obtainable from human subjects 
are very limited. A milestone in the research of human DC was the finding that DC 
could be generated in vitro from the considerably more populous monocytes with the 
help of recombinant growth factors granulocyte-macrophage colony stimulating factor 
(GM-CSF) and IL-4 (Sallusto and Lanzavecchia, 1994). Termed monocyte-derived 
DC, these cells have proven to be an extremely useful tool for the study of human DC. 
In addition, over the last decade, simple and efficient methods for isolation of primary 
DC have become commercially available, although their sparse numbers do continue 
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to pose a challenge. Nevertheless, after 40 years of DC research, the field of 
immunology holds an accomplished understanding of the functions and characteristics 
of human DC subsets. 
Three populations of human DC can be distinguished in peripheral blood based on 
their developmental pathways and functionality. All are derived from the common 
myeloid progenitor in the bone marrow, and during development, guided by a myriad 
of distinct cytokines and transcription factors, they differentiate into different subsets. 
 
 
1.2.1.1 Myeloid DC 
 
Human myeloid DC (mDC) are considered the body’s most efficient APC, positioned 
at the interface between innate and adaptive immunity. mDC are phenotypically 
characterized by expression of high levels of MHC class II, and two subpopulations 
can be distinguished by differential expression of further phenotypic markers. The 
mDC1 subset typically expresses blood dendritic cell antigen (BDCA)-1 and, 
constituting approximately 0.5% of PBMC, is considerably more frequent than mDC2. 
High expression levels of BDCA-3 distinguish mDC2, an extremely rare cell type, 
representing <0.1% of PBMC (Dzionek et al., 2000). 
mDC express PRR for the recognition of PAMP. More specifically, peripheral blood 
mDC1 express high levels of TLR2 and TLR5 and low levels of TLR4, TLR6 and 
TLR8 (Jarrossay et al., 2001), while mDC2 were shown to express high levels of 
TLR1, TLR3, TLR6 and TLR10, intermediate levels of TLR2 and low levels of TLR8 
(Jongbloed et al., 2010;Poulin et al., 2010). In addition, both subsets harbour PRR of 
other classes such as CLR and cytoplasmic PRR, and mDC are thus well equiped to 
sense a multitude of invading pathogens. In the steady state, mDC reside in peripheral 
tissues and survey the environment for potential incoming infectious agents. Upon 
encounter and uptake of pathogen material, triggering of PRR induces mDC activation, 
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which is characterized by up-regulation of the chemokine receptor CCR7, leading to 
increased migratory ability of the cells. Via chemotactic signals conveyed by CCR7 
ligands CCL19 and CCL21, activated, antigen-loaded mDC travel via lymphatic 
vessels to local lymph nodes (Forster et al., 2008). Apart from up-regulation of CCR7, 
activation of mDC is characterized by increased expression levels of MHC II and 
co-stimulatory molecules such as CD80 and CD86, as well as secretion of an array of 
cytokines including IL-6, IL-12, TNFα and others (Reis e Sousa, 2001). In lymphoid 
tissues, mDC present complexes of antigen peptides and MHC molecules to 
T lymphocytes, which sample these complexes via T cell receptors (TCR). Upon 
recognition of a cognate MHC-peptide complex via TCR, T cells undergo 
differentiation and clonal expansion into effector T cells. 
DC activation as triggered by PRR due to presence of PAMP in an infectious scenario 
is paramount to efficient T cell priming and instigation of an antigen-specific adaptive 
immune response. This is supported by reports showing that in the steady state, small 
numbers of DC constantly take up host cellular material from dying cells in the 
periphery and travel to the lymph nodes, and these cells do not stimulate autoimmune 
T cell responses but instead, they promote tolerance (Reis e Sousa, 2006). In contrast, 
uptake of cellular material from infected cells that contain PAMP leads to immunity.  
Scavanging of apoptotic cell material is a function fulfilled in particular by mDC2. 
This has been elucidated only recently, when this subtype was recognized as an 
equivalent of murine CD8α+ DC  (Jongbloed et al., 2010;Poulin et al., 2010) which 
have long known to be specialized in uptake of cell-associated antigens (Iyoda et al., 
2002). The studies by Jongbloed et al. and Poulin et al. demonstrate that 
phenotypically, BDCA3
+
 mDC2 resemble murine CD8α+ DC, as suggested by the 
expression of high levels of the C-type lectin receptor DNGR1 (Clec9A), adhesion 
protein Necl2 as well as TLR3, and further the transcription factor Batf3 which had 
previously been identified as a defining factor for the developmental lineage of 
CD8α+ DC in mice (Hildner et al., 2008). Interestingly, the authors of the study by 
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Poulin et al. have established a protocol for the in vitro generation of BDCA3
+
 mDC2 
from CD34
+
 hematopoietic stem cells from human cord blood. In addition, they show 
that primary BDCA3
+
 mDC2 can be isolated from spleen suspensions of humanized 
mice (Poulin et al., 2010). Both these methods could help facilitate research with this 
extremely rare cell type and its properties and functions could thus be elucidated 
further in the near future. 
So far, these studies have shown that human BDCA3
+
 mDC2 are efficient at uptake of 
exogenous material which they subsequently cross-present to CD8
+
 cytotoxic T cells. 
Cross-presentation is the ability to process exogenous antigens in such a way that they 
are presented on MHC class I molecules where they can be recognized by CD8
+
 
T lymphocytes. Typically, only peptides from endogenous antigens that are 
synthesized within the cell, such as products of viruses that have infected the cell and 
hijacked its protein synthesis machinery are presented on MHC class I molecules. In 
contrast, exogenous antigen taken up by an APC is processed in a different manner and 
is loaded onto MHC class II molecules. Complexes of exogenous peptides and 
MHC class II molecules are recognized by CD4
+
 T helper cells (TH cells) (Heath and 
Carbone, 2001). 
All nucleated cells express MHC class I on their cell surface (Swain, 1983), whereas 
expression of MHC class II is restricted to APC. Presentation of endogenous antigens 
coupled to MHC class I and their recognition by CD8
+
 T cells is a useful mechanism in 
viral infection. By direct presentation, virus infected cells can be recognized and 
destroyed by cytotoxic T lymphocytes (CTL). However, only professional APC such 
as mDC have the ability to potently prime an immune response leading to a substantial 
population of antigen-specific cytotoxic T cells, but infected mDC may be 
compromised in their functionality (Gabrilovich et al., 1994;Fugier-Vivier et al., 
1997). Moreover, not all viral pathogens infect mDC. Under such circumstances, the 
ability of specialized DC subsets to cross-present exogenous antigens is required 
(Bevan, 1987). While it is now understood that other DC subsets also have the 
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capacity to cross-present soluble or particulate antigen (Pooley et al., 2001), murine 
CD8α+ DC and human mDC2 are specialized in cross-presentation of cell-associated 
antigens. 
Tumour associated antigens (TAA) constitute cell-associated antigens, and they can 
equally be processed and cross-presented by these cell types. Similarly to viral 
infections, cellular immunity is desired in the context of cancer for elimination of 
tumour target cells. However, due to absence of PAMP associated with scavanged 
tumour cell material and therefore lack of PRR activation, cross-priming DC typically 
fail to elicit TAA-specific CTL responses. 
In immunotherapeutic concepts that aim to harness the antigen presenting ability of 
mDC subsets, the use of TLR agonists therefore represents an attractive approach. In 
essence, application of synthetic PAMP targeting specific TLR receptors mimics an 
infectious scenario. In the context of cancer immunotherapy, use of TLR agonists can 
thus lead to mDC activation, enabling efficient TAA (cross-)presentation and 
instigation of tumour specific adaptive immune responses. 
Not only direct activation of mDC subsets via PRR is, however, paramount to anti-
tumour immunity. Soluble mediators provided by leukocyte subsets other than mDC 
are required for efficient cross-presentation of TAA and functionality of CTL 
(Kolumam et al., 2005;Le Bon et al., 2006). One such example was demonstrated in a 
previous study in our laboratory. In an experimental mouse B16 melanoma 
pseudometastasis model, our colleagues have shown that type 1 interferon is crucial 
for the adjuvant activity of TLR7 agonist polyUs21 and, hence, an efficient anti-
tumour response (Rajagopal et al., 2010). They could further show that this type 1 
interferon was provided by plasmacytoid DC (pDC), which constitute a DC subset 
distict from mDC found both in mice and humans. 
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1.2.1.2 Plasmacytoid DC 
 
Before their classification within the DC lineage and nomenclature as pDC, this cell 
subset was commonly referred to as interferon-producing cells (Cella et al., 
1999;Siegal et al., 1999). pDC in human peripheral blood are characterized by the 
expression of the surface markers BDCA-2 and -4, as well as IL-3Rα (CD123), while 
they lack the surface marker CD11c which is typically expressed by mDC (Dzionek et 
al., 2000). Their ability to produce large amounts of type 1 interferons in response to 
microbial challenge had been recognized early on, and they were postulated to be of 
considerable importance in the defence against viral infections. Type 1 interferons 
promote the induction of TH1 immune responses, enhance cytotoxic T cell responses 
and play a role in immunoglobulin class switching in B cells (Cousens et al., 1999;Le 
Bon et al., 2001;Le Bon et al., 2006). The role of pDC in antigen presentation is 
somewhat controversial, with some reports indicating that they have the ability to 
present exogenous antigen and can induce tolerance to self-antigens (Kuwana et al., 
2001). Other studies suggest that they, in fact, fail to present exogenous antigens but 
are able to present endogenous antigens such as when directly infected with virus, and 
that they have the ability to prime cytotoxic T cell responses (Fonteneau et al., 
2003;Krug et al., 2003;Salio et al., 2004). pDC could therefore be of importance in 
viral infections not only due to their type 1 interferon producing capacity, but also as 
functional APC that can prime virus-specific T cells. 
Human pDC express high levels of TLR7 and TLR9, as well as low levels of TLR1, 
TLR6 and TLR10 (Hornung et al., 2002). It is not well studied and therefore unclear 
how ligands of TLR1, TLR6 and TLR10 effect pDC. However, it has been well 
established that TLR7 and TLR9 can be triggered by viral genomic RNA and DNA, 
respectively, resulting in potent production of type 1 interferon (Krug et al., 2001;Lund 
et al., 2003;Diebold et al., 2004;Heil et al., 2004). The synthetic compound imiquimod 
leads to type 1 interferon production via TLR7 stimulation in pDC, and is used for 
Chapter 1 Introduction 
 31 
treatment of basal cell carcinoma (Urosevic et al., 2005;Ghafouri-Fard, 2012). pDC 
have further been identified in the microenvironment of several other cancers (Zou et 
al., 2001), and harnessing their potential to enhance potent cellular immunity is 
increasingly being considered as an attractive concept in cancer immunotherapy 
(Schettini and Mukherjee, 2008). 
The importance of DC as APC directly linking innate and adaptive immunity reaches 
beyond their antigen processing and presenting abilities. The interaction between DC 
and the T lymphocytes is complex and requires more than the mere display of peptide-
MHC complex on the APC surface and its recognition by cognate TCR. Additional 
signals are required to facilitate antigen-specific T cell expansion, some of which are 
DC-derived. These signals are important in the instruction and tailoring of the effector 
functions of the induced adaptive immune response. 
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1.3 Adaptive immune activation 
 
Lymphocytes are the cellular components of the adaptive immune system. They 
originate from the common lymphoid progenitor in the bone marrow, and are divided 
into two subtypes – the B lymphocyte and T lymphocyte, commonly referred to as 
B cells and T cells. Both can be found in circulation and in lymphoid tissues either as 
naïve lymphocytes or, after encountering their specific antigen and differentiation in 
the course of an adaptive immune response, as effector lymphocytes. 
Depending on the type of challenge a host is faced with, different effector functions 
are required. Infections with extracellular pathogens such as bacteria necessitate 
primarily the initiation of humoral immunity to facilitate their opsonisation and 
neutralization, while viral infections call for cellular immunity which leads to 
recognition and elimination of infected target cells. 
 
 
1.3.1 B lymphocytes 
 
B lymphocytes are mediators of the adaptive humoral immune response. Through a 
unique B cell receptor (BCR) displayed on their cell surface, naïve B cells have the 
ability to recognize and bind antigens freely available in tissues, such as viral particles, 
bacterial cells or fragmented components of invading pathogens. The BCR represents 
a membrane-bound immunoglobulin which transmits signals to the cell’s interior upon 
binding of cognate antigen. With the help of interactions with TH cells, B cells 
differentiate into plasma cells which specialise in the production and secretion of large 
amounts of immunoglobulin molecules. Several classes of immunoglobulins have been 
identified, termed IgA, IgD, IgE, IgG, and IgM. They have different roles in the 
immune system, and while IgM is the antibody class secreted most rapidly in the time 
course of an immune response, in a mechanism referred to as ‘class switching’, 
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B lymphocytes have the ability to switch to the production of other immunoglobulin 
classes (Pan-Hammarstrom et al., 2007). Defects of humoral immunity have dramatic 
impact on the immune competence of a host, making them particularly susceptible to 
bacterial infections (Fleer, 2000). 
Upon binding of antigen via BCR, B cells can act as APC and internalize, process and 
display peptide-MHC class II complexes for recognition by CD4
+
 TH cells on their 
cells surface. Despite their ability to present antigens to T lymphocytes, the exact role 
and relevance of B cells as APC in the priming of naïve T cells is not clear. Their 
importance in orchestration of T cell responses is nevertheless undisputed, and B cell 
depletion in experimental models leads to disruption of T cell responses such as 
impaired CD4
+
 memory T cell development (Chen and Jensen, 2008).  
However, the primary role of B cells lies in provision of antigen-specific humoral 
immunity, and although they contribute to the orchestration of T cell responses, their 
significance in priming of T cells is limited. In viral infections and tumour challenges, 
cellular adaptive immune responses are required, and these are provided by 
T lymphocytes. 
 
 
1.3.2 T lymphocytes 
 
Naïve T lymphocytes bear specific TCR which allow them to recognize peptides 
presented to them in complexes with MHC molecules on the surface of APC. Upon 
encounter of a T cell with its cognate peptide-MHC complex, in a process referred to 
as T cell priming, the T cell differentiates and expands into effector cells. 
For successful differentiation and expansion of naïve T lymphocytes, the interaction 
between TCR and MHC-peptide complex, typically referred to as signal 1 of T cell 
priming, requires the exchange of further signals between T cell and APC. Signal 2 is 
conveyed by cell surface markers, such as, for example, CD28 expressed by T cells 
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and so-called co-stimulatory molecules CD80 and CD86, found on APC. A third 
signal is conveyed by soluble factors, present in the form of cytokines secreted by both 
APC, T cell and other cells of the immediate environment. 
In order to convey signals 2 and 3, DC require activation as provided by PAMP on 
invading pathogens. In absence of DC activation, signal 1 alone is exchanged between 
DC and T cell, which is thought to promote naïve T cell inactivation by anergy or 
deletion, leading to peripheral tolerance (Reis e Sousa, 2006).  
T cells expressing the surface marker CD8 recognize antigen peptides presented to 
them on MHC class I molecules. They have the ability to rapidly induce apoptosis of a 
target cell by release of perforins and granzymes, and due to these cytotoxic properties, 
CTL are of paramount importance in viral infections (Young et al., 1990). 
Degranulation and release of cytotoxic agents resembles the mechanism of action of 
the neutrophils of the innate immune system. However, the killing induced by CTL is 
highly specific and only affects the target cells that display the relevant peptide on 
MHC class I molecules, leaving uninfected bystander cells unharmed. This is achieved 
by exclusive release of cytotoxic agents precisely at the point of contact between the 
infected cell and CTL rather than their undirected release into the cell’s surroundings 
such as seen in neutrophils (Podack et al., 1988;Berke, 1994). 
For efficient cross-priming of naïve CD8
+
 T cells by DC, adequate signals 2 and 3 
have to be in place to accompany TCR interaction with MHC-peptide complex. DC 
activation leading to expression of high levels of co-stimulatory molecules CD80, 
CD86 and secretion of cytokines is induced by interaction of DC surface molecule 
CD40 and CD40 ligand (CD40L) expressed on TH cells (Bennett et al., 1997;Bennett 
et al., 1998), but can equally be triggered by PRR stimulation (Reis e Sousa, 2004). 
Interestingly, certain stimuli such as dsRNA recognized by TLR3 are particularly 
efficient at promoting cross-priming of CTL by DC (Schulz et al., 2005), and this is in 
part due to induction of type 1 interferon which potentiates this process (Le Bon et al., 
2006). 
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It is evident that by stimulation of specific PRR, pathogens elicit distict activation 
patterns of innate immune cells including DC. By differential secretion of cytokines in 
response to varying stimuli, DC transmit information about the nature of the pathogen 
to T cells and shape the adaptive immune response. Characteristics of signal 3 
determine to a large extent the polarization of naïve CD4
+
 T cells, which, in contrast to 
naïve CD8+ T cells, have the ability to differentiate into diverse effector cell types 
with contrasting functions (Diebold, 2008). 
The most prominent and well understood amongst TH cells are TH1 and TH2 cells. TH1 
responses are typically induced in presence of the cytokine IL-12. TH1 cells activate 
macrophages that have engulfed pathogen material, enhancing the macrophages’ 
microbicidal activity. Further, by production of the cytokines IFNγ, TNFα and IL-2, 
TH1 cells enhance priming of CTL, boosting cellular immunity (Liu et al., 2013).  
In contrast, TH2 cells primarily promote immunoglobulin class switching in 
B lymphocytes and are therefore crucial to the orchestration of the humoral immune 
response, important for clearing of infections with extracellular pathogens (Diebold, 
2008;Liu et al., 2013). While DC have the potential to deliver distinct signal 3 
depending on the activating stimulus, tissue derived factors such as TSLP-1 (Pedroza-
Gonzalez et al., 2011) and mediators secreted by other leukocyte populations can also 
affect the polarization of T cell priming. For instance, TH2 cells are induced in 
presence of the cytokine IL-4 secreted by surrounding T cells and activated mastcells, 
basophils and eosinophils of the innate immune system (Luzina et al., 2012). TH2 cells 
typically produce IL-4, IL-5 and IL-13, self-perpetuating their own induction.  
The polarization of TH cell responses towards one effector cell type or the other is 
increasingly understood to be a dynamic process, with different TH cell populations 
present during an immune response, mutually influencing their own induction. For 
instance, promotion of TH1 and TH2 responses may be in part regulated by a further 
class of TH cells that has been identified in the last decade, and is referred to as TH17 
cells due to substantial production of the cytokine IL-17 (Harrington et al., 2005;Park 
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et al., 2005). This subset is induced during T cell priming in presence of IL-6, IL-23 
and TGFβ as signal 3 cytokines. TH17 cells enhance neutrophil activation, and they 
therefore indirectly amplify the immune response mechanisms directed at extracellular 
pathogens. It has recently emerged that TH17 cells can also be harmful to the host by 
perpetuating chronic inflammation, for example in rheumatologic conditions and 
autoimmunity (Gullick et al., 2013). In contrast, CD4
+
 regulatory T cells (T reg), 
characterized by the expression of transcription factor FoxP3, play an important role in 
prevention of autoimmunity, with numerous studies documenting the detrimental 
consequences of T reg paucity or malfunction (Ochs et al., 2005;Liu et al., 2013). 
T reg are induced in presence of the immunosuppressive cytokine TGFβ, and their 
primary function is the regulation of the immune response by contact-dependent 
inhibition of APC and T cells and production of immunosuppressive cytokines 
including IL-10 and TGFβ (von Boehmer and Daniel, 2013). T reg induction can also 
be a result of naïve T cell priming by an unactivated DC that can not convey signals 2 
and 3 (Reis e Sousa, 2006). 
 
Collectively, the induction of CTL and TH cell responses by DC is dependent on the 
DC activation status. Lack of activation by PAMP in sterile inflammation can result in 
T cell anergy and antigen tolerance, which in the case of cancer is detrimental. 
Delivery of PRR stimuli to DC in form of TLR agonists for instigation of a tumour 
specific adaptive immune response is a much applied strategy in cancer 
immunotherapy. In particular, induction of cellular immunity in form of CTL and TH1 
responses is highly desirable. Activation of DC subsets, notably those able to cross-
present TAA, with appropriate TLR agonists, such as synthetic compounds that mimic 
viral infection, holds promise for future concepts in cancer immunotherapy.  
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1.4 Cancer and the immune system 
 
The oldest descriptions of cancer in humans are found in the ancient Egyptian 
document ‘Edwin Smith Papyrus’, dating back to the year 3000 BC. Described as a 
lump in breast tissue, the author concluded that there was no treatment for this disease. 
Several other reports originating from different ancient cultures referring to tumour-
like growths have been discovered, and in the 4
th
 century BC, the Greek physician 
Hippocrates finally coined the term ‘carcinoma’. In Greek, this word refers to a crab, 
most likely applied to the disease because the finger-like projections of the tumours 
called to mind the body shape of a crab. The Roman physician Celsus later translated 
the Greek term into ‘cancer’, the Latin word for crab, and respective translations are 
widely used in many languages to date (Hajdu, 2011). 
Today, cancer is the second leading cause of death in high-income countries after 
cardiovascular diseases (WHO, 2011). Malignant neoplasms can develop from 
practically any cell in the human body. Fundamentally, cancer is a disease of tissue 
growth regulation failure, leading to uncontrolled division of cells. Mutations in genes 
of a cell that promote or inhibit its growth and proliferation can occur due to many 
different causes, ranging from environmental factors such as radiation, exposure to 
toxins in form of alcohol or tobacco to infections, hormones and hereditary genetic 
predispositions. It is very challenging to assign individual risk factors their relative 
contributions to the development of cancer, and multiple factors are most likely 
necessary. This notion is supported by the fact that identical exposure to a toxin can 
lead to malignant neoplasm in one individual, while another remains unharmed. 
Similarly, not all patients carrying germline mutations of selected genes predisposing 
them to development of carcinoma will be affected in their lifetime. This suggests that 
several ‘check points’ have to be overcome by a cancer cell to thrive. The immune 
system plays a considerable role in this regard, with increasing evidence pointing 
towards its importance in tumour surveillance and immunoediting. 
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1.4.1 Cancer immunoediting 
 
The concept that adaptive immunity is responsible for preventing cancer devolopment 
in immunocompetent hosts was first postulated by Burnet and Thomas in the late 
1950s. Early clinical observations of increased incidence of cancer in patients 
receiving immunsuppressive therapy following organ transpantation supported this 
idea, and the proof for this and a better understanding of the underlying mechanisms 
was gradually obtained through the use of animal models. Today, it is widely 
recognized that the immune system can prevent cancer formation, but it is also evident 
that even in immunocompetent hosts, it often fails to do so. This basic concept is 
summarized by the cancer immunoediting hypothesis, a theory that postulates that 
from an immunological point of view, tumour formation can be described in three 
sequential phases termed ‘elimination’, ‘equilibration’ and ‘escape’ (Schreiber et al., 
2011). 
The elimination phase describes a state where the innate and adaptive immune systems 
work together to detect the presence of a developing tumour and destroy it before it 
becomes clinically apparent. A detailed understanding of how the immune system is 
alerted to the presence of malignant cells is yet to be elucidated, but potential 
mechanisms include release of damage-associated molecular patterns (DAMP) such as 
high mobility group box 1 (HMGB1) released from dying tumour cells or stress 
ligands including MICA/B that are frequently expressed on tumour cells (Guerra et al., 
2008). It is challenging to truly prove and observe the elimination phase in vivo, but its 
existence is implied by greater susceptibility to neoplasia in immunodeficient mice as 
compared to wildtype animals (Vesely et al., 2011). Similarly, in humans, despite 
sophisticated and balanced immunosuppressive regimens used in transplantation 
nowadays, immunocompromised patients remain more prone to development of 
malignancy (Gutierrez-Dalmau and Campistol, 2007). 
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Tumour cell variants that survive the stage of elimination enter the phase of 
equilibrium. Here, the immune system maintains residual tumour cells in a functional 
state of dormancy. These cells have the potential to resume growth at a later stage, 
possibly even after decades. Strong evidence for the existence of the immunological 
equilibrium phase of cancer immunoediting was provided by a study where 
immunocompetent mice that harboured occult tumour cells after carcinogen exposure 
remained tumour free for long periods of time, but developed tumours after ablation of 
T lymphocytes (Koebel et al., 2007). Equilibrium is thought to be the longest phase 
which can possibly extend throughout the lifetime of the host. However, tumour cells 
that have acquired immunoevasive mutations can ‘escape’ the adaptive immune 
processes of the equilibrium phase and proceed to grow into manifest tumours. 
Progression from equilibrium to escape can occur due to alterations of the tumour cells 
which lead to reduced immune recognition, such as loss of TAA, or loss of MHC class 
I proteins that present TAA. Equally, intracellular antigen processing in tumour cells 
can be impaired, for instance through loss of transporter proteins associated with 
antigen processing (TAP) which are crucial to shuttling of antigen to the 
endoplasmatic reticulum (ER) and hence an important step towards loading of TAA 
onto MHC class I molecules  (Dunn et al., 2002;Khong and Restifo, 2002). Further 
mechanisms of tumour escape include increased resistance to the cytotoxic effects of 
immunity, for example through induction of anti-apoptotic mechanisms (Vesely et al., 
2011). However, escape can equally result from the establishment of 
immunosuppression in the tumour microenvironment (Radoja et al., 2000). Through 
production of soluble mediators such as vascular endothelial growth factor α 
(VEGFα), transforming growth factor β (TGFβ), IL-10 and indoleamine 
2,3-dioxydase (IDO) tumours can promote an immunosuppressive state. Further, 
recruitment and induction of T reg and myeloid-derived suppressor cells (MDSC) can 
inhibit host-protective antitumour immune responses (Schreiber et al., 2011). With the 
understanding of cancer immunoediting, it becomes apparent that those tumour cells 
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that have survived to grow into clinically established tumours are those variants that 
have developed and continue to exploit successful strategies to circumvent the natural 
tumour-suppressive mechanisms of immunity. An immunosuppressive environment 
therefore often persists in established malignant tumours, which can be detrimental to 
patients’ prognosis and survival. Clinical studies have demonstrated that presence of 
T reg, MDSC and immunosuppressive cytokines are correlated with poor disease 
outcomes (Sato et al., 2005;Mustea et al., 2006;Hart et al., 2011). Some tumours are 
more prone to promote immunosuppression than others, with ovarian carcinoma being 
a prominent example of a tumour which is particularly efficient at fostering an 
immunosuppressive environment (Yigit et al., 2010). 
 
 
1.4.2 Ovarian carcinoma 
 
Several studies suggest an association between chronic pelvic inflammatory disease, 
an inflammatory condition of the female genital tract, and development of ovarian 
carcinoma (Kisielewski et al., 2013). Chronic inflammation is accompanied by 
genotoxic stress and enhanced cellular proliferation, angiogenesis and tissue invasion 
(Grivennikov et al., 2010). Notably, a chronic inflammatory environment leads to 
immunosuppression, an important mechanism of tumour escape (Baniyash, 2006). The 
existence of an immunosuppressive environment in established ovarian malignancies 
is well documented (Yigit et al., 2010) and is increasingly thought to also contribute to 
early tumour formation. 
However, the aetiology of ovarian carcinoma is multifactorial and comprises a number 
of non-immunological risk factors including hormone replacement therapy, obesity, 
nulliparity, and personal history of other malignancies, most notably breast cancer. 
Several genetic mutations that pre-dispose women to development of ovarian 
carcinoma have been identified and include mutations in breast cancer genes 
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(BRCA)-1 and -2. As their name suggests, germline mutations in the BRCA genes 
were originally identified as susceptibility factors for breast cancer (Hall et al., 1990), 
but carriers bear a considerable risk of developing other types of cancer as well such as 
pancreatic cancer, and most importantly ovarian carcinoma. The lifetime risk of a 
female bearing a germline mutation in BRCA-1 or BRCA-2 to develop ovarian 
carcinoma is approximately 30%, although such incidence estimations do vary 
considerably between different reports (Nicoletto et al., 2001).  
Several types of ovarian carcinoma have been identified based on their histological and 
morphological properties. Their classification is rather complex and has been subject 
to changes over the last decade (Gurung et al., 2013). Five subtypes of ovarian 
carcinoma can be distinguished according to their molecular and pathological features, 
including clear cell, mucinous, endometroid, low-grade serous and high-grade serous 
carcinoma (HGSC). The latter represents the most frequent tumour type constituting 
over 70% of cases (Gurung et al., 2013), and our study was conducted with material 
exclusively from patients suffering from HGSC. This tumour type was for a long time 
believed to arise from the ovarian surface epithelium, but more recent reports suggest 
that the cells of origin may, in fact, be fimbrial and therefore attributed to the fallopian 
tube (Delair and Soslow, 2012). Pathological features of HGSC include marked 
nuclear atypia and very high mitotic index. Genetic mutations of the tumour 
suppressor protein p53 are characteristic of this disease and are found in 97% of cases. 
Further molecular attributes of HGSC include BRCA loss and alterations in signalling 
pathways including forkhead box protein M1 (FoxM1), NOTCH and retinoblastoma 
protein (Gurung et al., 2013).  
A major factor responsible for poor prognosis and a low survival rate of HGSC 
patients is the lack of early symptoms, leading to the vast majority of patients being 
diagnosed at an advanced stage of the disease. A hallmark symptom of ovarian 
carcinoma is the development of ascites, and although this occurs at rather late stages, 
it is frequently the first sign that alarms the patient. Formation of ascites is a condition 
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during which liquid accumulates in the peritoneal cavity as a result of an imbalance 
between fluid production and resorption. The pathophysiology of ascites is 
multifactorial; the obstruction of venous and lymphatic vessels caused by tumour cells, 
reduced intravascular protein, increased capillary permeability as well as hormonal 
changes influencing the renal excretion all contribute to the development of ascites 
(Chung and Kozuch, 2008). The accumulated volume can often reach several litres and 
can lead to abdominal swelling, abdominal pain, nausea and vomiting. In order to 
relieve patients of these symptoms, multidisciplinary therapeutic concepts have been 
developed. An important part of symptomatic therapy is paracentesis, a procedure 
during which the liquid is drained out of the peritoneal cavity through a canule. This 
ensures rapid improvement of the patient’s condition but is purely symptomatic and 
therefore often not lasting, requiring repetition (Chung and Kozuch, 2008). 
Ascites harbours tumour cells as well as a considerable infiltration of leukocytes and a 
multitude of cytokines, chemokines and growth factors (Giuntoli et al., 2009a). T reg, 
MDSC and M2 macrophages all form part of the cellular composition of malignant 
ovarian tumours, as do soluble immunosuppressive proteins including VEGFα, IL-10 
and TGFβ (Conejo-Garcia et al., 2004;Sato et al., 2005;Yigit et al., 2010;Hart et al., 
2011;Yigit et al., 2011a). Clinical studies attribute a tumour-promoting role to these 
factors. Equally, the importance of pro-inflammatory cytokines in advancement and 
dissemination of established ovarian tumours is convincingly documented (Kulbe et 
al., 2007), once more highlighting a link between immunosuppression and chronic 
inflammation in malignant tumours and the significance of such an environment on 
disease progression. Interestingly, some reports suggest that the immune composition 
of tumours may impede the efficacy of chemotherapeutic agents. The cytokine IL-6 is 
implied to reduce the responsiveness of ovarian tumours to paclitaxel and cisplatin, 
which constitute the first line of chemotherapy currently used for treatment of ovarian 
carcinoma (Wang et al., 2010;Maccio and Madeddu, 2012). 
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Relapse due to chemoresistance is indeed a major cause of concern in ovarian 
carcinoma and an important reason for poor long-term survival. 
While chemotherapy represents an important component of current treatment regimes, 
cytoreductive de-bulking surgery remains the first line of therapy in ovarian 
carcinoma. The successful removal of tumour mass is highly desirable and considered 
the most important prognostic factor. However, optimal de-bulking is very 
complicated to achieve due to the typical peritoneal dissemination of ovarian 
carcinoma. Large numbers of small tumour nodules are distributed throughout the 
peritoneal cavity, and their complete excision is frequently not possible. Hence, 
despite the fact that even advanced tumours including the late stage IIIc of the disease 
as classified by Féderation Internationale de Gynécologie et d’Obstétrique (FIGO) 
remain confined to the peritoneal cavity, the current therapeutic measures are not 
adequate to conquer the challenges of this disease, and novel approaches are 
paramount for improvement of ovarian carcinoma patient survival.  
Due to an abundance of leukocyte subsets present in the tumour environment, 
immunotherapeutic interventions represent an appealing experimental approach to 
novel curative strategies. Cytotoxic CD8
+
 T cells cells can be detected in ascites and in 
solid ovarian tumours, and a high CTL/T reg ratio was found to be prognistically 
favourable (Sato et al., 2005;Giuntoli et al., 2009a). DC are also present in tumour 
tissue and ascites of ovarian carcinoma patients (Wertel et al., 2008), and although in 
murine models of the disease they have been attributed a pro-tumorigenic role, 
possibly by inducing tumour vascularisation (Conejo-Garcia et al., 2004;Huarte et al., 
2008) and suppressing T cell function, some evidence suggests that T cell stimulatory 
capacity of DC could be induced by TLR-mediated activation (Scarlett et al., 2009). 
However, soluble factors of the tumour environment can affect DC function 
(Gabrilovich et al., 1996;Conejo-Garcia et al., 2004), and future vaccination schemes 
aiming to harness DC subsets in situ therefore must consider immunosuppressive 
factors within the tumour environment and their impact on DC functionality. Targeting 
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and activation of selected DC subsets with TLR agonists in vivo for cancer 
immunotherapy constitutes an important line of research in our laboratory, and in this 
study, we therefore investigated how soluble factors in ovarian carcinoma associated 
ascites may influence TLR-mediated DC activation. 
 
 
1.4.3 Cancer immunotherapy 
 
Frequent failure of established cancer therapies including surgery, chemotherapy and 
radiation perpetuate the search for new therapeutic strategies, with immunotherapy 
gaining increasing recognition and importance in the field of oncology. Most 
immunotherapeutic concepts have only just reached the stage of pre- or early clinical 
trials despite the fact that the potential of our immune system to eliminate malignant 
tumours has been known to scientists for centuries. Reports dating back to years BC 
describe regression of malignancies in patients suffering from coincidental infections, 
and some clinicians made early curative attempts at cancer by applying local septic 
dressings to tumours, inducing tissue inflammation and high fever with the hope of 
thereby activating the immune system to eliminate the malignant mass. William B. 
Coley, an American surgeon, is considered a pioneer of the modern age in the field of 
cancer immunotherapy. Unlike his predecessors, Coley recognized the danger of sepsis 
imposed by the administration of live bacteria to tumour tissue. Early in his career, he 
therefore introduced what later became known as “Coley’s toxins” – a vaccine 
containing two species of killed bacteria, Streptococcus pyogenes and Serratia 
marcescens. Coley hypothesized that such killed pathogens would still be able to elicit 
an immune response without posing the same risks as live, replicating strains of 
bacteria. Coley’s protocols were widely used by other physicians of the era and 
although failure and severe side effects were not sparse, many stories of success were 
reported (Hoption Cann et al., 2003).  
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From today’s understanding, Coley’s approach was successful due to the presence of 
PAMP on bacteria and other pathogens. Coley’s vaccine consisted of a cocktail of 
killed bacteria strains, which contained PAMP in the form of cell wall components and 
nucleic acids from the bacterial genome which lead to APC activation by triggering of 
PRR. 
Decades later, this basic concept is still relevant in cancer immunotherapy. The 
ultimate goal of any immunotherapeutic approach is the priming and expansion of 
tumour-specific CD8
+
 cytotoxic T cells and their elimination of malignant cells. As 
professional APC with the ability to cross-present TAA, DC are pivotal to successful 
CTL priming. However, their ability to instigate an anti-tumour immune response is 
dependent on their activation.  
Cellular therapies which rely on ex vivo generated and expanded DC frequently 
employ defined cocktails of cytokines for DC activation. In these experimental 
approaches, DC are usually generated from monocytes by culture with GM-CSF and 
IL-4 to obtain monocyte-derived DC. Alternatively, preparations of PBMC are used. 
Before re-injection into to the patient’s circulation, the APC are loaded with TAA and 
cultured with specific cytokines to ensure their activation and subsequent tumour-
specific T cell priming in vivo (Harada, 2010). A prominent example of such 
personalized DC vaccination is the therapy with Sipuleucel-T (Provenge®), approved 
in 2010 by the United States Food and Drug Administration (FDA) for treatment of 
prostate cancer. The outcome of several clinical trials with Provenge® led to 
disappointing results (Huber et al., 2012). Cellular DC vaccinations are nevertheless 
considered promising by many researchers and clinical trials are ongoing. However, 
their personalized nature and therefore technically demanding preparation and high 
cost are regarded as limiting by others. 
An alternative and much promising approach is targeting of DC for in vivo antigen 
delivery by use of antibodies specific for surface receptors expressed on selected DC 
subsets, such as DEC-205 (Hawiger et al., 2001;Bonifaz et al., 2002), DNGR-1 
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(CLEC9A) (Sancho et al., 2008) or many others. Biochemically cross-linked 
conjugates or fusion proteins of antibody and antigen are used for vaccination, but in 
initial studies, it has been shown that unless DC are additionally activated by an 
adjuvant, vaccination results in induction of peripheral antigen tolerance (Bonifaz et 
al., 2002). Use of cytokines as done for ex vivo generated monocyte-derived DC is not 
ideal for in vivo activation of primary DC subsets, because the half-life of many 
cytokines in serum is short and their systemic administration further poses 
considerable risk of toxicity and undesired side effects. Moreover, the ability of 
cytokines to activate DC in vivo is debatable, with increasing evidence suggesting that 
direct activation via PRR is required to obtain DC with the ability to prime effective 
T cell responses (Joffre et al., 2009). 
All DC subsets express several TLR, and TLR agonists therefore represent suitable 
adjuvants frequently used in vaccination for DC activation in vivo (Duthie et al., 
2011). Some studies rely on systemic administration of soluble TLR agonists in 
conjuction with the targeting antibody-antigen complex (Trumpfheller et al., 2008), 
but in more recent and sophisticated approaches, conjugation of TLR agonists to the 
antibody-antigen complexes is attempted (Kreutz et al., 2012). Such targeted delivery 
of the TLR-agonist together with antigen ensures on one hand that DC which present 
the relevant antigen are activated and can prime antigen-specific CTL, and prevents 
side effects of systemic TLR agonist application on the other hand. 
To date, experience with DC vaccines in ovarian carcinoma is very limited. Several 
small trials using ex vivo generated DC were conducted but have led to rather 
disappointing results (Stiff et al., 2013). Studies combining chemotherapy with 
vaccination with TAA-loaded DC were well tolerated, elicited anti-tumour immune 
responses in some patients (Kandalaft et al., 2013), and prolonged survival (Chu et al., 
2012). However, the cohorts in all these studies to date were small and the results 
therefore do not allow conclusive interpretations. Nevertheless, immunotherapy in 
ovarian carcinoma remains a promising field of research, with identification of several 
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ovarian carcinoma associated TAA including Her2/neu, NY-ESO-1 and MUC1 paving 
the way for future DC based peptide vaccination concepts (Thibodeaux and Curiel, 
2011). A complication that persists and may impede immunotherapeutic strategies is 
the immunsuppressive environment of ovarian carcinoma fostered by the tumour 
(Yigit et al., 2010). Expression and interaction of inhibitory molecules on DC and 
T cells are parameters associated with immune suppression in the ovarian carcinoma 
environment (Kryczek et al., 2006;Krempski et al., 2011). Blockade of co-inhibitory 
pathways, so-called ‘checkpoint-blockade’, is an attractive clinical direction to boost 
anticancer immunity in patients, and this concept is being exploited by use of selective 
antibodies for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed 
cell death protein-1 (PD-1) and others (Pardoll, 2012). In addition, soluble 
immunosuppressive factors which are abundant in the ovarian carcinoma environment 
and in ascites (Yigit et al., 2011a;Yigit et al., 2011b) may equally hinder the efficacy 
of anti-tumour vaccinations. Due to its confinement to the peritoneal compartment, an 
understanding of the local immune environment can inform and improve future 
immunotherapeutic strategies in this disease considerably by identifying important 
aspects that constitute hurdles on the way towards instigation of efficacious anti-
tumour immune responses. 
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1.5 Aims of this study 
 
In this study, we aim to elucidate the influence of soluble factors in ascites obtained 
from patients suffering from high-grade serous ovarian carcinoma on activation of 
human DC subsets by TLR agonists in vitro. In particular, we are interested to 
investigate 
 
(1) if TLR-mediated DC activation is influenced by ovarian carcinoma associated 
ascites, and whether influences differ upon use of different TLR agonists. 
 
(2) which factors in ovarian carcinoma associated ascites are responsible for 
observed effects on TLR-mediated DC activation and whether the influence 
exerted by these factors can be overcome. 
 
(3) whether distinct human DC subsets are affected differently by ovarian 
carcinoma associated ascites upon TLR-mediated activation. 
 
Our long-term aim is to contribute to a better understanding of the tumour environment 
in ovarian carcinoma and to identify strategies that promote the efficacy of 
immunotherapeutic interventions in patients with malignant disease. 
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Chapter 2 
 
Material & Methods 
 
 
2.1 General laboratory equipment 
 
Gilson ‘Pipetman’ single channel pipettes  P2, P10, P20, P100, P200, P1000 
(Gilson, Luton, UK) 
Rainin ‘Pipet-Lite’ multi channel pipettes L50, L300 (Anachem, Luton, UK) 
Rainin disposable pipette tips for all pipette sizes (Anachem) 
Gilson ‘Pipetting Aid’ (Gilson) 
Stripette disposables 5ml, 10ml, 25ml (Costar® Sigma-Aldrich, Dorset, UK) 
Nunc-Immuno ‘Wash 12’ ELISA washer (Nunc, Roskilde, Denmark) with attached 
vacuum pump (Fisher Scientific, Loughborough, UK) 
Microcentrifuge ‘Centrifuge 5424’ (Eppendorf, Stevenage, UK) 
Centrifuge ‘5810R’ (Eppendorf) 
CO2 incubator (Sanyo Panasonic, Berkshire, UK) 
Tissue culture hood (Labcaire Scientific Laboratory Supplies, Hessle, UK) 
Laboratory refrigerator (4°C) / freezer (-20°C) (Vestfrost, Esbjerg, Denmark) 
Revco laboratory freezer (-86°C) (Thermo Scientific, Cramlington, UK) 
Inverted microscope (Motic, Wetzlar, Germany) 
Upright microscope (Ceti Medline, Oxon, UK) 
Vortex ‘Genie2’ (Scientific Industries, Bohemia, New York, U.S.A.) 
Titramax 100 Microplate shaker (Heidolph, Saffron Walden, UK) 
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2.2 Tissue culture reagents 
 
RPMI 1640 medium (Invitrogen, Paisley, UK) 
Fetal calf serum (FCS) (Sigma-Aldrich, Dorset, UK) 
Glutamine (Invitrogen) 
Penicillin/Streptomycin (Invitrogen) 
β-Mercaptoethanol (2-ME) (Gibco Life Technologies, Paisley, UK) 
1x Phosphate-buffered saline (PBS) (Gibco Life Technologies) 
Ethylene-diamine-tetra-acetic acid (EDTA) (Sigma-Aldrich) 
 
 
2.3 Patient specimens 
 
Material: 
Centrifuge tubes, 50 ml (Corning Inc., Amsterdam, The Netherlands) 
Centrifuge tubes, 15ml (VWR, Lutterworth, UK) 
FCS (Sigma-Aldrich) 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) 
CryoTube® Vials, 1.8 ml (Thermo Scientific) 
Syringes, 10 ml (Beckton Dickinson (BD), Oxford, UK) 
sterile filters, 0.2µm pore size (Appleton Woods, Birmingham, UK) 
 
Sample collection and storage protocol: 
The collection of ascites for this study was approved by the Guy’s Research Ethics 
Committee (REC Number: 09/H0804/45). Informed consent was obtained from all 
patients. 
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Ascites from patients suffering from epithelial ovarian carcinoma was collected by 
paracentesis (n = 9; Dr. Raju, Department of Gynaecological Oncology, St Thomas’ 
Hospital, London, UK). Peritoneal fluid from patients with benign ovarian conditions 
(fibroadenoma n = 1, fibrothecoma n = 2, benign cyst n = 2 or cystadenoma n = 1) was 
collected during surgery (Dr. Raju, Department of Gynaecological Oncology, St. 
Thomas Hospital, London, and Dr. Ahmed, University of Oxford, Nuffield 
Department of Obstetrics and Gynecology, Oxford, UK). Characteristics of collected 
specimens are summarized in Table 2.1.  
Upon receipt, fluid samples were divided into centrifuge tubes and centrifuged (1200 
rpm, 10 minutes), allowing the separation of the fluid into a cellular fraction and non-
cellular supernatant. The cells were frozen in FCS with 10% DMSO and stored in 
CryoTube® vials at -196°C in liquid nitrogen tanks. The non-cellular supernatant was 
stored in aliquots in 15 ml centrifuge tubes at -80˚C. Upon thawing, before use in cell 
cultures, the non-cellular fluid was passed through a syringe-driven sterile filter. 
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  Patient code Tumour type FIGO Stage 
Therapy at the time 
of ascites collection 
Malignant       
OC4 HGSC IV before de-bulking 
OC5 HGSC IV before de-bulking 
OC6 HGSC IIIc before de-bulking 
OC9 HGSC unknown before de-bulking 
OC13 HGSC unknown before de-bulking 
OC23 HGSC IIIB before de-bulking 
OC25 HGSC IIIB 
before de-bulking, 
post-chemotherapy 
OC26 
ovarian 
adenocarcinoma unknown before de-bulking 
        
Benign       
OC14 
mucinous 
cystadenoma N/A perioperative 
OC24 
fibroma 
cystadenoma N/A perioperative 
OC27 thecoma N/A perioperative 
OC34 fibrothecoma N/A perioperative 
OC35 benign cyst N/A perioperative 
OC36 
benign fimbrial 
cyst N/A perioperative 
Table 2.1 Characteristics of patient specimens recruited for this study 
This table provides a summary of all patient specimens used in this study. For data protection reasons, 
patient samples were anonymized and numbered (‘patient code’). Indicated is the histological tumour 
type, FIGO stage, and therapy received. All patients with malignant tumours received surgical therapy 
(de-bulking), and ascites samples were obtained by paracenthesis before de-bulking surgery. Except for 
patient OC25, no information about chemotherapy status is available. Surgical removal constituted the 
only therapy for patients suffering from benign ovarian tumours. Collection of benign peritoneal fluid was 
carried out during surgery (‘perioperative’). 
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2.4 PBMC isolation 
 
Material: 
Vacutainer® blood collection tubes, glass, heparinized, 9 ml (BD) 
Vacutainer® Push Button Blood Collection Set, 21G (BD) 
Alcotip Swabs (Universal Hospital Supplies, Enfield, UK) 
‘Buffy Coat’ leukocyte preparations (National Blood Service Tooting, London, UK) 
Centrifuge tubes, 50 ml (Corning Inc.) 
1 x PBS (Gibco Life Technologies) 
Lymphocyte Separation Medium 1077 (PAA Laboratories, Yeovil Somerset, UK) 
Trypan blue solution 0.4% (Sigma-Aldrich) 
Neubauer counting chamber (Fisher Scientific) 
 
Protocol: 
The collection of peripheral blood for this study was approved by the Guy’s Research 
Ethics Committee (REC Number: 09/H0804/45). Informed consent was obtained from 
all participants who gave blood by venipuncture. 
Peripheral blood from healthy volunteers was obtained by venipuncture and collected 
in heparinized vacutainer tubes. Alternatively, buffy coat leukocyte preparations were 
obtained from the National Blood Service. After dilution (1:2 dilution for peripheral 
blood obtained by venipuncture, 1:4 dilution for buffy coats) with PBS, the blood was 
layered over Lymphocyte Separation Medium 1077 in 50 ml centrifuge tubes. After 
centrifugation (1600 rpm, 20 minutes, brake off) the PBMC fraction was harvested 
into fresh 50 ml centrifuge tubes, pooled and washed twice with PBS (1200 rpm, 10 
minutes). An aliquot of cells was added to trypan blue solution 0.4%, which had been 
diluted 1:5 in PBS, and live cells were counted in an upright microscope at 40x 
magnification in a Neubauer counting chamber. 
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2.5 Enrichment of CD14
+
 monocytes 
 
Material: 
EasySep
®
 Human Monocyte Enrichment Kit (StemCell Technologies, Grenoble, 
France) 
Enrichment medium (1 x PBS containing 2% FCS and 1mM EDTA) 
Polystyrene tubes, round-bottom, 14 ml (BD) 
EasySep® “The Big Easy” Silver Magnet (StemCell Technologies) 
 
Protocol: 
CD14
+
 monocytes were isolated from PBMCs by negative selection using the 
EasySep
®
 Human Monocyte Enrichment Kit following the manufacturer’s 
instructions. Briefly, PBMC were re-suspended in recommended enrichment medium 
in a 14 ml polystyrene round-bottom tube at a density of 5x10
7
 cells/ml. The antibody 
enrichment cocktail provided in the kit was added at a concentration of 50 µl/ml cell 
suspension, followed by an incubation at 4°C for 10 minutes. Magnetic bead particles 
were added at a concentration of 50 µl/ml cells and after a further incubation for 5 
minutes at 4°C, the tube was placed in an EasySep
®
 magnet at room temperature (RT) 
for 2.5 minutes to allow magnetic separation of cells. After this time, the magnet with 
the tube was inverted and the fraction containing untouched CD14
+
 monocytes was 
collected in a fresh tube. The remaining magnetically labeled unwanted cells were 
retained inside the original tube and discarded. The purity of the enriched CD14
+
 
monocytes was assessed by flow cytometry and was typically over 95%. 
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2.6 Generation of monocyte-derived DC 
 
Material: 
Complete R10 medium (RPMI 1640 supplemented with 10% FCS, 2mM glutamine, 
100U/ml penicillin, 100mg/ml streptomycin, 50µM 2-ME) 
Granulocyte-macrophage colony stimulating factor (GM-CSF) (R&D Systems, 
Abingdon, UK) 
Interleukin-4 (IL-4) (R&D Systems) 
6-well tissue culture plates (Costar® Sigma-Aldrich) 
PBS w/EDTA (1x PBS supplemented with 5mM EDTA) 
 
Protocol: 
Enriched CD14
+
 monocytes were seeded on 6-well-plates at a density of 6-9x10
6
 
cells/well in 3 ml complete R10 medium and 20 ng/ml GM-CSF and 20 ng/ml IL-4. 
Cells were cultured at 37˚C in a 5% CO2 atmosphere for 7 days. GM-CSF and IL-4 
were replenished on day 2 and day 5 along with 500 µl fresh complete R10 medium 
per well. Cells were harvested on day 7 of culture with PBS w/EDTA. The 
differentiation of monocytes into monocyte-derived DC was verified by flow 
cytometric analysis of the surface markers CD14 and CD1a. 
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2.7 Activation assay of monocyte-derived DC 
 
Material: 
Complete R10 medium 
96-well tissue culture plates, flat-bottom (Costar® Sigma-Aldrich) 
PBS w/EDTA (1x PBS supplemented with 5mM EDTA) 
TLR agonists: 
- R848 (stock conc. 2 mg/ml) (Invivogen, Toulouse, France) 
- LPS (stock conc. 5 mg/ml) (Invivogen) 
- Poly I:C (stock conc. 2 mg/ml) (GE Healthcare, Amersham, UK) 
Neutralizing antibodies: 
- αIL-10 antibody (mouse IgG2b clone 25209) (R&D Systems) 
- αTGF-β antibody (mouse IgG1 clone 27235) (R&D Systems) 
- αVEGFα antibody (mouse IgG2b clone 26503) (R&D Systems) 
- αLIF antibody (mouse IgG2b clone 9824) (R&D Systems) 
- αIL-6 antibody (mouse IgG2b clone 1936) (R&D Systems) 
- αPGE2 antibody (mouse IgG1 clone 2B5) (Cayman Europe, Tallinn, Estonia) 
- mouse IgG1 isotype control antibody (clone 11711) (R&D Systems) 
- mouse IgG2b isotype control antibody (clone 20116) (R&D Systems) 
Patient specimens: 
- malignant ascites from ovarian carcinoma patients 
- peritoneal fluid from patients with benign ovarian tumours 
 
Protocol: 
Monocyte-derived DC were seeded on 96-well tissue culture plates at a density of 
1x10
5
 cells/well in complete R10 medium, with a final well volume of 200 µl. 
Triplicate wells were used for all samples. TLR agonist concentrations were titrated in 
pilot experiments (chapter 3, Figure 3.3). Concentrations that induced robust up-
Chapter 2 Material & Methods 
 57 
regulation of activation markers were determined as R848 3 µg/ml, LPS 1 µg/ml and 
poly I:C 100 µg/ml, and these concentrations were used in subsequent experiments 
throughout the project. Where indicated, sterile filtered, non-cellular peritoneal fluid 
from patients with malignant or benign ovarian tumours was added to samples to reach 
either 10% or 25% cell culture concentration. Cells were incubated for 18h overnight 
at 37˚C in a 5% CO2 atmosphere. Supernatants were harvested and analyzed for 
cytokine levels. In addition, cells were harvested with PBS containing 5mM EDTA for 
analysis of surface marker expression by flow cytometry. 
In order to identify the factors that suppress DC activation, cells were cultured as 
described above, with the addition of neutralizing antibodies. The antibodies were 
added to cell cultures concomitantly with respective TLR agonists. Individual 
antibodies were used either separately or in combinations with a final concentration of 
5 µg/ml per antibody. Respective isotype control antibodies were included in every 
experiment and were used at equivalent concentrations of 5 µg/ml per antibody. 
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2.8 Enrichment of primary DC subsets (panDC) 
 
Material: 
EasySep
®
 Human panDC Enrichment Kit (StemCell Technologies) 
Enrichment medium (1 x PBS containing 2% FCS and 1mM EDTA) 
Polystyrene tubes, round-bottom, 14 ml (BD) 
EasySep® “The Big Easy” Silver Magnet (Stemcell Technologies) 
 
Protocol: 
Primary DC subsets were isolated from PBMCs by negative selection using EasySep
®
 
Human panDC Enrichment Kits following the manufacturer’s instructions. Briefly, 
PBMC were re-suspended in enrichment medium in a 14 ml polystyrene round-bottom 
tube at a density of 5x10
7
 cells/ml. Reagents provided in the respective EasySep
®
 
negative enrichment kits were added and incubation times were followed according to 
the manufacturer’s protocols. Subsequently, the tube was placed in an EasySep
®
 
magnet for a designated amount of time to allow magnetic separation of cells. The 
magnet with the tube was inverted and the negatively selected fraction containing the 
desired untouched DC was collected in a fresh centrifuge tube. The magnetically 
labeled unwanted cells remained bound inside the original tube and were discarded. 
mDC1 population was further purified by FACS sorting.  
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2.9 FACS sorting of mDC1 from panDC 
 
Material: 
Microcentrifuge vials 1.5ml (Costar® Sigma-Aldrich) 
FACS buffer (1 x PBS containing 5mM EDTA, 1% heat-inactivated FCS and 
0.02% NaN3) 
CD1c (BDCA-1)-APC conjugated antibody (mouse IgG2a, clone AD5-8E7) (Miltenyi 
Biotech) 
CD19-FITC conjugated antibody (mouse IgG1, clone LT19) (Immunotools) 
FACS tubes (BD) 
FACS Aria cell sorter (BD) 
 
Protocol: 
After enrichment by negative magnetic selection as described above, panDC were 
transferred into microcentrifuge vials and washed with FACS buffer before incubation 
with antibodies diluted in FACS buffer (1:10 dilution for CD1c-APC antibody; 1:100 
dilution for CD19-FITC antibody) for 30 mins at 4˚C in the dark. Cells were then 
washed 2x and samples were transferred into FACS tubes for cell sorting, which was 
performed by qualified staff at the cell sorting facility of the Division of Immunology, 
Infection and Inflammatory Disease. The desired cell fraction, defined as CD1c
+
CD19
-
 
cells, was collected in fresh FACS tubes and used further in activation assays. 
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2.10 Activation assay of primary mDC1 
 
Material: 
Complete R10 medium 
96-well tissue culture plates, flat-bottom (Costar® Sigma-Aldrich) 
PBS w/EDTA (1x PBS supplemented with 5mM EDTA) 
TLR agonists: 
R848 (stock conc. 2 mg/ml) (Invivogen) 
αIL-10 neutralizing antibody (mouse IgG2b clone 25209) (R&D Systems) 
 
Protocol: 
mDC1 obtained by FACS sorting as described above were seeded on 96-well tissue 
culture plates at a density of approximately 6x10
4
 cells per well. Triplicate wells were 
used for all samples. The same concentration of TLR7 agonist R848 as with 
monocyte-derived DC was used (3 µg/ml). Where indicated, sterile filtered, non-
cellular peritoneal fluid from ovarian carcinoma patients was added to samples to 
reach 10% final cell culture concentration. Where indicated, αIL-10 neutralizing 
antibody (5 µg/ml) was added to samples concomitantly with R848 and ascites. Cells 
were incubated for 18h overnight at 37˚C in a 5% CO2 atmosphere. Supernatants were 
harvested and analyzed for cytokine levels. In addition, cells were harvested with 
PBS containing 5 mM EDTA for analysis of surface marker expression by flow 
cytometry.  
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2.11 Depletion of IL-10 or PGE2 from ascites 
 
2.11.1 Depletion of IL-10 using Protein G coated agarose beads 
 
Material: 
Centrifuge tubes, 15ml (VWR) 
αIL-10 antibody (mouse IgG2b clone 25209) (R&D Systems) 
mouse IgG2b isotype control antibody (clone 20116) (R&D Systems) 
Protein G coated agarose beads (Thermo Scientific) 
 
Protocol: 
IL-10 neutralizing antibody or relevant IgG2b isotype control antibody were added to 
sterile filtered ascites at a concentration of 5 µg/ml or 20 µg/ml and the samples were 
incubated for 30 minutes at 4˚C. After addition of 100µl Protein G agarose beads the 
samples were incubated for 30 minutes at room temperature. Samples were centrifuged 
at 1500 RPM for 5 minutes, and the supernatant was carefully harvested. 
Centrifugation at identical speed and duration was repeated to ensure removal of 
residual agarose beads, and carefully harvested ascites supernatant was used in 
activation assays. 
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2.11.2 Depletion of IL-10 using Streptavidin magnetic beads 
 
Material: 
Centrifuge tubes, 15ml (VWR) 
αIL-10 antibody (mouse IgG2b clone 25209) (R&D Systems) 
mouse IgG2b isotype control antibody (clone 20116) (R&D Systems) 
anti-mouse IgG antibody, biotinylated (goat Ig clone Poly4053) (BioLegend) 
Magnetic Streptavidin MicroBeads (Miltenyi Biotec) 
LD magnetic columns (Miltenyi Biotec) 
MidiMACS magnet and magnetic stand (Miltenyi Biotec) 
1 x PBS (Gibco) 
 
Protocol: 
αIL-10 neutralizing antibody or respective mouse IgG2b isotype control antibody were 
added to 3 ml sterile filtered ascites at a concentration of 10 µg/ml and incubated for 
30 minutes at 4˚C. Subsequently, biotinylated α-mouse IgG antibody was added to the 
samples at a concentration of 20 µg/ml, followed by incubation for 30 minutes at 4˚C. 
Next, Streptavidin MicroBeads were added at a concentration of 100 µl bead stock 
solution per 1 ml ascites (300 µl per sample) and samples were incubated for 
15 minutes at 4˚C. LD magnetic columns were placed into the block magnet and 
calibrated with 500 µl PBS. Each ascites sample was loaded onto a calibrated column, 
and the flow-through was collected in a fresh centrifuge tube. This procedure was 
repeated two more times with fresh, PBS calibrated magnetic columns for a total of 
three passages of ascites samples over columns. 
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2.11.3 Depletion of IL-10 using Protein G coated magnetic beads 
 
Material: 
PureProteome Protein G Magnetic Beads (Millipore, Livingston, UK) 
αIL-10 antibody (mouse IgG2b clone 25209) (R&D Systems) 
mouse IgG2b isotype control antibody (clone 20116) (R&D Systems) 
chromatographically purified mouse IgG (Invitrogen) 
PureProteome Magnetic Stand (Millipore) 
Microcentrifuge vials 1.5ml (Costar® Sigma-Aldrich) 
1 x PBS w/0.1% Tween 20 
 
Protocol: 
The manufacturer’s (Millipore) protocol for binding of antibodies to Protein G 
Magnetic Beads was followed. Briefly, 50 µl Protein G Magnetic Beads were 
incubated in a microcentrifuge vial with 10 µg/ml αIL-10 neutralizing antibody or 
respective mouse IgG2b isotype control antibody for 10 minutes at RT with 
continuous mixing in the mixing block at 1000 RPM. Subsequently, beads were 
washed with 500 µl PBS w/Tween 20 with the help of the magnetic stand. 
Subsequently, 200 µg chromatographically purified mouse IgG2b was added to each 
sample in order to saturate vacant IgG binding sites on Protein G Magnetic Beads. An 
incubation for 10 minutes at RT in the mixing block at 1000 RPM was followed by 
3x washing with 500 µl PBS w/Tween 20 with help of the magnetic stand. 
Antibody-coated Protein G Magnetic Beads were added to 1 ml sterile filtered ascites 
and incubated for 1 hour or overnight at 4˚C. After incubation, magnetic beads were 
removed by placing the microcentrifuge tubes into the magnetic stand and transfer of 
the bead-free ascites into a fresh microcentrifuge tube. This procedure was repeated 
two more times to ensure complete removal of magnetic beads.  
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2.11.4 Depletion of IL-10 or PGE2 using NHS coated magnetic beads 
 
Material: 
PureProteome N-Hydroxysuccinimide (NHS) FlexiBind Magnetic Beads (Millipore) 
Equilibration Buffer (1mM HCl) (Millipore) 
Wash/Coupling Buffer (PBS, pH 7.4) (Millipore) 
Quench Buffer (100mM Tris-HCl, 150 mM NaCl, pH 8.0) (Millipore) 
Amicon® Ultra-0.5 30K Centrifugal Filter Devices (Millipore) 
αIL-10 antibody (mouse IgG2b clone 25209) (R&D Systems) 
mouse IgG2b isotype control antibody (clone 20116) (R&D Systems) 
αPGE2 antibody (mouse IgG1 clone 2B5) (Cayman Europe) 
mouse IgG1 isotype control antibody (clone 11711) (R&D Systems) 
PureProteome Magnetic Stand (Millipore) 
Microcentrifuge vials 1.5ml (Costar® Sigma-Aldrich) 
 
Protocol: 
To ensure successful coupling of antibody to the PureProteome NHS Magnetic Beads, 
the antibodies must be present at a concentration of 2 mg/ml or above. The stock 
concentration of both isotype control antibodies as well as the αIL-10 antibody was 
500 µg/ml and a further concentration was therefore required to reach 2 mg/ml. For 
this, a defined amount of antibody (100µg) in solution was pipetted into an Amicon® 
Ultra-0.5 30K Device, and centrifuged at 14,000 x g for 7 minutes. The obtained 
concentrated antibody solution was recovered from the device and the volume was 
adjusted to 50 µl, resulting in a final antibody concentration of 2 mg/ml. The anti-
prostaglandin E2 (αPGE2) antibody is supplied at a concentration of 2 mg/ml and no 
further concentration was therefore required. 
For the coupling of antibodies to PureProteome NHS Magnetic Beads, the protocol 
recommended by the manufacturer’s protocol was followed closely. Briefly, beads 
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were washed 1x with ice-cold Equilibration Buffer and 50 µl of antibody solution 
(2 mg/ml) was immediately added, followed by an incubation for 2 hours at RT. 
Subsequently, beads were washed 5x with Quench Buffer followed by an incubation of 
2 hours at RT in Quench Buffer. The beads were washed 4x with Wash/Coupling 
Buffer. Such antibody-coated beads were then incubated with ascites from ovarian 
carcinoma patients to deplete the desired cytokines IL-10 or PGE2. For the depletion, 
the αIL-10 or αPGE2 antibody-coated beads and were incubated with ascites 
overnight at 4˚C. To control for the specificity of the depletion, isotype control mouse 
IgG coated beads were also incubated with ascites samples for mock depletion. After 
overnight incubation, beads were removed from ascites samples using the 
PureProteome Magnetic Stand. IL-10 and PGE2 levels were measured in the depleted 
samples to verify whether complete and specific removal of the respective proteins 
was achieved. The depleted ascites was further assessed by mouse IgG-specific ELISA 
to ensure no unbound residual neutralizing antibody was present in these samples after 
depletion. Ascites depleted of IL-10, PGE2 and mock-depleted samples were stored at 
-80˚C until their use in activation assays. 
 
 
  
Chapter 2 Material & Methods 
 66 
2.12 Enrichment of naïve T cells 
 
Material: 
EasySep
®
 Human Naïve CD4
+
 T cell Enrichment Kit (StemCell Technologies) 
Enrichment medium (1 x PBS containing 2% FCS and 1mM EDTA) 
Polystyrene tubes, round-bottom, 14 ml (BD) 
EasySep® “The Big Easy” Silver Magnet (StemCell Technologies) 
 
Protocol: 
Naïve CD4
+
 T cells were isolated from PBMC by negative selection using the 
EasySep
®
 Human Naïve T cell Enrichment Kits following the manufacturer’s 
instructions. Briefly, PBMC were re-suspended in recommended enrichment medium 
in a 14 ml polystyrene round-bottom tube at a density of 5x10
7
 cells/ml. Reagents 
provided in the respective EasySep
®
 negative enrichment kits were added and 
incubation times were followed according to the manufacturer’s protocols. The tube 
was then placed in an EasySep
®
 magnet to allow magnetic separation of cells. After 
this time, the magnet holding the tube was inverted and the fraction containing 
untouched naïve T cells was collected in a fresh 14 ml polystyrene round-bottom tube. 
The remaining magnetically labeled unwanted cells were retained inside the original 
tube, which was discarded. The tube containing the desired cells was again placed into 
the EasySep® magnet for a further round of separation after which the contents were 
inverted into a fresh centrifuge tube. The purity of the enriched naïve T cells as 
assessed by flow cytometry was typically over 98%. 
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2.13 Allogeneic mixed leukocyte reaction 
 
Material: 
1 x PBS (Gibco Life Technologies) 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, Paisley, 
UK) 
FCS (Sigma-Aldrich) 
Centrifuge tubes, 15ml (VWR) 
Complete R10 medium 
96-well tissue culture plates, round-bottom (Costar® Sigma-Aldrich) 
 
Protocol: 
Naïve T cells were enriched by negative selection as described above and subsequently 
labeled with CFSE. For this, T cells were washed twice with PBS and re-suspended in 
1 µM CFSE solution in a 15ml centrifuge tube at a density of 1.0 x 10
7
 cells/ml and 
incubated at RT for 10 minutes. To quench the staining, a volume of FCS equivalent to 
that of CFSE solution used was added for 2 minutes at RT, before cells were washed 
with complete R10 medium and processed further. 
Monocyte-derived DC were pre-cultured overnight under varying conditions with or 
without TLR agonists and/or ascites as described previously. To ensure no carryover 
of TLR agonists and/or ascites, DC were washed twice with fresh R10 medium before 
being added to the CFSE-labeled CD4
+
 T cells at ratios of 1:100 or 1:200 (DC : T 
cells). Samples were performed in triplicates in round-bottom 96-well plates, with 
50 000 naïve T cells per well. The cultures were incubated at 37˚C in a 5% CO2 
atmosphere for 6 days. After harvest, cells were analyzed by flow cytometry to assess 
T cell proliferation by CFSE dilution and T cell polarization by intracellular cytokine 
staining. 
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2.14 Flow Cytometry 
 
Material: 
Microcentrifuge vials 1.5ml (Costar® Sigma-Aldrich) 
FACS buffer (1 x PBS containing 5mM EDTA, 1% heat-inactivated FCS and 
0.02% NaN3) 
Fixation Buffer (BioLegend, Cambridge, UK) 
Permeabilization Buffer (BioLegend) 
Monensin Solution (BioLegend) 
FoxP3 Staining Buffer Set (eBioscience, Hatfield, UK) 
LIVE/DEAD® Fixable Dead Cell Stain Kit (Invitrogen) 
Paraformaldehyde 37% (VWR) 
FACS tubes (BD) 
FACS Canto II analyzer 
FACS Clean solution (BD) 
FACS Rinse solution (BD) 
FACS Flow solution (BD) 
FlowJo Software (Treestar. Ashland, Oregon, U.S.A.) 
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Specificity Fluorochromes Isotype Clone Staining dilution Manufacturer 
      
Surface markers:      
CD1a PE mouse IgG1κ HI149 1:5 BD 
CD1c (BDCA-1) APC mouse IgG2a AD5-8E7 1:10 Miltenyi 
CD3 APC-Cy7 mouse IgG1κ SK7 1:20 BD 
CD4 APC mouse IgG1 MEM-241 1:100 Immunotools 
CD8 APC mouse IgG2a MEM-31 1:100 Immunotools 
CD14 FITC mouse IgG1 MEM-18 1:100 Immunotools 
HLA-DR PerCP-Cy5.5 mouse IgG2a L243 1:5 BD 
CD40 PE mouse IgG2a LOB7/6 1:10 AbD Serotec 
CD45RA PE mouse IgG2b MEM-56 1:100 Immunotools 
CD86 V450 mouse IgG1κ 2331 (FUN-1) 1:10 BD 
CD123 APC mouse IgG2a AC145 1:10 Miltenyi 
CD141 (BDCA-3) APC mouse IgG1 AD5-14H12 1:10 Miltenyi 
CD273 PE mouse IgG1κ MIH18 1:10 BD 
CD274 PE-Cy7 mouse IgG1κ MIH1 1:10 BD 
CD303 (BDCA-2) FITC mouse IgG1 AC144 1:10 Miltenyi 
      
Intracellular markers:      
FoxP3 AlexaFluor 647 mouse IgG1 259D/C7 1:10 BD 
IFN-γ PerCP-Cy5.5 mouse IgG1κ 4S.B3 1:10 eBioscience 
IL-10 BrillViolet 421 rat IgG1κ JES3-9D7 1:10 BioLegend 
IL-17A PE mouse IgG1 BL168 1:10 BioLegend 
 
 
  
Table 2.2 Compilation of antibodies used for flow cytometry 
This table provides a summary of all antibodies used throughout this study for flow cytometry analysis. 
Specificity, isotype, clone and host species are listed together with dilutions used for staining. 
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Protocol: 
All antibodies used in this study are listed in Table 2.1 together with their working 
dilutions. 
Samples for surface marker staining were transferred into microcentrifuge vials and 
washed with FACS buffer before incubation with antibodies diluted in FACS buffer 
for 30 mins at 4˚C in the dark. Cells were then washed 2x and samples were 
transferred into FACS tubes for acquisition. 
For intracellular detection of cytokines, cell were incubated with Monensin solution 
for 6 hours before harvesting. Surface marker staining was performed as described 
above, after which cells were fixed by incubation with Fixation Buffer for 20 mins in 
the dark at RT. After centrifugation, Fixation Buffer was discarded and cells were 
washed 5x in Permeabilization Buffer. Subsequently, cells were stained for 20 mins in 
the dark at RT with desired antibodies diluted in Permeabilization Buffer. Cells were 
washed 2x with Permeabilization Buffer and 1x in FACS buffer before being 
transferred into FACS tubes for acquisition. 
For FoxP3 staining, T cells were first stained with a CD3 antibody according to the 
surface marker staining procedure described above. After the second wash with FACS 
buffer, the samples were pulse vortexed and incubated with FoxP3 
Fixation/Permeabilization working solution for 30 mins in the dark at RT. After 
permeabilization, cells were washed 1x with Permeabilization Buffer, and 
subsequently incubated with the FoxP3 antibody diluted in Permeabilization Buffer for 
30 mins in the dark at RT. After washing 1x with Permeabilization Buffer and 1x with 
FACS buffer, cells were transferred into FACS tubes for acquisition. 
Viability assessment was performed for selected experiments to investigate whether 
ovarian carcinoma associated ascites influenced viability of monocyte-derived DC. 
This staining was therefore conducted separately and not in combination with other 
surface markers. The protocol recommended by the manufacturer was followed. 
Briefly, fluorescent reactive dye was reconstituted in DMSO provided in the kit and 
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diluted 1:1000 in PBS. Cells were incubated with this working solution for 30 minutes 
on ice and washed once. Subsequently, cells were fixed in paraformaldehyde (4% 
working dilution in PBS) for 15 minutes at RT. Cells were washed once with FACS 
buffer and transferred into FACS tubes for acquisition. 
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2.15 Cytokine analysis of cell culture supernatants 
 
2.15.1 Flow Cytomix 
 
Material: 
Flow Cytomix Simplex Kits specific for detection of human IL-6, TNF-α, IL-1β, IL-2, 
IL-4, IL-10, IFN-γ, IL-17A/F (eBioscience) 
Flow Cytomix Basic Kit (eBioscience) 
FACS tubes (BD) 
FACS Canto II (BD) 
Flow Cytomix Analysis Software (eBioscience) 
 
Protocol: 
For analysis of cytokines in cell culture supernatants obtained from activation assays 
with monocyte-derived DC, a combination of Flow Cytomix Simplex Kits for 
detection of IL-6, TNF-α, IL-10 and IL-1β was used. For IL-6 and TNFα, 
supernatants were diluted 1:10 with assay buffer provided in the Flow Cytomix basic 
kit in order to ensure the values fell within sensitivity range of the assay. For 
measurement of IL-10 and IL-1β, supernatants were used undiluted. For analysis of 
cell culture supernatants from allogeneic MLR experiments, Flow Cytomix Simplex 
Kits for detection of IL-2, IL-4, IL-10, IFN-γ and IL-17A/F were used in combination. 
The manufacturer’s protocol for Simplex Kits was followed using dilution buffers, 
reagents and a 96-well filter plate all provided in the Flow Cytomix Basic Kit. Samples 
were transferred into FACS tubes for acquisition on the FACS Canto II, and data was 
analyzed and quantified using Flow Cytomix Analysis Software. 
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2.15.2 ELISA for detection of TNF-α  
 
Material: 
Human TNF-α ELISA MAX Standard Set (BioLegend; cat. no. 430203) containing 
- TNF-α capture antibody, purified (isotype and clone not specified by 
BioLegend) 
- TNF-α detection antibody, biotinylated (isotype and clone not specified by 
BioLegend) 
- TNF-α standard, lyophilized 
- Avidin-HRP 
Immuno MAXISORP plates, 96 wells (Nunc, Roskilde, Denmark) 
Wash Buffer (1 x PBS containing 0.05% Tween 20) 
1 x PBS (Gibco Life Technologies) 
Assay Diluent (1 x PBS containing 10% heat-inactivated FCS) 
3,3’5,5’-Tetramethylbenzidine (TMB) Substrate (BD) 
Stop Solution (2NH2SO4) 
 
Protocol: 
ELISA plates were coated with TNF-α capture antibody diluted in PBS (1:200 dilution 
of stock solution; absolute antibody concentration is not specified by BioLegend) and 
incubated overnight at 4˚C. All subsequent incubations were performed on a 
microplate shaker, and between each two steps, plates were washed 4x with ELISA 
wash buffer. Non-specific binding sites were blocked with Assay Diluent and 
incubated for 1 hour at RT, after which TNF-α standard and samples were added to 
triplicate wells appropriately diluted in Assay Diluent. Samples without TLR agonists 
or those stimulated with TLR3 agonist poly I:C were measured neat. Samples 
stimulated with R848 or LPS were diluted 1:10 or 1:50 in order to ensure that the 
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values fell within the sensitivity range of the assay. Where αIL-10 antibody had been 
added to cultures, a dilution of supernatants of 1:100 or 1:200 was necessary.  After 
incubation for 2 hours at RT, TNF-α detection antibody diluted in Assay Diluent 
(1:200 dilution of stock solution; absolute antibody concentration is not specified by 
BioLegend) was added to all wells for 1 hour at RT followed by application of avidin-
HRP for 30 minutes at RT. A thorough wash 5x was followed by application of TMB 
substrate. The reaction was stopped by adding stop solution, optical density (OD) was 
measured on an ELISA microplate reader and all samples evaluated with reference to 
the standard curve for cytokine quantification. 
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2.15.3 ELISA for detection of IL-6 and IL-12p40 
 
Material: 
Immuno MAXISORP plates, 96 wells (Nunc) 
Coating Buffer (0.1M Na2HPO4, pH 9.0) 
Wash Buffer (1 x PBS containing 0.05% Tween 20) 
ELISA Buffer (1 x PBS containing 2.5% FCS and 0.02% NaN3) 
IL-6 capture antibody, purified (BD) (rat IgG1 clone MQ2-13A5; 0.5 mg/ml) 
IL-6 detection antibody, biotinylated (BD) (rat IgG2a clone MQ2-39C3; 0.5 mg/ml) 
IL-6 Standard, in buffered solution (BD) 
IL-12p40 capture antibody, purified (BD) (mouse IgG1 clone C8.3; 1 mg/ml) 
IL-12p40 detection antibody, biotinylated (BD) (mouse IgG1 clone C8.6; 0.5 mg/ml) 
IL-12p40 Standard, in buffered solution (BD) 
ExtrAvidin®-Alkaline Phosphatase (Sigma-Aldrich) 
SIGMAFAST p-Nitrophenyl phosphate (PNPP) Tablets (Sigma-Aldrich) 
 
Protocol: 
ELISA plates were coated with respective capture antibody diluted in coating buffer 
(for IL-6 1:125 dilution of stock, 4 µg/ml coating concentration; for IL-12p40 1:200 
dilution of stock, 5 µg/ml coating concentration) and incubated overnight at 4˚C. 
Plates were washed 2x with wash buffer and non-specific binding sites were blocked 
by incubating all wells with ELISA buffer for 2 hours at RT. After washing 2x, 
standard and samples were added to triplicate wells at appropriate dilutions in ELISA 
buffer. For both IL-6 and IL-12, supernatants were diluted in the same way. Samples 
without TLR agonists or those stimulated with TLR3 agonist poly I:C were measured 
neat. Samples stimulated with R848 or LPS were diluted 1:10 or 1:50 in order to 
ensure that the values fell within the sensitivity range of the assay. Where αIL-10 
antibody had been added to cultures, a dilution of supernatants of 1:50 or 1:100 was 
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necessary. After overnight incubation at 4˚C, plates were washed 4x and respective 
detection antibody (for both IL-6 and IL-12p40 1:200 dilution of stock, 2.5 µg/ml 
detection antibody concentration) was added to all wells and allowed to incubate for 1 
hour at RT. After 4x washing, Extravidin-AP was added to all wells and plates were 
incubated for 1 hour at RT. A 4x wash was followed by application of PNPP substrate 
tablets dissolved in water. OD was measured on an ELISA microplate reader and all 
samples evaluated with reference to the standard curve for cytokine quantification. 
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2.15.4 ELISA for detection of mouse IgG1 and mouse IgG2b 
 
Material: 
Immuno MAXISORP plates, 96 wells (Nunc) 
1 x PBS (Gibco Life Technologies) 
Wash Buffer (1 x PBS containing 0.05% Tween 20) 
Assay Diluent (1 x PBS containing 10% heat-inactivated FCS) 
Anti-mouse IgG1 antibody, purified (rat IgG clone RMG1-1) (BioLegend) 
Anti-mouse IgG2b antibody, purified (rat IgG clone RMG2b-1) (BioLegend) 
Anti-mouse IgG antibody, biotinylated (goat Ig clone Poly4053) (BioLegend) 
ExtrAvidin®-Alkaline Phosphatase (Sigma-Aldrich) 
SIGMAFAST p-Nitrophenyl phosphate (PNPP) Tablets (Sigma-Aldrich) 
 
Protocol: 
ELISA plates were coated with respective capture antibody diluted in PBS (for both 
anti-mouse IgG1 and IgG2b 1:250 dilution of stock, 2 µg/ml coating concentration) 
and incubated overnight at 4˚C. Plates were washed 2x with wash buffer and non-
specific binding sites were blocked by incubating all wells with Assay Diluent for 2 
hours at RT. After washing 2x, standard and samples were added to triplicate wells at 
appropriate dilutions in ELISA buffer. The anticipated IgG concentrations were 
difficult to estimate, and therefore a wide range of sample dilutions (undiluted, 1:10, 
1:100, 1:1000, 1:10000) was used in all ELISA experiments to ensure that the values 
fell within the sensitivity range of the assay. After overnight incubation at 4˚C, plates 
were washed 4x and biotinylated detection antibody (1:1000 dilution of stock, 
0.5 µg/ml detection antibody concentration) was added to all wells and allowed to 
incubate for 1 hour at RT. After 4x washing, Extravidin-AP was added to all wells and 
plates were incubated for 1 hour at RT. A 4x wash was followed by application of 
PNPP substrate tablets dissolved in water. OD was measured on an ELISA microplate 
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reader and all samples evaluated with reference to the standard curve for cytokine 
quantification. 
 
 
 
2.16 Cytokine analysis of malignant ascites and benign peritoneal fluid samples 
 
Material: 
PGE2 Parameter Assay kit (Arbor Assays, Ann Arbor, MI, U.S.A.) 
CTLA-4 Platinum ELISA kit (eBioscience) 
Arginase-1 ELISA kit (Hycult Biotech, Uden, The Netherlands) 
LIF ELISA kit (R&D) 
VEGF-α, CCL18, IL-6, IL-10, TNFα, IFN-γ and IL-17 matched antibody pairs (all 
R&D) 
 
Protocol: 
For measurement of PGE2, CTLA-4 and Arginase-1, the manufacturer’s specific 
instructions provided with each kit were followed closely. For CTLA-4, a dilution of 
ascites samples of 1:2 was used. For PGE2, samples were measured diluted either 1:2, 
1:10 or 1:20. For Arginase-1, ascites samples were diluted 1:2 or 1:10. 
The measurements of LIF, VEGF-α, CCL18, IL-6, IL-10, TNFα, IFN-γ and IL-17 in 
malignant ascites and benign peritoneal fluid samples were performed by Dr. Ann 
Jagger and Dr. Hayley Evans from the research group of Dr. Leonie Taams (Centre for 
Molecular & Cellular Biology of Inflammation, King’s College London). 
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2.17 Statistical analysis 
Data were analyzed using PRISM Graph Software (La Jolla, California, U.S.A.). 
Appropriate statistical tests were applied for different experiments, taking into 
consideration the composition of each experiment, relevant experimental cohorts and 
scientific questions. Differences were considered significant at a p-value < 0.05. 
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Chapter 3 
 
Impact of ovarian carcinoma associated ascites on TLR-
mediated monocyte-derived DC activation 
 
Introduction 
 
Development of ascites is a clinical hallmark of many peritoneal cancers, with all 
ovarian carcinoma patients at late stages of their disease presenting with substantial 
amounts of accumulated liquid within the peritoneal cavity. As outlined in chapter 1, 
the composition of ovarian carcinoma associated ascites is complex and harbours a 
plethora of soluble immunosuppressive factors (Yigit et al., 2011a). These proteins 
within the fluid influence and act upon surrounding cells of the tumour environment, 
including DC which have been shown to be present in ascites from ovarian carcinoma 
patients (Wertel et al., 2008). Many experimental immunotherapeutic approaches aim 
to activate DC subsets in situ in various tumour models, and these concepts are being 
explored in our laboratory as well as by other research groups worldwide (Tacken and 
Figdor, 2011;Ueno et al., 2011;Kreutz et al., 2012). TLR agonists are frequently used 
as adjuvants in this context, their immunostimulatory capacity and potential to boost 
vaccine efficacy having been convincingly documented by numerous studies (Duthie 
et al., 2011). 
One of the challenges faced in vaccination strategies aiming to target and activate DC 
in situ is that of interference of local immunosuppressive factors with the activatory 
stimulus delivered by the vaccine. These can be present either in form of soluble 
components of the tumour environment, which have been shown in previous studies to 
influence DC phenotype and function in ovarian carcinoma (Gabrilovich et al., 
1996;Conejo-Garcia et al., 2004). However, direct contact between DC and other 
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suppressive leukocytes as well as tumour cells may also alter activation and phenotype 
of DC. It is of course desirable to gradually gain an understanding of these complex 
influences of the tumour environment in their entity, but a dissection into cell-cell 
interactions and soluble factors can be very helpful when trying to attribute observed 
effects to individual factors. In our study, we therefore removed tumour cells and 
infiltrating leukocytes by centrifugation and sterile filtration before use of ascites 
samples in our assays, allowing us to focus exclusively on soluble factors within the 
ovarian carcinoma environment and their impact on TLR-mediated DC activation, 
bearing in mind however that in vivo, cell-cell interactions equally play a role in 
immunosuppression in ovarian carinoma. Understanding the immediate tumour 
environment is of considerable importance and promise in ovarian carcinoma. Given 
its localized nature with restriction of metastases to the peritoneal cavity even in late 
stages of the disease, tackling the hurdles that these local factors pose to 
immuotherapeutic approaches could improve experimental concepts even in advanced 
clinical stages. 
With particular regard to our study, we were interested to learn whether soluble factors 
within ovarian carcinoma associated ascites influence activation of DC with TLR 
agonists and if so, how DC reconcile these signals from the tumour environment with 
TLR-mediated activation. DC are a rare leukocyte type, only comprising 
approximately 1% of mononuclear cells in human peripheral blood. In the early years 
after their characterization (Van Voorhis et al., 1982), the lack of standardized 
methods for enrichment of DC as well as their paucity made studies of primary human 
DC very challenging and therefore sparse. While simple methods for purification of 
DC from PBMC have become widely available, the low numbers of this cell type in 
peripheral blood continue to pose a challenge and restrict the feasibility and execution 
of assays performed with primary DC populations. The discovery that DC could be 
generated from the much more frequent peripheral blood monocytes in vitro with the 
use of recombinant GM-CSF and IL-4 (Sallusto and Lanzavecchia, 1994;Bender et al., 
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1996;Pickl et al., 1996;Romani et al., 1996) propelled the research on human DC 
forward immensely, allowing for the generation of large numbers of these cells and 
making detailed studies of human DC characteristics and functions in many different 
experimental settings practicable.  
In our study, we were interested to investigate TLR-mediated activation of human DC 
in presence of ovarian carcinoma associated ascites. No protocols for these particular 
study aims had been previously established in our laboratory, and it was therefore 
necessary to design and optimize experimental procedures. The ethical approval of our 
study only allows for withdrawal of 100 ml of peripheral blood from each healthy 
volunteer at any one time, and the numbers of primary DC that could be obtained from 
this material would therefore not be sufficient to perform assays with numerous 
samples. We intended to employ several different TLR agonists and varied culture 
conditions in terms of ascites concentration, and for these reasons, we have chosen to 
use monocyte-derived DC as an experimental model to study the influence of ovarian 
carcinoma associated ascites on TLR-mediated activation of DC. The insights gained 
from these experiments would then allow us to perform assays with primary DC using 
a few chosen conditions affording a much smaller number of samples. 
Monocyte-derived DC share many properties of primary myeloid DC and are therefore 
regarded as a suitable model system for in vitro studies of DC. They exhibit DC 
morphology and express phenotypic markers typical for myeloid DC, such as high 
levels of CD1a, CD11c, HLA-DR, CD40 and CD80, and lack the monocyte marker 
CD14. Their antigen presentation and T cell stimulatory capacity in MLR is 
remarkable and exceeds that of other APC such as B cells (Sallusto and Lanzavecchia, 
1994;Pickl et al., 1996). Despite these indisputable similarities to primary myeloid DC, 
caution should be taken when extrapolating findings to primary DC subsets. It remains 
unclear to what extent DC generation from monocytes takes place in vivo. Some 
reports suggest that monocytes differentiate into DC under inflammatory conditions, 
and such inflammatory DC, referred to as ‘Tip-DC’ (tumor-necrosis-factor and 
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inducible nitric oxide synthase-producing inflammatory DC), could represent an 
equivalent to in vitro generated monocyte-derived DC (Rivollier et al., 2012). 
However, Tip-DC have been shown to develop normally in GM-CSF receptor 
deficient mice (Greter et al., 2012). With increasing awareness of the dynamic nature 
of blood leukocyte populations, studies relying on identification and classification of 
DC subsets according to their development pathways from bone marrow progenitors 
are gaining more recognition and importance (Satpathy et al., 2012). In this respect, 
regardless of what their in vivo equivalent may be, monocyte-derived DC are defined 
as progeny of the monocyte/macrophage lineage, and it is therefore only natural that 
they bear certain differences to primary DC subsets. It is imperative that these 
distinctions are considered when interpreting and drawing conclusions from studies 
using monocyte-derived DC. 
Despite these reservations, monocyte-derived DC remain a useful and widely accepted 
tool in the field of human DC research, and the following chapters outline our findings 
when using these cells to elucidate the influence that soluble factors within the ovarian 
carcinoma environment exert on TLR-mediated DC activation. 
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3.1 In vitro generation of monocyte-derived DC 
 
Human primary DC subsets are sparse in peripheral blood, and the amount of blood 
that can be drawn at any one timepoint from a healthy volunteer for research purposes 
in our study is restricted to 100 ml due to ethical regulations. Myeloid DC constitute 
approximately 0.5-1% of PBMC, and hence the number of primary DC obtained from 
these amounts of peripheral blood is insufficient when performing activation assays 
comprising several different cell culture conditions. Therefore, for this study, we used 
in vitro generated monocyte-derived DC as a model system to study the influence of 
ovarian carcinoma-associated ascites on TLR-mediated DC activation. 
Monocytes were isolated from peripheral blood of healthy volunteers by negative 
magnetic selection. The purity of the isolated CD14
+
 monocytes as assessed by flow 
cytometry was consistantly above 90% (Figure 3.1 A). The untouched monocytes were 
cultured for 7 days in presence of GM-CSF (20 ng/ml) and IL-4 (20 ng/ml), resulting 
in their differentiation into monocyte-derived DC over this time period. In the course 
of their differentiation, the cells underwent morphological changes resulting in 
increased granularity and cell size as detected by flow cytometry (Figure 3.1 B; please 
note the different scale in both forward scatter (FSC; x-axis) and sideward scatter 
(SSC; y-axis)). The differentiation was verified by flow-cytometric surface marker 
analysis (Figure 3.1 C). Surface marker CD14 is expressed in high levels on 
monocytes, and is gradually down-regulated in the course of differentiation into 
monocyte-derived DC, although low levels are detectable even after 7 days. Surface 
marker CD1a behaves in opposing fashion, with freshly isolated monocytes being 
negative for this protein while it is highly expressed by monocyte-derived DC. 
Interestingly, two distinct populations, CD1a
int
 and CD1a
hi
, can be identified on day 7. 
A previous report has described this phenomenon and the authors attributed 
differential cytokine secretion profiles and capacity to skew TH cell differentiation to 
these two populations (Chang et al., 2000). In this project, we used both populations 
Chapter 3 Results 
 85 
together and did not further investigate their functional differences in our assays. Cells 
were harvested on day 7 and used in activation assays as described below. 
  
Figure 3.1 Differentiation of CD14
+
 monocytes into monocyte-derived DC 
(A) Monocytes from healthy volunteers were enriched from PBMC by negative magnetic selection, 
and their purity was regularly assessed by flow cytometry. Shown is a representative example of a 
staining profile, indicating a purity of 92.6% CD14
+
 monocytes after gating on all cells excluding 
couplets and debris. (B) After 7 days of culture in the presence of GM-CSF and IL-4, the size and 
granularity of the cells increased considerably. Please note the difference in scale on both x- and 
y-axis. (C) The differentiation of monocytes into DC was verified by surface marker staining for CD14 
and CD1a. The bigger size of cells on day 7 led to higher autofluorescence and background staining, 
resulting in higher CD14 and CD1a background levels on day 7 (grey shaded curves).  
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3.2 Activation of monocyte-derived DC with TLR agonists 
 
In order to study the influence of ovarian carcinoma-associated ascites on 
TLR-mediated DC activation, the establishment of experimental protocols that ensure 
a robust activation of monocyte-derived DC with TLR agonists was essential. 
Monocyte-derived DC have been described to express high levels of TLR2 and TLR4 
and low levels of TLR1, TLR3, TLR5, TLR6 and TLR8 (Jarrossay et al., 2001). Based 
on these reports, we conducted pilot experiments, subjecting monocyte-derived DC to 
an overnight incubation in complete medium either without stimulant, or with addition 
of TLR3 agonist poly I:C, TLR4 agonist LPS or TLR7/8 agonist R848 (Figure 3.2). In 
order to determine the concentrations that induced optimal activation of monocyte-
derived DC, three concentrations were chosen for each TLR agonist based on 
published literature and previous experience in our laboratory, and tested in this initial 
assay. As a read-out for activation of DC, the cytokine IL-6 was measured by ELISA 
in cell culture supernatants after overnight incubation (Figure 3.2 A). When cells were 
cultured in medium only without TLR stimulus, no IL-6 production was detectable 
(Figure 3.2 A, ‘medium’ value in the first graph). In response to R848 and LPS, 
monocyte-derived DC produced substantial levels of IL-6 in a dose-dependent fashion, 
with higher TLR agonist concentrations showing greater IL-6 induction. The two 
highest concentrations of TLR3 agonist poly I:C also induced notably higher IL-6 
levels than untreated cells, the concentrations reached were however 20- to 40-fold 
lower than after stimulation with LPS or R848, respectively. 
To further verify monocyte-derived DC activation by all three TLR agonists, we 
assessed the expression of the surface markers CD86, CD40 and HLA-DR by flow 
cytometry after overnight incubation with the two highest previously tested 
concentrations of each TLR agonist (Figure 3.2 B). Incubation with R848 and LPS 
induced a robust up-regulation of all three surface molecules at both tested 
concentrations. CD86 was also up-regulated in presence of both concentrations of 
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poly I:C, while HLA-DR up-reglation was only induced by 30µg/ml of poly I:C and 
CD40 levels remained unchanged in presence of poly I:C altogether. 
Our laboratory has extensive experience with CpG oligodeoxynucleotides as potent 
activators of DC via TLR9, and controversial reports in the literature regarding the 
expression of TLR9 on monocyte-derived DC (Jarrossay et al., 2001;Hoene et al., 
2006;Diebold, 2009) prompted us to include these TLR9 agonists in our pilot assay to 
assess whether they induce detectable activation of these cells in our experimental 
setup. Three different classes of CpG oligodeoxynucleotides (CpG-A, CpG-B and 
CpG-C) were tested at three different concentrations each. We could detect neither an 
enhanced IL-6 production, nor an increase in CD86 up-regulation compared to 
untreated cells (data not shown). This lack of activation by CpG 
oligodeoxynucleotides did not support the previously published reports where TLR9 
expression and responsiveness to CpG stimuli were attributed to monocyte-derived DC 
(Hoene et al., 2006), but were rather in line with studies where lack of response to 
CpG oligodeoxynucleotides by monocyte-derived DC was seen (Bauer et al., 2001).  
Based on the data from these initial assays, for subsequent experiments in this research 
project, we used TLR3 agonist poly I:C (100 µg/ml), TLR4 agonist LPS (1 µg/ml) and 
TLR7/8 agonist R848 (3 µg/ml) to study the influence of ovarian carcinoma associated 
ascites on monocyte-derived DC activation mediated via TLR. 
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Figure 3.2 Titration of TLR agonists for activation of monocyte-derived DC. 
(A) Monocyte-derived DC were cultured overnight in complete medium either in absence of 
TLR stimuli, or with addition of TLR agonists R848, LPS or poly I:C (pI:C) at the indicated 
concentrations. IL-6 levels were measured by ELISA in cell culture supernatants, and (B) for each 
TLR agonist, the two concentrations that induced the highest IL-6 levels were further tested with 
regards to up-regulation of the surface molecules CD86, CD40 and HLA-DR as assessed by flow 
cytometry. Samples for cytokine assessment were performed in triplicate wells on a 96-well plate, 
while cells for flow cytometric analysis were cultured in 24-well plates. One pilot experiment was 
conducted each for cytokine and surface marker assessment (n=1). 
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3.3 In vitro viability of monocyte-derived DC in presence of ovarian 
carcinoma associated ascites 
 
In order to study the impact of ascites from ovarian carcinoma patients on the 
activation of monocyte-derived DC in this project, we intended to add ascites to 
overnight in vitro cultures at the concentrations of 10% or 25%. A necessary factor to 
consider in this experimental setup was the potential influence of ascites on the 
viability of monocyte-derived DC. This question was important to address, because 
increased cell death in culture wells containing ascites compared to others could skew 
our data by influencing the markers that we used as a read-out for DC activation.  We 
therefore performed experiments to assess cell viability after overnight culture in 
presence of 25% ascites. We studied the influence of ascites on the viability of both 
cells activated by R848 as well as not activated cells (Figure 3.3). The fixable viability 
dye used has the ability to react with cell amines, staining amines on the cell surface of 
live cells resulting in a relatively dim fluorescence (first histogram peak). Dying cells 
are equally stained on their surface, but in addition, because the integrity of the cell 
membrane is compromised, the dye penetrates the cells, reacting also with free amines 
inside the cells. This results in a higher fluorescence signal compared to live cells, 
detectable as a second peak in the histogram. As a positive control for cell death, we 
cultured cells in medium not supplemented with FCS (incomplete medium). Here, we 
detected an increased rate of cell death compared to cells cultured in complete 
medium, with over 20% versus 5% of cells losing viability after overnight culture. 
We observed a slight increase in death rate in cells activated with R848 as compared to 
cells cultured without TLR stimulus (approx. 10% versus 5%). Importantly however, 
cell death was unaffected by presence of 25% ascites regardless of whether cells were 
concomitantly activated with R848 or not. These data confirmed that the use of  
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up to 25% of ascites from ovarian carcinoma patients in our in vitro cultures of 
monocyte-derived DC did not compromise cell viability and this experimental setup 
was therefore suited to study the influence of ascites on TLR-mediated DC activation. 
 
 
  
Figure 3.3 Ovarian carcinoma associated ascites does not impair cell viability in vitro. 
Monocyte-derived DC were cultured overnight in presence or absence of ascites from ovarian 
carcinoma patients (25% final concentration in cell culture) with or without TLR7/8 agonist R848. After 
harvest, cells were stained with a fixable viability dye (Live/Dead Aqua®). The upper panel shows 
gating on all cells excluding debris in the forward vs. sideward scatter. In the lower panel, viable cells 
are shown as the left histogram peak (lower fluorescence intesity), while dying cells show higher 
fluorescence levels and are visible as the second histogram peak. A representative example of 3 
independent experiments is shown (n=1). 
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3.4 Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
monocyte-derived DC activation in vitro 
 
Assessment of the effects of ovarian carcinoma associated ascites on the activation of 
monocyte-derived DC by TLR agonists in vitro was a central point of interest in our 
study. Having established protocols that ensure robust activation of monocyte-derived 
DC with the TLR agonists poly I:C, LPS and R848 (see above; Figure 3.2), in the 
following set of experiments, we added cell-free, sterile-filtered ascites to our cultures 
to study its influence on the cells’ activation. To provide sufficient nourishment and 
growth conditions for overnight cultures of monocyte-derived DC, complete, 
supplemented medium was used and the concentration of ascites was limited to 10% or 
25%. 
 
3.4.1 Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
up-regulation of CD86 but not CD40, HLA-DR or PD-L1 
 
After overnight incubation under varying cell culture conditions, expression levels of a 
range of surface markers were measured by flow cytometry. These data were used as a 
read-out to evaluate monocyte-derived DC activation by TLR agonists in vitro in 
absence versus presence of ovarian carcinoma associated ascites. Upon activation with 
R848, LPS or poly I:C, we observed a reduced up-regulation of the co-stimulatory 
molecule CD86 in presence of ascites (Figure 3.4 A). This effect was consistent when 
treating monocyte-derived DC from the same healthy donor with ascites samples from 
several ovarian carcinoma patients, as well as when using ascites from one patient in 
assays with monocyte-derived DC from different healthy controls. We observed 
statistically significant CD86 suppression at a concentration of 25% ascites in cell 
culture for all three TLR agonists. When  
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Figure 3.4 Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
up-regulation of CD86. 
(A) Monocyte-derived DC were stimulated overnight with 3µg/ml R848, 1µg/ml LPS, 100µg/ml 
polyI:C in the presence of 0%, 10% or 25% of ascites from patients with ovarian carcinoma. 
Alternatively (B) no TLR stimuli were added to cell cultures. The mean fluorescence intensity 
(MFI) of the surface markers CD86 and (C) HLA-DR and (D) CD40 was assessed by flow 
cytometry. n=12 (DC from six different healthy volunteers, encoded by six colours, were cultured 
with ascites from 5 different ovarian carcinoma patients, encoded by different symbols. Altogether, 
12 independent experiments were performed.; One-way ANOVA (Friedman test with Dunn post 
test): * = p<0.05; ** = p<0.01; *** = p<0.001; ns = not significant. 
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cells were activated with TLR7/8 agonist R848, the lower concentration of 10% of 
ascites in culture was already sufficient to significantly reduce CD86 levels. In most 
experiments, presence of 10% of ascites also led to reduced CD86 levels upon 
activation with LPS or poly I:C, but this was not statistically significant, most likely 
due to several donors within the cohorts where no suppression was observed. Cells that 
were not activated via TLR did not show ascites-induced reduction of CD86 levels 
(Figure 3.4 B). 
The impact of ascites on the up-regulation of surface markers HLA-DR and CD40 
(Figure 3.4 C-D) upon TLR activation was not consistent in our experiments and 
mostly showed no clear suppression pattern. In presence of 25% ovarian carcinoma 
associated ascites, poly I:C activated DC did show reduced HLA-DR levels, and when 
activated with LPS, partially impaired CD40 up-regulation was observed. These 
differences were, however, rather small and somewhat overshadowed by an overall 
lack of consistency across different blood donors and ascites samples when monitoring 
these two surface markers. 
In a limited number of experiments, we further examined the expression levels of the 
molecules programmed cell death 1 ligand 1 (PD-L1) (CD274) and OX-40 ligand 
(OX-40L) (CD252) on monocyte-derived DC, because they are important markers of 
DC activation and bear essential roles in the process of co-stimulation and/or co-
inhibition of T cells during antigen presentation. In these experiments, only 10% of 
ascites in culture was used in conjuction with TLR activation (Figure 3.5). Upon 
activation with R848 and LPS, PD-L1 expression was up-regulated but levels were not 
significantly altered in presence of 10% ovarian carcinoma associated ascites 
(Figure 3.5 A). Poly I:C did not induce a significant up-regulation of PD-L1, and it is 
therefore difficult to interpret the reduction of PD-L1 expression in presence of ascites 
which appears statistically significant. It is important to note that only 3 independent 
experiments are available and summarized in the graph depicting poly I:C stimulation, 
and that the MFI values were subject to large variation between donors.  
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More repeats of this assay using poly I:C would be necessary to conclusively interpret 
these data. 
Assessment of the expression levels of OX-40L indicated that this molecule is not 
up-regulated on monocyte-derived DC upon stimulation with all three TLR agonists 
used in our study, and addition of ovarian carcinoma associated ascites equally did not 
alter OX-40L levels (Figure 3.5 B). 
  
Figure 3.5 Influence of TLR agonists and ovarian carcinoma associated ascites on 
expression levels of cell surface markers PD-L1 and OX-40L. 
Monocyte-derived DC were cultured without stimuli (‘medium’) or stimulated overnight with 3µg/ml 
R848, 1µg/ml LPS, 100µg/ml polyI:C. Ovarian carcinoma associated ascites was added to 
cultures at a final concentration of 10% where indicated. (A) The mean fluorescence intensity 
(MFI) of the surface markers PD-L1 (CD274) and (B) OX-40L (CD252) was assessed by flow 
cytometry. For PD-L1 R848 n=10, LPS n=5, poly I:C n=3. For OX-40L R848 n=6, LPS n=4, 
poly I:C n=3. One-way ANOVA (Friedman test with Dunn post test): * = p<0.05; ** = p<0.01; *** = 
p<0.001; ns = not significant. 
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3.4.2 Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
production of IL-6, IL-12p40 and TNFα  but not IL-1β  or IL-10 
 
When cultured in complete medium without any stimuli overnight, monocyte-derived 
DC do not produce detectable levels of any cytokines measured in our study. However, 
upon activation with TLR agonists, monocyte-derived DC produce an array of 
cytokines which, in addition to surface marker expression, can function as read-out 
parameters for cell activation (Figure 3.6 A). In our study, we monitored the levels of 
the cytokines IL-6, TNFα, IL-12p40, IL-1β and IL-10, and this provided an additional 
way to CD86 up-regulation to assess the impact of ascites on TLR-mediated 
monocyte-derived DC activation in our experimental setup. After overnight cultures, 
supernatants were harvested and cytokine levels were measured by ELISA. 
Upon activation with TLR7/8 agonist R848 and TLR4 agonist LPS, monocyte-derived 
DC produced high levels of the pro-inflammatory cytokine IL-6, and we further 
observed high production of TNFα and IL-12p40. In comparison, the TLR3 agonist 
poly I:C induced low levels of IL-6 and TNFα and failed to induce production of 
IL-12p40 (Figure 3.6 A). Importantly for our scientific question, in cultures activated 
with R848 and LPS, in presence of both 10% or 25% ascites, the levels of the 
cytokines IL-6, IL-12p40 and TNFα were significantly reduced (Figure 3.6 B). The 
suppression was robust and reproducible with monocyte-drived DC from different 
healthy donors as well as ascites samples from several ovarian carcinoma patients. 
Upon poly I:C activation, addition of ascites did not significantly reduce IL-6 
production, and although statistical analysis indicated suppressed TNFα levels upon 
addition of ascites, the importance of this finding may be limited due to the overall low 
levels of this cytokine induced in response to TLR3 stimulation (Figure 3.6 B). 
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Figure 3.6 Ovarian carcinoma associated ascites partially suppresses TLR-mediated 
production of IL-6, IL-12 and TNFα . 
(A) Monocyte-derived DC were stimulated overnight with 3µg/ml R848, 1µg/ml LPS or 100µg/ml 
polyI:C and (B-C) ascites from patients with ovarian carcinoma was either absent (0%) or added to 
cultures at concentrations of 10% or 25%. IL-6, TNFα, IL-1β and IL-10 levels were measured in cell 
culture supernatants by bead ELISA (Flow Cytomix), IL-12p40 was measured by sandwich ELISA. 
For IL-6, IL-12p40 and TNFα: n=12 (DC from six different healthy volunteers were cultured with 
ascites from 5 different ovarian carcinoma patients. Altogether, 12 independent experiments were 
performed. Cells from three volunteers were cultured with only one ascites sample each, while cells 
from the remaining three donors were cultured with two, three or four different ascites samples, 
respectively. For IL-1β and IL-10: n=9 (DC from six different healthy volunteers cultured with ascites 
from 5 different ovarian carcinoma patients. Altogether, 9 independent experiments were performed. 
Cells from four volunteers were cultured with only one ascites sample each, while cells from the 
remaining two donors were cultured with two or three different ascites samples, respectively). One-
way ANOVA (Friedman test with Dunn post test): * = p<0.05; ** = p<0.01; *** = p<0.001; ns = not 
significant. 
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TLR-mediated activation further induced the production of IL-1β. The effect of ascites 
on its levels, however, varied considerably between donors, and no consistant pattern 
of suppression or enhanced induction in presence of ascites became evident in our 
study (Figure 3.6 C). We further examined levels of the immunosuppressive cytokine 
IL-10, since we hypothesized that in opposing fashion to the pro-inflammatory 
cytokines IL-6, IL-12 and TNFα, IL-10 production by DC may be enhanced by ascites 
to promote an immunoregulatory environment. However, similarly to IL-1β, IL-10 
levels remained unaffected by ascites (Figure 3.6 C).  
Chapter 3 Results 
 98 
3.5 Peritoneal fluid from patients with benign ovarian tumours partially 
suppresses TLR-mediated up-regulation of CD86 and induction of IL-6 
and IL-12 but not TNFα  
 
Our observations of a significant influence of ovarian carcinoma associated ascites on 
the TLR-mediated activation of monocyte-derived DC as outlined on the previous 
pages were intriguing and thought-provoking. However, early on in our study, we 
recognized the need for suitable control material to use in parallel to ascites from 
ovarian carcinoma patients in our experiments. More specifically, we were interested 
in obtaining samples of peritoneal fluid associated with non-malignant conditions in 
order to recognize particular characteristics of the malignant ovarian carcinoma 
environment. Benign ovarian tumours constitute a heterogenous group of conditions 
such as fibromas, fibroadenomas, benign ovarian cysts and others. Although the 
formation of ascites is typically not associated with these conditions, some patients do 
present with a small amount of peritoneal fluid. Such samples were collected by our 
clinical collaborators during surgery for the removal of the patients’ benign tumours of 
the ovary, and we were able to use such benign peritoneal fluid in our activation 
assays. The samples were processed identically to the malignant ascites, removing 
cellular material by centrifugation followed by sterile filtration before use in cell 
cultures. 
We conducted experiments identical in their setup to those with malignant ascites, 
activating monocyte-derived DC from healthy donors with R848, LPS or poly I:C in 
absence or presence of 10% or 25% benign peritoneal fluid. Similarly to the effects 
seen with malignant ascites, we observed a highly significant impairment of CD86 
up-regulation in presence of 25% benign peritoneal fluid when cells were activated 
with either of the studied TLR agonists (Figure 3.7 A). Upon activation with LPS or 
poly I:C, even the lower concentration of 10% peritoneal fluid in culture resulted in 
significantly decreased expression levels of CD86. We further observed impaired 
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production of the cytokines IL-6 and IL-12p40 in presence of 10% or 25% benign 
peritoneal fluid upon stimulation with R848 or LPS. In comparison, as shown 
previously (Figure 3.6 A), activation of monocyte-derived DC with poly I:C failed to 
induce IL-12p40 and led to considerably lower levels of IL-6 than R848 and LPS. We 
detected no suppression of IL-6 upon TLR3 activation in presence of benign peritoneal 
fluid (Figure 3.7 A). 
A further parameter measured as read-out from this activation assay was 
TLR-mediated TNFα induction. Strikingly, we saw no suppression of this cytokine by 
benign peritoneal fluid after R848 or LPS activation whatsoever (Figure 3.7 B). This 
marked an important difference between benign peritoneal fluid and ascites from 
ovarian carcinoma, which, as shown above, impaired TNFα induction significantly 
(see above, Figure 3.6 B). Interestingly, when activated with poly I:C, 25% of benign 
peritoneal fluid showed statistically significant impairment of TNFα production. 
However, as explained previously, given the overall low levels of cytokine induced, 
the importance of this finding may be limited. 
 
Taken together, the collective data from in vitro assays using R848, LPS and poly I:C 
for activation of monocyte-derived DC in absence versus presence of either ovarian 
carcinoma associated ascites or benign peritoneal fluid highlighted 
immunosuppressive properties of both the malignant and benign sample groups. An 
important difference that our data demonstrated was the suppression of the 
pro-inflammatory cytokine TNFα, which was exclusively seen in presence of  
malignant ascites while benign peritoneal fluid left TNF-α levels unaffected. These 
findings supported the notion that the environment of malignant ovarian tumours can 
be distinguished from that of benign conditions, and therefore may affect 
immunological processes in a different way.  
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Figure 3.7 Peritoneal fluid associated with benign ovarian tumours partially suppresses 
TLR-mediated up-regulation of CD86 and production of IL-6 and IL-12 but not TNFα . 
Monocyte-derived DC were stimulated overnight with 3µg/ml R848, 1µg/ml LPS, 100µg/ml polyI:C in 
the presence of 0%, 10% or 25% of peritoneal fluid from patients with benign ovarian tumours. (A) 
CD86 levels were assessed by flow cytometry and the cytokines IL-6, IL-12p40 and (B) TNFα were 
measured in cell culture supernatants by bead ELISA (Flow Cytomix; IL-6 and TNFα) or sandwich 
ELISA (IL-12p40). n=12 (DC from 8 different healthy volunteers were cultured with peritoneal fluid 
from 6 different patients. Altogether, 12 independent experiments were performed. Cells from four 
volunteers were cultured with only one peritoneal fluid sample each, while cells from the remaining 
four donors were cultured with two different peritoneal fluid samples); One-way ANOVA (Friedman 
test with Dunn post test): * = p<0.05; ** = p<0.01; *** = p<0.001; ns = not significant. 
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Discussion 
 
 
TLR mediated activation of DC subsets constitutes an important component of many 
experimental concepts explored in cancer immunotherapy. Notably, vaccine designs 
aiming to activate APC in situ within the tumour environment by targeting specific DC 
subsets are a promising, much studied strategy. In such settings, DC receive stimuli 
promoting their activation delivered by the vaccine during concomitant exposure to the 
tumour environment which often comprises an array of immunosuppressive factors. 
Understanding how DC integrate these conflicting influences is an important step 
towards improved protocols for in situ DC activation in future.  
In this project, we explored the influence of ascites from patients suffering from 
advanced stage ovarian carinoma on DC activation via TLR agonists. For reasons 
outlined in the introduction to this chapter, we have first chosen to use in vitro 
generated monocyte-derived DC to address our scientific questions. 
When sterile filtered, cell-free ascites was added to DC cultures, we observed a 
significant impairment of TLR-mediated up-regulation of the co-stimulatory molecule 
CD86 and production of the cytokines IL-6, IL-12p40 and TNFα. Our results showed 
high reproducibility when monocyte-derived DC from different healthy donors were 
cultured with ascites from the same ovarian carcinoma patient, and equally when DC 
from one healthy donor were either treated with different ascites samples or, in several 
different experiments, repeatedly treated with the same fluid. 
Interestingly, not all markers of activation were affected by the presence of ovarian 
carcinoma ascites, since the TLR agonist-induced increase in the expression levels of 
the surface markers HLA-DR and CD40 remained unchanged. Similarly, the induction 
of the pro-inflammatory cytokine IL-1β and the immunosuppressive protein IL-10 
were not altered by ascites. This shows that ovarian carcinoma ascites exerts its 
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suppressive influence on TLR-mediated DC activation with a certain specificity, 
interferring with distinctive pathways and leaving other unaffected. 
The surface marker CD86, also referred to as B7-2, is a member of the B7 family 
comprising several other co-stimulatory and co-inhibitory molecules expressed by 
APC, most notably CD80 (B7-1) and PD-L1 (B7-H1) and PD-L2 (B7-DC), 
respectively (Greenwald et al., 2005). During antigen presentation, peptides are 
displayed on MHC molecules on the surface of APC and are sensed by TCR on 
T lymphocytes. An accessory signal between the protein CD28 on the surface of 
T cells and CD80 and/or CD86 expressed on APC is necessary for the successful 
priming and activation of the interacting T cell, leading to its expansion, cytokine 
secretion and execution of effector functions. Lack of such co-stimulation results in T 
cell tolerance or anergy (Reis e Sousa, 2006). 
However, in order to prevent uncontrolled and excessive lymphoproliferation, 
engagement of co-inhibitory molecules is crucial after initial activation. Interestingly, 
the same molecules on APC, CD80 and CD86, can convey such abrogating signals by 
interacting with the co-inhibitory cytotoxic T lympocyte antigen-4 (CTLA-4) on 
T cells. The nature of the signal, either co-stimulatory or co-inhibitory, is therefore 
dependent on both molecules participating in the interaction, and receptor promiscuity 
is a common trait of many B7 family members. For example, the co-inhibitory 
molecules PD-L1 and PD-L2 exert their functions by interaction with the receptor 
PD-1, but PD-L1 has recently also been shown to bind to CD80 (Greenwald et al., 
2005;Keir et al., 2008). 
The relative expression levels of co-stimulatory and co-inhibitory molecules on APC 
can influence the outcome of T cell priming, skewing it towards activation or anergy. 
The importance of this balance in the orchestration of an efficient immune response 
against tumours is evident from the promising results achieved with the blockade of 
the co-inhibitory checkpoints by monoclonal antibodies. Clinical trials using CTLA-4 
blocking antibody Ipilimumab and PD-1 blocking antibodies Lambrolizumab and 
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Nivolumab in the treatment of advanced melanoma are currently underway in phase 1 
(Hamid et al., 2013;Wolchok et al., 2013). 
Ovarian carcinoma tumour cells reportedly express the co-inhibitory molecule PD-L1 
and interact with tumour infiltrating lymphocytes (TIL), impairing their cytotoxic 
activity (Hamanishi et al., 2007). This mechanism has also been implicated to promote 
peritoneal dissemination of tumour cells and thereby accelerate disease progression 
(Abiko et al., 2013). 
Macrophages expressing co-inhibitory molecules of the B7 family have been identified 
in the ovarian carcinoma environment and have been shown to suppress the initiation 
of effector T cell responses (Kryczek et al., 2006). A monocyte population with T cell 
inhibitory properties has equally been identified in ovarian carcinoma ascites, lacking 
cell surface expression of the co-stimulatory proteins CD80 and CD86 (Loercher et al., 
1999). Surprisingly, although the physiological relevance of this is unclear, a 
subpopulation of TIL isolated from ovarian carcinoma ascites have been reported to 
express CD80 and CD86 (Melichar et al., 2000). The relevance of the expression of 
these molecules by T cells remains poorly understood, but some evidence from the 
field of transplantation suggests that through interaction with T reg, T cells expressing 
CD80 and CD86 downregulate alloresponses and prevent graft-versus-host-disease 
(GVHD) (Greenwald et al., 2005). The mechanism behind this is thought to be the 
reception of inhibitory signals via CD80 and CD86 from CTLA-4 expressed on T reg 
(Paust et al., 2004). 
These reports collectively point towards presence of certain factors within the ovarian 
carcinoma environment that interfere with the pathways regulating the expression 
patterns of B7 family members in several leukocyte populations. Our findings of 
significantly impaired up-regulation of CD86 on monocyte-derived DC upon TLR 
stimulation in presence of ovarian carcinoma ascites support this notion. In a limited 
number of experiments, we also investigated expression levels of the co-inhibitory 
molecule PD-L1 on DC in absence or presence of ascites upon TLR stimulation, but 
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observed no consistant changes in expression levels of this molecule induced by 
ascites. However, it is important to note that in order to provide cells with favourable 
in vitro growth conditions, we only investigated the influence of up to 25% ascites in 
culture on DC activation. It is possible that this dilution of certain factors within 
ascites led to a reduction of their final cell culture concentration below a threshold 
necessary to exert influence on the levels of PD-L1. 
Additionally, in our study we only addressed the influence of soluble factors within 
ascites on DC activation. Mechanisms that influence surface expression of B7 family 
members may require contact between cellular components of the tumour 
environment. One such process has been identified in a recent study by Qureshi et al., 
where the authors elegantly demonstrated that CD80 and CD86 are removed from the 
surface of APC and internalized by T cells via trans-endocytosis upon interaction with 
CTLA-4 (Qureshi et al., 2011). Similar mechanisms requiring direct cell-cell contact 
could be effecting other surface markers, but these questions were not addressed in our 
study. 
The above mentioned limitations regarding exclusive use of cell-free ascites and its 
restricted concentration in culture could also contribute to the reasons why levels of 
CD40 and HLA-DR remained unaffected in our experiments. However, we did 
occasionally notice changes in expression levels of these two markers in presence 
versus absence of ascites, but these were not consistent between experiments. It is 
feasible that this is due to inter-individual differences between monocyte-derived DC 
donors, ascites samples and/or their respective combinations, but in order to recognize 
patterns, dissect the reasons and understand the implications thereof, much bigger 
experimental cohorts than available for this study would be required. 
 
Apart from surface marker expression, we also monitored the influence of ascites on 
cytokine induction by monocyte-derived DC. We detected a significantly impaired 
production of IL-6, IL-12p40 and TNFα in presence of ascites from ovarian carcinoma 
Chapter 3 Results 
 105 
patients. The network of cytokines within the tumour environment and its impact on 
disease progression and prognosis has been subject to extensive study in the field of 
cancer immunology. Chronic inflammation is understood to be linked to 
carcinogenesis, and particularly in ovarian carcinoma, the cytokines IL-6 and TNFα 
are implicated as major drivers in this regard (Szlosarek et al., 2006;Kulbe et al., 
2007;Maccio and Madeddu, 2012). However, assessing the environment of ovarian 
carcinoma under steady-state conditions was not the aim of our study, but rather the 
question whether upon TLR activation, we can achieve potent DC activation leading to 
a production of these pro-inflammatory cytokines. Despite their documented role in 
advancing disease as drivers of chronic inflammation, production of pro-inflammatory 
cytokines is an important component in the initiation of a potent anti-tumour response. 
In order to lead to differentiation of T cells into effector cells, antigen presentation and 
co-stimulation as described above necessitate an accompanying third signal which is 
conveyed by cytokines. The cytokines are produced by the activated APC and act on 
the engaged T cell, contributing heavily to the polarization of the resulting T cell 
response (Diebold, 2008). Direct activation via PRR is thought to be necessary for 
cytokine production (signal 3) by APC, thereby rendering the APC fully activated and 
capable of conveying all three signals necessary for T cell priming and differentiation 
(Edwards et al., 2002;Sporri and Reis e Sousa, 2005). Up-regulation of co-stimulatory 
molecules on APC (signal 2) does most likely not require direct PRR stimulation and 
can be induced by indirect activation through inflammotory mediators produced by 
surrounding cells (Sporri and Reis e Sousa, 2003;Joffre et al., 2009). 
The cytokine IL-12 induces differentiation of naïve T cells into TH1 cells, which are 
potent producers of IL-2, IFNγ, TNFα, lymphotoxin (LT), IL-3 and GM-CSF. While 
IL-2 stimulates lymphocyte and NK cell proliferation, IFNγ, TNFα and LT activate 
NK cells and macrophages, promoting their cytotoxic and phagocytic as well as 
antigen presenting activity, respectively. The factors IL-3 and GM-CSF act as growth 
factors in myelopoiesis, encouraging the production of granulocytes, macrophages and 
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DC in the bone marrow. Overall, a dominating TH1 response primarily promotes cell-
mediated immunity as opposed to humoral immune responses, and is therefore 
desirable in the context of tumour immunotherapy (Murphy et al., 2008). A 
suppression of IL-12 production by DC as observed in our study could reduce TH1 
induction, with unfavourable consequences for the polarization of the resulting 
adaptive immune response. It is important to note, however, that for T cell skewing 
away from TH1 to take effect, the reduction of IL-12 may have to be accompanied by 
concomitant presence of cytokines and/or co-stimulatory molecules inducing other 
types of TH cell responses. 
A further factor that was potently induced by TLR activation of monocyte-derived DC 
but strongly suppressed in presence of ascites in our experiments was IL-6. This 
cytokine has equally been described to influence the direction of the induced T cell 
response following antigen presentation, in particular effecting the balance between 
promotion of T regs and TH17 cells (Manel et al., 2008;Volpe et al., 2008;Kimura and 
Kishimoto, 2010). The balance of T reg versus TH17 responses bears prognostic value 
in ovarian carcinoma, with high T reg numbers in the tumour environment being 
associated with poor clinical outcomes (Curiel et al., 2004;Sato et al., 2005) and TH17 
being linked to prolonged survival and therefore considered favourable (Kryczek et al., 
2009). In contrast, in the context of autoimmune diseases such as rheumatoid arthritis 
(RA), the opposite ratio is desirable, with T regs having a protective role and TH17 
driving pathological inflammation. IL-6 blockade has yielded positive results in 
experimental treatment of RA patients, increasing their T reg numbers in peripheral 
blood and thereby skewing the ratio of T reg/TH17 cells towards a more regulatory 
T cell response (Pesce et al., 2013).  Our results in this study show that TLR-induced 
IL-6 production by DC is significantly impaired in presence of ovarian carcinoma 
ascites. It is difficult to extrapolate these observations to the effects they may have on 
the T cell response, because the latter is orchestrated by many additional factors. 
However, providing the presence of other soluble factors such as TGFβ or IL-10, one 
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may hypothesize that reduced IL-6 levels could contribute towards an increased 
T reg/TH17 ratio, which may be of disadvantage for immunotherapeutic concepts in 
ovarian carcinoma. A further cytokine that promotes TH17 induction is IL-1β (Sutton 
et al., 2006), hence we investigated the influence of the ovarian carcinoma 
environment on IL-1β production by DC but did not see consistent alteration of this 
cytokine in presence of malignant ascites. 
TNFα is a cytokine first discovered for its ability to induce necrosis of tumour tissue 
(Carswell et al., 1975) and it has since been shown to have multiple functions in the 
immune system, acting as a pyrogen, vasodilatator and initiator of the acute phase 
response during infection. TNFα induces the production of an array of pro-
inflammatory cytokines such as IL-6 and IL-1β and in systemic infections, circulating 
TNFα has been identified as a pivotal factor inducing cachexia by promoting lipolysis 
and interferring with other metabolic processes (Beutler et al., 1985). In acute sepsis, 
effects of high TNFα levels can be detrimental, leading to complications such as 
cytokine storm, hypotensive crisis through systemic vasodilatation, coagulopathy and 
ultimately multiple organ failure and death. The importance of TNFα as a causative 
factor for these symptoms has been implicated by animal models where partial 
protection of otherwise fatal infections was achieved by preventive administration of 
TNFα blocking agents (Lorente and Marshall, 2005). However, the benefits of TNFα 
blockade in sepsis have not been consistent throughout pre-clinical studies, and seem 
to depend on multiple factors including type of pathogen and host species used in the 
study (Lorente and Marshall, 2005). Equally, the translation of TNFα blockade into 
clinical use in sepsis in humans has only shown limited success, but clinical trials 
using TNFα blockers for treatment of this condition are nevertheless ongoing, with the 
aim of gaining a better understanding of the complexity of the clinical inflammatory 
response (Qiu et al., 2011). 
In contrast, the use of TNFα inhibitors such as etanercept or infliximab has gained 
tremendous success in the therapy of RA (Upchurch and Kay, 2012). In the context of 
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the localized synovial inflammation present in RA, TNFα promotes recruitment of 
monocytes, neutrophils and lymphocytes to these sites by inducing vasodilatation and 
expression of adhesion molecules on endothelial cells of the local vasculature. It also 
induces the production of pro-inflammatory cytokines, sustaining an inflammatory 
environment and thereby fostering disease progression. RA patients who benefit from 
anti-TNFα therapy are subjected to continuous use of these biologicals over many 
years, and side effects of these therapeutic regimes have highlighted the importance of 
TNFα in the control of latent infections such as tuberculosis or hepatitis, with 
documentedely increased risk of exacerbation of these diseases during anti-TNFα 
therapy (Rubbert-Roth, 2012). Long-term use of TNFα inhibitors is being debated as a 
potential risk factor for the development of malignancies and remains subject to 
controversy. Thus far, this notion is not conslusively supported by the vast majority of 
clinical data available (Rosenblum and Amital, 2011;Park and Ranganathan, 2012), 
possibly with the exception of non-melanoma skin cancer (Le Blay et al., 2012). 
TNFα has been implicated to be a central regulator of the pro-inflammatory milieu in 
ovarian carcinoma, sustaining a cytokine and chemokine network including IL-6, 
VEGFα, CCL2 and CXCL12 and thereby promoting pelvic inflammation and tumour 
dissemination and progression (Kulbe et al., 2007). It has been shown that malignant 
ovarian epithelium produces higher levels of TNFα as compared to normal tissue, and 
ovarian carcinoma cells express the TNFα receptor TNFRI (Szlosarek et al., 2006). 
Within the tumour environment, stromal cells as well as various leukocyte populations 
such as macrophages and DC are a further important source of TNFα. 
In this study, we have observed substantial production of TNFα by monocyte-derived 
DC upon stimulation with TLR agonists, and the levels of this cytokine were 
significantly reduced when activation took place in presence of ovarian carcinoma 
associated ascites. In the context of our study, these data once again show 
immunosuppressive properties of the ovarian carcinoma tumour environment, because 
in the context of an acute immune response, TNFα is required for maturation of DC 
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and their capacity to migrate to lymphnodes where priming of naïve T cells takes place 
(Banchereau and Steinman, 1998;Stoitzner et al., 1999). Hence, TNFα is indirectly 
crucial for the initiation of anti-tumour responses by DC (Miwa et al., 2012). 
Interestingly, when comparing ascites from ovarian carcinoma patients to peritoneal 
fluid associated with benign ovarian tumours with regards to their respective effects on 
TLR-mediated activation of monocyte-derived DC, we observed a striking difference 
in TNFα supression. Benign peritoneal fluid left TNFα production induced by TLR 
stimuli unaffected, while malignant ascites robustly suppressed the production of this 
cytokine. Other monitored markers of activation, namely IL-6, IL-12p40 and the 
surface marker CD86 were equally suppressed in presence of both the benign and 
malignant fluids. Hence, while this points towards similarities in composition of the 
soluble factors within the environment of benign and malignant ovarian tumours, 
important differences remain and should be explored in more depth, as they may lead 
to a better understanding of particularities of malignant milieus that distinguish them 
from benign conditions. 
With specific regard to our study, the pathways leading to TNFα production upon TLR 
stimulation in monocyte-derived DC were differentially influenced by soluble factors 
present within the environment of malignant versus benign ovarian tumours. As 
outlined above, TNFα promotes the recruitment of leukocyte subsets to the tumour 
environment, is important for DC maturation and migration and through these and 
other functions contributes to the creation of a pro-inflammatory environment. A 
suppressed induction of TNFα upon TLR activation may therefore hinder efficient 
initiation of immune responses and may represent an important obstacle in 
experimental concepts relying on in situ DC activation in ovarian carcinoma. 
In order to gain a better understanding of the mechanisms underlying the 
immunosuppressive properties of the ovarian carcinoma environment, an investigation 
of the constitution of ascites represented the next step in our study. We further 
explored the contribution of individual ascites components to the impairment of TLR-
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mediated monocyte-derived DC activation, and our respective findings are outlined in 
detail in the following chapters. 
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Chapter 4 
 
Investigating components of ovarian carcinoma associated 
ascites that impair TLR-mediated monocyte-derived DC 
activation 
 
Introduction 
 
Regardless of the underlying pathophysiological causes leading to formation of ascites, 
this material harbours a large array of proteins, many of which have numerous 
functions in the human immune system. As several studies have revealed, ovarian 
carcinoma fosters an immunosuppressive tumour environment comprising many 
cytokines and chemokines with known immunosuppressive properties. These factors 
are produced by tumour cells themselves and/or leukocytes infiltrating the tumour, can 
be found in the immediate tissue surroundings and are consequently also present in 
ascites from patients suffering from ovarian carcinoma (Yigit et al., 2010;Wertel et al., 
2011;Yigit et al., 2011a;Yigit et al., 2011b). A review of available studies 
characterizing the ovarian carcinoma tumour environment revealed considerable 
differences between absolute levels of different proteins as well as large variations 
between ascites samples from different individuals. This is only natural, given the 
dynamic nature of tumour tissue, frequent migration of leukocyte populations and the 
innumerable plethora of other factors that collectively determine the precise 
composition of the tumour environment at any given timepoint. The consistency and 
reproducibility of the suppressive effects of malignant ascites on TLR-mediated 
activation of DC as observed in our study and presented in the previous chapter was 
therefore all the more remarkable. The findings indicated that despite their inevitable 
differences, some similarities between the individual ascites samples used in our 
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experiments do exist. Exploring these similarities further could lead to the discovery of 
particular factors that act as obstacles hindering TLR-mediated activation of DC. Once 
the mechanisms underlying the observed suppression are understood, they could be 
tackled and potentially overcome. 
A simple and efficient way to explore the role of a protein in any given scenario is its 
selective blockade or neutralization. Historically, immunoglobulins were discovered as 
substances in human serum that had the ability to neutralize bacteria and other 
‘toxins’. They were therefore first referred to as anti-toxins before Paul Ehrlich 
proposed the term antibody which was deemed more accurate and appropriate with the 
finding that ligands of immunoglobulins are not strictly toxins (Lindenmann, 1984). 
Koehler and Milstein reported in 1975 that a virtually endless supply of monoclonal 
antibodies of any desired specificity could be produced with the help of hybridoma cell 
lines, which was a landmark in scientific research (Kohler and Milstein, 1975). 
Nowadays, generation of antibodies against any defined antigen is possible, and 
countless scientific applications rely on the use of immunoglobulins. They can be 
designed to fulfill an array of functions, among which is the selective neutralization of 
their particular ligands. Neutralization typically leads to the abrogation of the 
biological activity of the specific ligand, and this approach lends itself to studies 
exploring the biological function of particular agents. 
Due to the convincing reproducibility of our experiments where ascites from different 
ovarian carcinoma patients consistently suppressed TLR-mediated DC activation, we 
hypothesized that a common component of all ascites samples predominantly induced 
the observed suppressive effect. An array of carefully selected antibodies specifically 
neutralizing particular proteins in our cell cultures was therefore an ideal tool for our 
study, allowing us to dissect the contribution of individual factors in ascites to the 
suppression of TLR-mediated DC activation. This chapter describes our attempts to 
tackle these exciting and highly relevant scientific questions and reveals the insights 
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we have gained into the composition and attributes of the ovarian carcinoma ascites 
environment.  
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4.1 Composition of ovarian carcinoma associated ascites 
 
In order to identify the factors contributing to the observed suppressive effects of 
ascites from ovarian carcinoma patients on TLR-mediated DC activation, it was 
important to first elucidate the composition of the malignant ascites. Previous reports 
have analyzed protein levels in ascites samples from ovarian carcinoma patients 
(Giuntoli et al., 2009b;Yigit et al., 2011b) and have found an array of 
pro-inflammatory and immunosuppressive cytokines and chemokines present at 
varying levels. To understand the composition of the material used in this study, we 
analyzed all malignant ascites samples for levels of the immunosuppressive proteins 
IL-10, leukemia inhibitory factor (LIF), arginase-1 (Arg-1) and prostaglandin E2 
(PGE2). We further determined the concentrations of the angiogenesis-promoting and 
immunosuppressive factor VEGFα, chemokine ligand 18 (CCL18), and the 
pro-inflammatory cytokines IL-6, TNFα and IFNγ. All measured proteins were present 
in detectable levels in at least one ascites sample (Figure 4.1), with the exception of 
soluble CTLA-4 (sCTLA-4) which could not be detected in any of our samples (data 
not shown). Most proteins measured were present in the majority of samples, although 
their levels varied considerably. By assigning one symbol throughout all graphs 
depicted in Figure 4.1 to each of the 8 ascites samples that were used throughout this 
study, we aim to demonstrate that each ascites sample is of a unique composition, 
harboring different levels of various proteins which together orchestrate an immune 
environment specific for the tumour environment of each individual patient.  
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Figure 4.1 Levels of proteins in ovarian carcinoma associated ascites vary considerably 
between individuals. 
Protein levels in ascites samples collected from ovarian carcinoma patients were measured by 
sandwich ELISA. Eight malignant ascites samples used throughout the study are shown. Each 
symbol represents one patient sample throughout the graphs. n = 8. 
Levels of IL-10, LIF, VEGF-α, CCL18, IL-6, TNFα and IFN-γ were measured by Hayley Evans or Ann 
Jagger (research group of Dr. Leonie Taams, Centre for Molecular & Cellular Biology of Inflammation, 
King’s College London). 
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4.2 Correlation between protein levels in ascites and suppression of 
TLR-mediated monocyte-derived DC activation 
 
Our experimental results thus far have shown suppression of a number of markers of 
TLR-mediated monocyte-derived DC activation. Although the suppression was 
consistant across ascites samples from different patients, we noticed differences in the 
intensity of suppression of our read-out markers CD86 and cytokines IL-6, IL-12p40 
and TNFα. We were interested to explore whether this was due to experimental 
variation or whether the composition and levels of individual factors detected in our 
ascites samples may have influenced the suppressive activity of each particular sample. 
We therefore correlated levels of all measured proteins in individual ascites samples 
with the suppression of CD86 up-regulation on monocyte-derived DC as well as IL-6, 
IL-12p40 and TNFα production after R848 activation in presence of 10% ascites in 
cell culture as compared to R848-activated samples without ascites. The formula used 
to calculate the suppression was as follows:  
 
 
When suppression of CD86 up-regulation by individual ascites samples was paired 
with levels of the cytokine IL-10 in the respective samples, we observed a strong 
positive correlation, i.e. the more IL-10 present in an ascites sample, the stronger was 
the suppression of surface marker CD86 induced by this particular fluid (Figure 4.2). 
We detected the same positive correlation between IL-10 levels in ascites and 
suppression of IL-6 and IL-12p40. The lack of statistical significance of the correlation 
between IL-10 and IL-12p40 suppression was due to one outlying value, where an 
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ascites sample with comparably low IL-10 levels induced a suppression of IL-12p40 
production over 90%. Strikingly, although TNFα production was also impaired in 
presence of malignant ascites (see chapter 3, Figure 3.6 B), the magnitude of 
suppression did not correlate with IL-10 levels in ascites (Figure 4.2, bottom right 
graph).  
  
Figure 4.2 IL-10 in ovarian carcinoma associated ascites correlates positively with the 
suppression of CD86, IL-6 and IL-12p40, but not TNFα . 
Levels of IL-10 in ascites samples are correlated to the suppression of TLR-mediated up-regulation of 
CD86 and production of IL-6, IL-12p40 and TNFα. Suppression is expressed in per cent reduction of 
surface marker or cytokine levels when 10% ascites was added to the cell culture as compared to no 
ascites present; n = 26 (DC from 9 different healthy volunteers were cultured with ascites from 8 
different ovarian carcinoma patients. Altogether, 26 independent experiments were performed. Cells 
from four volunteers were cultured with two ascites samples each, while cells from two donors were 
cultured with three different ascites samples each, and the remaining three donors’ cells were 
cultured with four different ascites samples each. The Pearson coefficient was calculated to assess 
statistical significance of correlations. 
Levels of IL-10 in ascites samples were measured by Hayley Evans or Ann Jagger (research group of 
Dr. Leonie Taams, CMCBI, King’s College London). 
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The levels of most other determined proteins found in OC-associated ascites did not 
correlate with the degree of its suppressive properties (Table 4.1). However, we 
observed statistically significant negative correlations between the levels of VEGFα 
and suppression of CD86 induction, as well as between Arg-1 and CD86 suppression, 
and Arg-1 and inhibition of IL-6 production (Figure 4.3 A-B). Although the statistical 
analysis suggests a positive correlation between TNFα levels in ascites and 
suppression of CD86, IL-6 and IL-12p40, given that only one sample contained 
detectable levels of TNFα (see above, Figure 4.1), this correlation is likely to be 
skewed and should, therefore, be disregarded (Figure 4.3 C). 
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Table 4.1 Correlation of cytokine levels in ovarian carcinoma associated ascites with the 
suppressive activity of individual ascites samples as assessed by suppression of 
TLR-mediated CD86 up-regulation and production of the cytokines IL-6, IL-12p40 or TNFα . 
Distribution of cytokine levels in ascites samples was assessed by d’Agostino and Pearson omnibus 
normality test. For normally distributed cytokine levels (Arg-1, VEGFα, IL-6), the Pearson correlation 
coefficient was calculated. For cytokines lacking normal distribution of levels between ascites 
samples (LIF, PGE2, CCL18, TNFα, IFNγ),  the Spearman correlation coefficient was calculated. 
Pearson r or Spearman r coefficient; two-tailed; * = p<0.05 ** = p<0.01. Statistically significant 
correlations are shaded grey, and respective graphs are depicted below in Figure 4.3. 
Levels of LIF, VEGFα, CCL18, IL-6, TNFα and IFNγ in ascites samples were measured by Hayley 
Evans or Ann Jagger (research group of Dr. Leonie Taams, CMCBI, King’s College London). 
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Figure 4.3 Correlation of levels of VEGFα , Arg-1 and TNFα  in ovarian carcinoma associated 
ascites with the suppression of TLR-mediated CD86 up-regulation and/or production of the 
cytokines IL-6, IL-12p40. 
Suppression is expressed in per cent reduction of surface marker and cytokine levels when 10% 
ascites was added to the cell culture as compared to absence of ascites. (A) Correlation between 
VEGFα levels and CD86 suppression: Pearson r = -0.5524 p = 0.0034 (B) Correlation between Arg-1 
levels and CD86 suppression: Pearson r = -0.5513 p = 0.0035; correlation between Arg-1 levels and 
IL-6 suppression: Pearson r = -0.4527 p = 0.0202 and (C) Correlation between TNFα levels and 
CD86 suppression: Spearman r = 0.5845 p = 0.0017; correlation between TNFα levels and IL-6 
suppression: Spearman r = 0.4775 p = 0.0136; correlation between TNFα levels and IL-12p40 
suppression: Spearman r = 0.4470 p = 0.0221 
Levels of VEGFα and TNFα in ascites samples were measured by Hayley Evans or Ann Jagger 
(research group of Dr. Leonie Taams, CMCBI, King’s College London). 
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4.3 Neutralization of IL-10 in cell cultures alleviates the ascites-induced 
suppression of R848-mediated activation of monocyte-derived DC 
 
The analysis of correlations between various protein levels in ascites and magnitude of 
suppression of monocyte-derived DC activation upon TLR8 stimulation suggested an 
important role for the immunosuppressive cytokine IL-10 in our experimental 
scenario. To explore its contribution to the suppression further, and to also examine the 
possible role of other proteins that have not necessarily shown a dose-dependent 
correlation with degree of suppression, we conducted experiments using specific 
neutralizing antibodies for an array of selected cytokines with known 
immunosuppressive properties. All cytokines that we neutralized in the following set 
of experiments were detected in our malignant ascites samples (see above, Figure 4.1) 
with the exception of TGFβ which we had not measured. We nevertheless decided to 
include a neutralizing antibody for TGFβ in our experiments, because the presence of 
this cytokine in ovarian carcinoma associated ascites has been reported previously 
(Giuntoli et al., 2009b;Yigit et al., 2011b) and it is further known to suppress DC 
activation (Flavell et al., 2010). In addition to IL-10 and TGFβ, we neutralized the 
immunosuppressive cytokines LIF and VEGFα, as well as IL-6. Although IL-6 is 
considered a rather pro-inflammatory agent in many settings, it has been reported to 
exert immunosuppressive effects within ovarian carcinoma (Dijkgraaf et al., 2012) and 
other tumour environments by constitutive activation of signal transducer and activator 
of transcription 3 (STAT3) (Nguyen-Pham et al., 2012), which can lead to impairment 
of immune cell function, including DC activation (Yu et al., 2007). 
For reasons of practicability of our assays in terms of sample and cell numbers, we 
chose to initially study the effects of selective cytokine neutralization on DC activation 
in presence of ascites using one TLR agonist only. The TLR7/8 agonist R848 showed 
most consistant induction of high levels of CD86 as well as IL-6, IL-12p40 and TNFα, 
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and the levels of both CD86 and all three cytokines were significantly suppressed in 
presence of 10% ovarian carcinoma ascites (see chapter 3, Figures 3.4 and 3.6). 
An identical setup to previous experiments was followed, with overnight activation of 
monocyte-derived DC with the TLR7/8 agonist R848 (3 µg/ml) in absence or presence 
of ovarian carcinoma associated ascites at a final concentration of 10% in cell cultures. 
In addition, neutralizing antibodies were added to selected samples, either alone or in 
combination of all five neutralizing antibodies together. We conducted initial titration 
experiments (Figure 4.4) testing two different concentrations per antibody, which were 
carefully chosen according to the manufacturer’s data sheets while also taking into 
account the respective concentrations of cytokines as determined in our ascites 
samples (see above, Figure 4.1). In these initial experiments, we observed a partial 
alleviation of ascites-induced IL-6 suppression and a complete restoration of CD86 
up-regulation and IL-12p40 and TNFα induction where αIL-10 neutralizing antibody 
was added to cell cultures. This effect was antibody-dose dependent, with the higher 
concentration of 1 µg/ml αIL-10 antiboy leading to superior levels of all cytokines. 
None of the other neutralizing antibodies showed any effect on DC activation levels. 
After these initial experiments, in order to make the subsequent assays more 
practicable and to also account for potential saturation of αIL-10 antibody at the 
concentration of 1 µg/ml, we consistently used the concentration of 5 µg/ml for all 
antibodies in subsequent experiments. Referring back to the manufacturer’s 
recommendations, with the exception of TGFβ, this concentration exceeded the 
required dose to ensure complete neutralization of the respective cytokines. We had 
not measured TGFβ levels in ascites samples in our study, but the provided data sheets 
suggest that the use of 5 µg/ml αTGFβ neutralizing antibody ensures a neutralization 
of more than 90% when TGFβ is present at a concentration of 0.25 ng/ml. Although 
absolute cytokine levels vary between samples and may even vary from study to study 
depending on assays used to determine TGFβ concentrations, the average levels found 
in 35 ascites samples from advanced stage ovarian carcinoma patients in a previous 
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report were approximately 2.5 ng/ml (Yigit et al., 2011a). Given that we used ascites at 
a final concentration of 10% in cell cultures, TGFβ levels could be expected to be 
around 0.25 ng/ml, and the use of 5 µg/ml αTGFβ neutralizing antibody should 
therefore largely ensure the neutralization of this protein in our assays. 
  
Figure 4.4 Titration of specific neutralizing antibodies in cell cultures of R848-activated 
monocyte-derived DC and ovarian carcinoma associated ascites. 
Monocyte derived DC were cultured in the presence of 3µg/ml R848, 10% ascites and neutralizing 
antibodies at two different concentrations as indicated. CD86 expression levels were measured by 
flow-cytometry, and cytokine levels were measured in cell culture supernatants by Flow Cytomix 
analysis (IL-6 and TNFα) or sandwich ELISA (IL-12p40). This assay was perfomed only once as a 
pilot experiment in order to determine optimal antibody concentrations (n=1). 
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In the following set of experiments, we saw results in accordance with those obtained 
in the pilot experiment. Both the expression levels of co-stimulatory molecule CD86 as 
well as the production of the cytokines IL-6, IL-12p40 and TNFα remained unaffected 
when either LIF, VEGFα, TGFβ or IL-6 were neutralized in cell cultures with 
respective antibodies (Figure 4.5). However, where IL-10 neutralizing antibody was 
added, monocyte-derived DC activation was restored to (IL-12p40) or even elevated 
beyond (CD86, IL-6 and TNFα) the levels of R848-induced activation in absence of 
ascites. This observed effect was robust and reproducible when using monocyte-
derived DC from different donors as well as ascites samples from several ovarian 
carcinoma patients, and was therefore statistically highly significant. Addition of all 
neutralizing antibodies in combination also restored DC activation, and this effect is 
likely to be driven mainly by IL-10 neutralization, because the levels of activation did 
not differ significantly between samples where only IL-10 or all cytokines together 
were neutralized. IL-10 therefore emerged as a pivotal factor impeding TLR-mediated 
activation of monocyte-derived DC in presence of ovarian carcinoma associated 
ascites in vitro, and its neutralization alleviated the suppressive effects mediated by 
malignant ascites. 
It is important to note that upon R848 stimulation, monocyte-derived DC produce 
IL-10. When adding neutralizing antibodies to cell cultures, such autocrine IL-10 is 
neutralized alongside ascites-derived IL-10. It is therefore not possible to exclude an 
effect of autocrine IL-10 on monocyte-derived DC activation under these experimental 
conditions. As pointed out above, where IL-10 was neutralized in cell cultures, levels 
of the activation markers CD86, IL-6 and TNFα were restored beyond baseline levels 
of cells activated with R848 alone in absence of ascites (Figure 4.5). This discrepancy 
pointed towards a role of autocrine IL-10 in suppression of these three markers. 
Interestingly, IL-12p40 levels were restored to baseline levels only, suggesting that 
IL-12p40 suppression is affected by ascites-derived but not autocrine IL-10. 
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A detailed study of the relative contributions of autocrine versus ascites-derived IL-10 
to the suppression of TLR-mediated DC activation in our experiments was extensively 
addressed in this project, and the approaches we used to elucidate these questions are 
described in detail in Chapter 5. 
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Figure 4.5 Neutralization of IL-10 in cell cultures alleviates the suppression of R848-mediated 
monocyte-derived DC activation. 
Monocyte derived DC were cultured in the presence of 3µg/ml R848, 10% ascites and neutralizing 
antibodies (5µg/ml) as indicated. Neutralizing antibodies were added to cultures concomitantly with 
R848 and ascites, and were added alone or in combination as indicated. (A) CD86 expression levels 
were measured by flow-cytometry, and (B) cytokine levels were measured in cell culture supernatants 
by Flow Cytomix analysis (IL-6 and TNFα) or sandwich ELISA (IL-12p40). n=9-13 (DC from 8 
different healthy volunteers were cultured with ascites from 7 different ovarian carcinoma patients. 
Altogether, 13 independent experiments were performed. Cells from three volunteers were cultured 
with only one ascites sample each, while cells from two donors were cultured with three, and cells 
from one donor were cultured with four different ascites samples, respectively. IL-6 neutralizing 
antibody was only used in 9 out of 13 experiments). One-way ANOVA (Friedman test with Dunn post 
test): *** = p<0.001. Please note that the quantification of IL-6 in samples containing IL-6 neutralizing 
antibody (αIL-6 and all AB) is compromised. 
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4.4  Neutralization of IL-10 restores LPS- but not poly I:C-mediated 
monocyte-derived DC activation in presence of ovarian carcinoma 
associated ascites 
 
As shown above, our findings pointed towards a central role of IL-10 as an important 
suppressive factor impairing R848-mediated activation of monocyte-derived DC in 
presence of malignant ascites. We were intrigued to explore whether IL-10 was 
equally important in the suppression of DC activation upon stimulation with TLR4 
agonist LPS and TLR3 agonist poly I:C. We therefore performed a small number of 
experiments using the identical panel of neutralizing antibodies as above, selectively 
blocking the factors LIF, VEGFα, IL-6, TGFβ and IL-10 in overnight cultures of 
monocyte-derived DC stimulated with LPS or poly I:C. Similarly to R848, in 
LPS-activated cells, we observed an alleviation of suppression of CD86 up-regulation 
where IL-10 was neutralized, while, interestingly, cells stimulated with poly I:C 
showed no alteration of CD86 levels in presence of αIL-10 neutralizing antibody 
(Figure 4.6 A). None of the other neutralizing antibodies affected CD86 levels either in 
LPS- or in poly I:C-activated monocyte-derived DC. We collected supernatants from 
these assays to determine concentrations of the cytokines IL-6, IL-12p40 and TNFα 
induced under the varying culture conditions. In LPS-activated cultures, IL-10 
neutralization resulted in potent restoration of levels of all three cytokines 
(Figure 4.6 B), again mimicking the effects we observed with TLR7/8 agonist R848. 
The effect is strikingly obvious, and the lack of statistical significance in this set of 
data is therefore most likely due to the small cohort of four independent experiments 
(n = 4). 
As outlined in chapter 3, in comparison to activation with R848 or LPS, upon poly I:C 
stimulation, monocyte-derived DC produce considerably lower levels of cytokines. We 
nevertheless attempted to measure IL-6, TNFα and IL-12p40 levels in these assays, 
Chapter 4 Results 
 128 
but many values fell below the sensitivity threshold of our sandwich ELISAs, and 
these data are therefore not available. 
Collectively, the assays employing specific neutralizing antibodies for selected 
cytokines have shown that while the mechanisms of suppression of monocyte-derived 
DC activation by both R848 and LPS are mediated primarily by IL-10, this factor does 
not appear to play a role when activation is induced by TLR3 agonist poly I:C. 
Although these findings are intriguing, due to the poor cytokine induction by poly I:C, 
CD86 provided the only reliable activation marker in our assays, and this limited our 
possibilites to further dissect the underlying mechanisms and factors in ascites 
underlying the suppression of activation by poly I:C in monocyte-derived DC. We 
therefore did not pursue this path in more detail, but focussed in our subsequent 
experiments further on TLR7/8-mediated DC activation and suppression thereof by 
ovarian carcinoma associated ascites. 
  
Chapter 4 Results 
 129 
  
Figure 4.6 Neutralization of IL-10 in cell cultures alleviates the suppression of LPS- but 
not poly I:C-mediated monocyte-derived DC activation. 
Monocyte derived DC were cultured in the presence of 1µg/ml LPS or 100µg/ml poly I:C, 10% 
ascites and neutralizing antibodies (5µg/ml) as indicated. Neutralizing antibodies were added 
to cultures concomitantly with TLR agonists and ascites, and were added alone or in 
combination as indicated. (A) CD86 expression levels were measured by flow-cytometry, and 
(B) cytokine levels were measured in cell culture supernatants by Flow Cytomix analysis (IL-6 
and TNFα) or sandwich ELISA (IL-12p40). For LPS n=4 (4 independent experiments; 
monocyte-derived DC from 4 different healthy donors, cultured with one of two different 
ascites each) and for poly I:C n=3 (3 independent experiments; monocyte-derived DC from 3 
different healthy donors, cultured with one of two different ascites each). One-way ANOVA 
(Friedman test with Dunn post test): ns = not significant. Please note that the quantification of 
IL-6 in samples containing IL-6 neutralizing antibody (αIL-6 and all AB) is compromised. 
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4.5 Ovarian carcinoma associated ascites impairs the T cell stimulatory 
capacity of monocyte-derived DC in vitro 
 
DC are professional APC and their function as such is pivotal to the initiation of an 
anti-tumour immune response. They are required for the presentation of TAA to naïve 
CD4
+
 and CD8
+
 T lymphocytes which are thereby primed and expand to form 
populations of tumour specific CD4
+
 TH and CD8
+
 cytotoxic T effector cells. Having 
observed impaired activation of monocyte-derived DC in presence of malignant ascites 
in our previous experiments, we explored the question whether such reduced activation 
further negatively influenced the T cell stimulatory capacity of DC and if so, whether 
impaired functionality equally appeared to be dependent on IL-10. 
To address this, we conducted allogeneic MLR, using monocyte-derived DC from one 
healthy donor and stimulating them overnight with TLR7/8 agonist R848 in absence or 
presence of 10% of ovarian carcinoma associated ascites and/or neutralizing IL-10 
antibody. After overnight culture, the DC were thoroughly washed to prevent carry-
over of R848, ascites or αIL-10 neutralizing antibody and seeded onto fresh plates 
together with CFSE stained naïve CD4+ T cells at different DC : T cell ratios (1:25, 
1:50, 1:100 and 1:200). After incubation over 6 days, cells were harvested and T cell 
proliferation was assessed by CFSE dilution as measured by flow cytometry (Figure 
4.7). We observed an increased induction of T cell proliferation by DC pre-cultured in 
presence of R848 as compared to medium only. Importantly, where ascites was present 
in DC cultures, the T cell stimulatory capacity was reduced, and again restored beyond 
baseline levels (R848 only) upon IL-10 neutralization. These data were consistent for 
all experiments performed but did not reach statistical significance, most likely due to 
the limited number of assay repetitions performed (n = 4). Our observations in these 
experiments complimented the previous results and showed that reduced activation of 
monocyte-derived DC in presence of ovarian  
  
Chapter 4 Results 
 131 
  
Figure 4.7 Ovarian carcinoma associated ascites impairs the T cell stimulatory capacity of 
monocyte-derived DC, but functionality can be restored by IL-10 neutralization. 
For allogeneic MLR, monocyte-derived DC from healthy donors were cultured overnight in complete 
medium only, or stimulated with 3µg/ml R848 in the presence or absence of 10% ascites (AF) and/or 
IL-10 neutralizing antibody (AB) (5µg/ml) as indicated. Subsequently, such pre-treated DC were 
washed and co-cultured with CFSE-stained CD4
+
 naïve T cells from an other healthy donor at a 
1:100 or 1:200 ratio for 6 days. Naïve T cells from the same donor were used consistently for all 
experiments. The proliferation of T cells was determined by CFSE dilution after 6 days. (A) A 
representative example of flow-cytometry analysis is shown (DC : T-cell ratio 1:200). After gating on 
CD3+ cells, proliferating and non-proliferated T lymphocytes are shown as assessed by CFSE 
dilution. (B) Cumulative data from 4 independent experiments showing proliferation in percent of 
CD3
+
 cells that have undergone at least one round of division. n=4 (4 independent experiments; 
monocyte-derived DC from 3 different healthy donors; DC from two donors were cultured with only 
one ascites sample, while the third donor’s cells were cultured with ascites from two different ovarian 
carcinoma patients. 
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carcinoma associated ascites negatively influences the T cell stimulatory capacity of 
these APC, resulting in reduced T cell proliferation in vitro. 
In addition to T cell proliferation, we also considered the possibility that DC 
pre-cultured in presence of ascites may alter the type of CD4
+
 T cell response induced. 
To address this, we performed intracellular staining of T cells for transcription factor 
FoxP3 as well as the cytokines IL-10, IL-17 and IFNγ after 6 days of MLR culture 
(Figure 4.8). We noticed a slight decrease in FoxP3
+
 cells upon activation with R848, 
but detected no alteration between R848 activated samples with or without ascites 
and/or αIL-10 antibody, with percentages of FoxP3+ cells ranging between 3.5 - 4.5% 
in these samples (Figure 4.8 bottom row). The percentage values of IFNγ+ cells 
decreased slightly from 22% to 17% with R848 activation, and a slight increase from 
17% to 21% was then noted with the addition of ascites (Figure 4.8 top row). The 
percentage of IFNγ+ cells doubled where αIL-10 antibody was added to DC cultures, 
but since we saw no decrease of IFNγ induction in presence of ascites, this is most 
likely due to neutralization of autocrine IL-10. In all samples, only a very small 
percentage of T cells (<1%) produced IL-10 or IL-17. 
The data from these MLR assays show that the influence of ovarian carcinoma 
associated ascites on monocyte-derived DC outlasts their immediate exposure to the 
fluid, and that not only their direct activation via TLR8 is reduced but equally their 
capacity to stimulate naïve T cells is partially impaired. 
  
Chapter 4 Results 
 133 
  
Figure 4.8 The CD4
+
 T cell response induced by monocyte-derived DC in MLR reactions is not 
altered towards a regulatory or TH17 phenotype by ovarian carcinoma associated ascites. 
For allogeneic MLR, monocyte-derived DC from healthy donors were cultured overnight in complete 
medium only, or stimulated with 3µg/ml R848 in the presence or absence of 10% ascites (AF) and/or 
IL-10 neutralizing antibody (AB) (5µg/ml) as indicated. Subsequently, such pre-treated DC were 
washed and co-cultured with CFSE-stained CD4
+
 naïve T cells from an other healthy donor at a 
1:200 ratio for 6 days. The proliferation of T cells was determined by CFSE dilution after 6 days. After 
gating on CD3+ cells that have undergone at least one round of division, percentage values of 
proliferating cells producing the cytokines IFNγ, IL-10 or IL-17, or cells positive for transcription factor 
FoxP3 are shown. One representative example is shown of 2 independent experiments for IFNγ, 
IL-10 IL-17, and of 3 independent experiments for FoxP3. 
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4.6 Factors other than IL-10 in ovarian carcinoma associated ascites 
contribute to suppression of TLR-mediated monocyte-derived DC 
activation 
 
Although our experimental results thus far pointed towards a pivotal role of IL-10 as 
mediator of suppression of monocyte-derived DC activation via TLR in presence of 
ascites from ovarian carcinoma patients, given the complex composition of this tumour 
environment, we could not exclude that other ascites-derived factors not yet addressed 
in our study were also contributing to the impairment of DC activation. 
We therefore performed experiments to compare activation levels of monocyte-derived 
DC activated with R848 in presence or absence of ascites, having eliminated the 
influence of IL-10 by including specific IL-10 neutralizing antibody to both culture 
conditions. Levels of CD86, IL-6, IL-12p40 and TNFα were markedly lower in 
samples containing ascites, suggesting that factors other than IL-10 were impeding 
monocyte-derived DC activation in these samples (Figure 4.9 A). This difference only 
reached statistical significance for the surface marker CD86, however the trend was 
also consistent for all three cytokines. The relevance of these data is augmented when 
compared with control experiments using peritoneal fluid from patients with benign 
ovarian tumours (Figure 4.9 B). When IL-10 was neutralized in these cultures, we 
detected no difference between samples with or without peritoneal fluid, indicating 
that once IL-10 is eliminated as a driver of suppression, no further factors in benign 
peritoneal fluid impede TLR-mediated monocyte-derived DC activation. 
Again, as seen previously (see chapter 3, Figure 3.7 B), benign peritoneal fluid failed 
to suppress TNFα production (Figure 4.9 B, bottom graph), which marked a difference 
to malignant ascites (see Figure 4.9 A bottom graph and chapter 3, Figure 3.6 B).  
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Figure 4.9 Factors other than IL-10 that impair TLR-mediated monocyte-derived DC activation 
are present in ovarian carcinoma ascites but not peritoneal fluid from patients with benign 
ovarian tumours. 
Monocyte-derived DC were stimulated overnight with 3µg/ml R848 in the presence or absence of 
(A) 10% malignant ascites (AF) from OC patients or (B) 10% peritoneal fluid (PF) from benign ovarian 
tumours and IL-10 neutralizing antibody (5µg/ml) as indicated. CD86 expression levels were 
assessed by flow-cytometry, and cytokine levels were measured in cell culture supernatants by flow 
cytometry analysis (A: IL-6 and TNFα) or sandwich ELISA (A: IL-12p40 and B: TNFα, IL-6 and 
IL-12p40); for malignant samples n=6 (DC from five different healthy volunteers were cultured with 
ascites from 5 different ovarian carcinoma patients. Altogether, 6 independent experiments were 
performed. Cells from four volunteers were cultured with only one ascites sample each, while cells 
from the remaining donor were cultured with two different ascites samples.; for benign samples n=9 
(DC from five different healthy volunteers were cultured with peritoneal fluid from 6 different patients. 
Altogether, 9 independent experiments were performed. Cells from three volunteers were cultured 
with only one ascites sample each, while cells from the remaining two donors were cultured with three 
different ascites samples each); One-way ANOVA (Friedman test with Dunn post test): * = p<0.05, 
ns = not significant. 
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We further recall that although TNFα was potently suppressed by ovarian 
carcinoma-associated ascites, no correlation between magnitude of suppression and 
IL-10 levels in ascites had been detected (see above, Figure 4.2 bottom right graph). 
All these observations taken together led us to hypothesize that one or several 
additional suppressive factors other than IL-10 are present in ascites and absent from 
benign peritoneal fluid, and that more specifically, these may contribute to and 
possibly correlate with the suppression of TNFα production by monocyte-derived DC 
upon R848 stimulation. 
As reviewed in the introduction to this chapter, a large number of proteins with 
immunosuppressive properties have been reported to accumulate in ovarian 
carcinoma-associated ascites. The most promising candidates we considered included 
sCTLA-4, Arg-1 as well as binding immunoglobulin protein (BIP), but we could 
exclude the role of all these factors in our assays after several simple pilot experiments 
briefly outlined below. 
sCTLA-4 was not detectable in any of our samples (data not shown) and was therefore 
swiftly dismissed. Arg-1 was abundant in some ovarian carcinoma ascites samples, but 
one of the three benign ovarian samples that were available to us at this time also 
displayed very high levels of Arg-1 (Figure 4.10 A). A lack of correlation of Arg-1 in 
malignant ascites samples with TNFα suppression (see above, Table 4.1) further made 
this protein an unlikely candidate. In collaboration with Dr. Valerie Corrigall, CMCBI, 
King’s College London, BIP was measured in both malignant and benign fluid 
samples, with malignant samples showing higher levels of this immunosuppressive 
protein (Figure 4.10 B, this ELISA was performed and analyzed by Dr. Chris Hall). 
Following these encouraging results, in order to study in more detail the influence of 
BIP on R848-mediated activation with a focus on suppression of TNFα, we conducted 
experiments adding recombinant BIP to monocyte-derived DC cultures at a range of 
concentrations resembling those found in our ascites samples (recombinant BIP was 
provided by Dr. Corrigall). CD86 up-regulation remained unaffected by BIP, but 
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surprisingly, we observed enhanced levels of TNFα as well as IL-6 and IL-12p40 in 
cultures where BIP was added (Figure 4.10 C). As this was contradictory to our 
hypothesis, we did not further pursue this candidate protein as a possible contributor to 
suppression of TLR-mediated monocyte-derived DC activation. 
  
Figure 4.10 Arg-1 and BIP levels in malignant ascites versus benign peritoneal fluid samples and 
influence of recombinant BIP on R848-mediated DC activation. 
(A) Arg-1 levels were measured in all malignant ascites and benign peritoneal fluid samples available to 
us at the given time in the study by sandwich ELISA. (B) BiP sandwich ELISA with all of our available 
malignant and benign samples was performed by Dr. Chris Hall (CMCBI, King’s College London), who 
also analyzed these data. For both Arg-1 and BiP, Mann-Whitney U test was used for statistical analysis. 
(C) Monocyte-derived DC were stimulated overnight with 3µg/ml R848 with or without recombinant BIP 
at three different concentrations as indicated. CD86 expression was assessed by flow cytometry and 
cytokine levels in cell culture supernatants were measured by sandwich ELISA. This assay using 
recombinant BIP was performed one time only (n=1).  
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4.7 PGE2 and IL-10 in ovarian carcinoma associated ascites have an additive 
effect on suppression of TLR-mediated TNFα  induction 
 
PGE2 is a protein with multiple functions in the human body ranging from smooth 
muscle relaxation, vasodilatative activity to a well documented, if complex and not yet 
fully understood role in the immune system. PGE2 is a derivate of arachidonic acid 
(AA) belonging to the class of eicosanoids, and it exerts its functions via four different 
receptors EP1 – EP4 (Kalinski, 2012). Monocyte-derived DC express receptors EP2 
and EP4 and PGE2 has been described to modulate cytokine expression, including 
IL-10, IL-12p40 and TNFα in these and other immune cells (Kalinski et al., 
1997;Laudanski et al., 2004;Hubbard et al., 2010;Poloso et al., 2013). Further, PGE2 
has previously been detected in ovarian carcinoma-associated ascites (Lavoue et al., 
2012) and ovarian carcinoma cells show overexpression of cyclooxygenase-1 and -2 
(COX-1 an COX-2, respectively), the key enzymes in the synthesis of eicosanoids 
including PGE2. For these reasons, PGE2 was a promising candidate and possible 
factor in ovarian carcinoma-associated ascites contributing to suppression of 
TLR-mediated activation of monocyte-derived DC. 
Pilot experiments using recombinant PGE2 in cell cultures yielded promising results, 
showing impaired R848-induced TNFα production in presence of PGE2 (Figure 4.11). 
We tested three concentrations of recombinant PGE2 in this assay, chosen in reference 
to a previous study which reported levels of PGE2 in ovarian carcinoma ascites of up 
to 40 ng/ml (Lavoue et al., 2012). Similarly to TNFα, the levels of IL-6 and IL-12p40 
were reduced where recombinant PGE2 was added to cell cultures, but in contrast, 
CD86 up-regulation was enhanced by PGE2. For all cytokines, the suppressive effect 
was dose dependent, with higher concentrations of PGE2 inducing more prominent 
suppression. As a next step following these encouraging results, we neutralized PGE2 
in cell cultures containing ovarian carcinoma ascites, and  
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observed a partially restored TNFα production in samples where PGE2 was blocked 
(Figure 4.12 A), while CD86, IL-6 and IL-12p40 levels remained unaffected 
(Figure 4.12 B). Concomitant neutralization of IL-10 and PGE2 led to higher TNFα 
production than neutralization of IL-10 alone (Figure 4.12 C). While the neutralization 
of IL-10 was the major factor alleviating TNFα suppression, the contribution of PGE2 
was consistant, and albeit small, the increase in TNFα production upon additional 
PGE2 neutralization was statistically significant.  
To exclude the possibility that the observed effects of PGE2 were caused by 
neutralization of autocrine PGE2 produced by DC upon TLR activation, we neutralized 
PGE2 in R848-activated cultures without ascites. We saw no effect of PGE2 
neutralization on TNFα levels in response to R848-mediated activation 
(Figure 4.12 D), which led us to believe that autocrine PGE2 does not play a role in the 
suppression of TLR-induced TNFα production by monocyte-derived DC.  
Figure 4.11 Impact of recombinant PGE2 on R848-mediated monocyte-derived DC activation. 
Monocyte-derived DC were stimulated overnight with 3µg/ml R848 with or without recombinant PGE2 at 
three different concentrations as indicated. CD86 expression was assessed by flow cytometry and 
cytokine levels in cell culture supernatants were measured by sandwich ELISA. This assay using 
recombinant PGE2 was performed one time only (n=1).  
Chapter 4 Results 
 140 
 
  
Figure 4.12 Neutralization of PGE2 partially restores R848-induced TNFα production and 
enhances TNFα  levels beyond those reached by IL-10 neutralization alone. 
Monocyte-derived DC were stimulated overnight with 3µg/ml R848. (A-B) Malignant ascites and 
neutralizing antibodies (5µg/ml) against PGE2 were added as indicated; n=11 (11 independent 
experiments; monocyte-derived DC from four different healthy volunteers were cultured with ascites from 
four different ovarian carcinoma patients. Altogether, 11 independent experiments were performed. Cells 
from three volunteers were cultured with three different ascites sample each, while cells from the 
remaining donor were cultured with only two different ascites samples. (C) Neutralizing antibodies 
against IL-10 and PGE2 were added as indicated to cultures containing 3µg/ml R848 and 10% ascites; 
n=9 (DC from four different healthy volunteers were cultured with ascites from 5 different ovarian 
carcinoma patients. Altogether, 9 independent experiments were performed. Cells from three volunteers 
were cultured with two ascites samples each, while cells from the remaining two donors were cultured 
with either one or two different ascites samples, respectively. One-way ANOVA (Friedman test with 
Dunn post test): * = p<0.05; *** = p<0.001; ns = not significant; (D) Monocyte-derived DC were 
stimulated overnight with 3µg/ml R848. To exclude a role of autocrine PGE2 on monocyte-derived DC 
activation, PGE2-specific neutralizing antibody (5µg/ml) was added as indicated. n=3. Wilcoxon matched 
pairs test; ns = not significant. Cytokine levels in all cell culture supernatants were measured by 
sandwich ELISA.  
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To further confirm PGE2 as a factor that distinguishes the malignant ovarian 
carcinoma environment from that of benign ovarian tumours, we measured the levels 
of PGE2 in malignant ascites and benign peritoneal fluid samples used in our study 
(Figure 4.13). The levels of PGE2 in malignant ascites vary between patients and while 
some samples were negative for this protein, most malignant ascites samples contained 
detectable levels of PGE2. Interestingly however, all samples of peritoneal fluid from 
benign ovarian conditions showed very low or not detectable levels of PGE2. Hence, 
our data suggest that PGE2 is a factor absent from benign ovarian tumours but often 
present in the malignant OC environment that specifically impairs TLR-mediated 
TNFα induction by monocyte-derived DC. 
 
  
Figure 4.13 PGE2 levels in ascites from ovarian carcinoma patients or in peritoneal fluid from 
patients suffering from benign tumours of the ovary. 
PGE2 levels in malignant ascites (n=9) and benign peritoneal fluid (n=6) were measured by sandwich 
ELISA. Mann-Whitney U test was used for statistical analysis. 
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4.8 TLR-mediated activation of primary myeloid DC in presence of ovarian 
carcinoma associated ascites 
 
For reasons of practicability as outlined in the introduction to chapter 3, we conducted 
this study with the use of in vitro generated monocyte-derived DC. Work with primary 
human DC subsets is challenging due to the low numbers present in peripheral blood, 
typically the only material readily available from healthy donors. However, in the 
wider context of our study, especially when extrapolating our data to experimental and 
clinical settings and immunotherapeutic strategies exploring in vivo targeting strategies 
of primary DC subsets, it is of interest to investigate how our findings translate to 
myeloid DC, and whether ovarian carcinoma associated ascites impairs their activation 
by TLR agonists in similar fashion to monocyte-derived DC. 
Human DC are divided into plasmacyoid and myeloid DC subsets which bear specific 
roles and functions as extensively described in chapter 1. We have decided to study the 
influence of ovarian carcinoma associated ascites on TLR-mediated activation of the 
myeloid DC 1 (mDC1) subset. While mDC2 are thought to be specialized in cross-
presenting cell-associated antigens to CD8
+
 T cells and therefore of pivotal importance 
to anti-tumour immunity, this subpopulation is extremely sparse and sufficient 
numbers of these cells for conducting activation assays can’t be obtained from 
peripheral blood. We therefore decided to focus our efforts on the mDC1 subset, which 
can be distinguished within PBMC with the help of the phenotypic marker BDCA-1 
(CD1c) (Dzionek et al., 2000). Kits for DC isolation from peripheral blood are 
commercially available, and to ensure we obtain very high purity of mDC1, we 
combined the use of a panDC negative selection enrichment kit with fluorescent-
activated cell sorting. BDCA-1 is also expressed by a small number of B lymphocytes 
(Small et al., 1987), and a concomitant staining with the B cell marker CD19 is 
therefore necessary to ensure accurate recognition of the desired mDC1 cell 
population. An analysis of the sorted cells including gating strategy was provided by 
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our departmental flow cytometry facility, and is shown in Figure 4.14 A. The starting 
population of PBMC was 4.2 x 10
8
 which was obtained from a buffy coat from the 
National Blood Service. However, 4.2 x 10
8
 constituted only 30% of all PBMC 
isolated from this buffy coat sample, with the remaining cells used for other 
experiments. From 4.2 x 10
8
 PBMC, using a negative selection kit, we isolated 
7.6 x 10
6
 panDC (containing pDC, mDC1 and mDC2). Staining of panDC with 
BDCA1 and CD19 specific antibodies was followed by FACS sorting, and the 
obtained cell population of pure BDCA1
+
CD19
- 
mDC1 was approximately 1x10
6
 
(13% of panDC; 0.24% of starting PBMC). Since mDC1 are an abundant DC 
subpopulation and the FACS sort gating analysis indicates that 48.2% of all sorted 
cells fell within the BDCA1
+
CD19
-
 gate (Figure 4.14 A), the yield of 13% revealed 
that many cells were lost in the process of FACS sorting. Although the obtained 
number of cells (1x10
6
 mDC1) was rather low, it nevertheless allowed us to perform 
an experiment with several culture conditions as tested previously with monocyte-
derived DC. mDC1 express TLR8 (Jarrossay et al., 2001), and R848 was therefore a 
suitable agonist to induce mDC1 activation. While we observed an increase in CD86 
levels upon culture with R848, interestingly, we did not see a suppression but rather a 
slight enhancement of CD86 up-regulation in presence of 10% ovarian carcinoma 
associated ascites (Figure 4.14 B). Neutralization of IL-10 with a specific antibody in 
cultures containing ascites did not alter the levels of CD86 considerably. In two of 
three experiments performed, we also determined the levels of IL-6 and TNFα in cell 
culture supernatants. We observed a production of considerable levels of both 
cytokines upon R848 activation, no suppression of IL-6 and a slight enhancement of 
TNFα levels in presence of ascites (Figure 4.14 B). IL-10 neutralization induced levels 
of both IL-6 and TNFα beyond those of samples cultured with R848 only, showing 
that autocrine IL-10 is affecting mDC1 activation. 
Although these findings only constitute pilot experiments, it would appear that primary 
mDC1 may not be as susceptible to suppression of TLR8-mediated activation by 
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ovarian carcinoma ascites as monocyte-derived DC. However, due to the extremely 
limited data available, these results cannot yet be interpreted conclusively. These 
experiments were performed primarily as a proof of concept to establish protocols for 
purification of a primary human mDC subset, which we have achieved successfully. 
While the numbers that could be obtained limit the feasibility of assays that can be 
performed with these cells, by using higher starting numbers of PBMC from whole 
buffy coats from the National Blood Service, the format could be scaled up and 
specific questions regarding influence of ovarian carcinoma ascites on mDC activation 
could be addressed using these protocols. Design of future experiments to this effect is 
currently under consideration in our laboratory. 
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Figure 4.14 Influence of ovarian carcinoma associated ascites on R848-mediated activation of 
primary mDC1. 
(A) Pan-DC were obtained by magnetic negative selection and stained with antibodies for CD19 and 
mDC1 marker BDCA-1 before FACS sorting. A representative example of the FACS sort gating is 
shown, with mDC1 defined as BDCA1+CD19- population. (B) mDC1 were stimulated overnight with 
3µg/ml R848 in the presence or absence of 10% malignant ascites from OC patients and IL-10 
neutralizing antibody (5µg/ml) as indicated. CD86 expression levels were assessed by flow-
cytometry, and cytokine levels were measured in cell culture supernatants by FlowCytomix analysis. 
For CD86 n=3 (3 independent experiments; mDC from 3 different healthy donors, cultured with 1 
ascites); cytokines were measured in two of three experiments; n=2 
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Discussion 
 
Data presented in this chapter inform about the composition of soluble factors within 
the ovarian carcinoma tumour environment, revealing the presence of an array of 
known immunosuppressive proteins. The contribution of these factors to the 
impairment of TLR-mediated activation of monocyte-derived DC was addressed with 
the use of specific neutralizing antibodies. Identifying proteins that suppress DC 
activation is an important step towards gaining an understanding of the ovarian 
carcinoma environment and the obstacles it may pose to immunotherapeutic strategies 
relying on activation of DC in situ.  
Using selective neutralizing antibodies for an array of factors with known 
immunosuppressive properties, we attempted to elucidate their individual roles in the 
impairment of TLR-mediated activation of monocyte-derived DC. Our data have 
shown that neutralization of VEGFα, LIF, TGFβ and IL-6 did not alleviate the 
suppressive effect of ovarian carcinoma associated ascites on monocyte-derived DC, 
and these factors therefore do not contribute to the impairment of DC activation in our 
study. These findings were perhaps somewhat surprising, because factors such as 
TGFβ and VEGFα have previously been shown to negatively effect DC activation 
(Gabrilovich et al., 1996;Wallet et al., 2005). It is feasible that the tested proteins exert 
suppressive effects on DC only within a certain concentration range, and that amounts 
present in ascites during our cultures were not within this spectrum. Equally, these 
factors might bind to several receptors which may regulate DC activation in different 
ways. To elucidate all these possibilites, experiments with recombinant proteins at 
different concentrations, and use of specific receptor agonists and antagonists would 
be necessary, but this was not within the scope of our study. 
It is important to note that the biological activity of the used neutralizing antibodies 
had not been tested in our study. Such experiments would complement this work, as 
they would allow for a more robust interpretation of the data obtained. Only with proof 
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of the capacity of the used antibodies to effectively neutralize the desired factors in 
vitro can one draw the definite conclusion that a particular agent does not play a role in 
an experimental system. The neutralizing ability of antibodies can be tested with the 
use of recombinant proteins, the in vitro neutralization of which can be verified either 
by simple quantitative measurement such as ELISA, or functional assays using 
responder cell lines. Appropriate experiments to verify the functionality of the used 
antibodies against VEGFα, LIF, TGFβ and IL-6 are currently under consideration in 
our laboratory. Notably, with regards to our study, the use of cytokine-receptor 
blockers as an alternative to neutralizing antibodies represents an attractive option to 
verify the obtained data. 
With the use of the selective neutralizing antibodies used to date, we could identify 
IL-10 and PGE2 as two factors impairing TLR-mediated activation of monocyte-
derived DC in distinct yet complementary ways. Our experimental data have shown 
that selective neutralization of IL-10 alleviated the suppression of monocyte-derived 
DC activation by TLR agonists potently and consistently, pointing towards a central 
role of IL-10 as driver of the observed suppression. 
Interestingly, upon IL-10 blockade, the up-regulation of the surface marker CD86 and 
the production of IL-6 and TNFα were restored beyond the levels achieved in cells 
which were activated with R848 in absence of ascites. This observation was in line 
with the well documented IL-10 production by monocyte-derived DC upon TLR 
stimulation (Chang et al., 2000;Schreibelt et al., 2010), and has shown that autocrine 
IL-10 impairs the cells’ own activation and its neutralization can therefore further 
enhance DC activation. Notably, our preliminary and very limited data using primary 
mDC indicated that ascites-derived factors including IL-10 may not have a suppressive 
influence on R848-mediated activation of this primary DC subset. However, mDC are 
also known to produce IL-10 upon TLR activation (Jarrossay et al., 2001), and 
similarly to our assays with monocyte-derived DC, neutralization of IL-10 in mDC1 
cultures enhanced activation levels beyond those achieved with TLR stimulation alone, 
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pointing also here towards a role of autocrine IL-10. Our attempts to address the 
impact of ascites-derived versus autocrine IL-10 on DC activation in our experiments, 
and the implications thereof, will be discussed in detail in chapter 5. 
IL-10 is a much studied immunosuppressive protein with a documented role in ovarian 
carcinoma. In previous clinical studies, IL-10 was detected in ascites from ovarian 
carcinoma patients, and IL-10 serum levels are elevated in women suffering from the 
disease when compared to others with benign ovarian tumours or healthy controls not 
affected by any ovarian conditions (Gotlieb et al., 1992;Santin et al., 2001;Mustea et 
al., 2006;Yigit et al., 2011a). 
Macrophages and T reg are considered an important source of IL-10 in the tumour 
microenvironment (Yigit et al., 2010;Wang et al., 2011). T reg are attracted to the 
malignant tissue via chemotactic signals such as CCL22, a factor produced by tumour 
cells and local leukocyte subsets, and the infiltration with T reg bears negative 
prognostic significance (Curiel et al., 2004). Similarly, monocytes are recruited to the 
tumour environment by chemotactic factors such as MCP-1 which is produced by 
ovarian carcinoma cells and can be detected in tumour tissue as well as ascites from 
ovarian carcinoma patients (Negus et al., 1995). Other factors which have been 
implicated to play a role in attracting monocytes to the tumour environment include 
macrophage colony stimulating factor (M-CSF), chemokine receptor 2 (CCR2) and 
VEGFα (Bingle et al., 2002). Once monocytes infiltrate the tumour tissue, their 
differentiation into macrophages is influenced by factors in situ, many of which favour 
their polarization into an M2 phenotype. Factors that lead to the induction of M2 
macrophages include LIF, IL-4 and IL-10 (Sica et al., 2006;Duluc et al., 2007), all of 
which can be detected in ovarian carcinoma microenvironment (Yigit et al., 2011b). 
The M2 macrophage phenotype is characterized by an IL-10
hi
 and IL-12
lo
 cytokine 
secretion profile, and this cell population is specifically referred to as TAM. Apart 
from IL-10, other factors secreted by TAM shape the composition of the local tissue 
towards a pro-tumorigenic, immunosuppressive state by recruiting specific cell types 
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such as T reg (Curiel et al., 2004) and promoting tumour cell proliferation and neo-
vascularization (Sica et al., 2006). The impact of TAM on the tumour environment is 
manifold and can influence disease progression. The infiltration of solid tumours with 
TAM has been repeatedly suggested to be of prognostic significance, with high TAM 
infiltration being associated with poorer clinical outcomes in breast, prostate and 
cervix cancer and others (Bingle et al., 2002). Although TAM are present in the 
ovarian carcinoma enviroment, the studies investigating their prognostic value in this 
disease have thus far been inconclusive (Bingle et al., 2002;Zhang et al., 2012). A 
study by Wan et al. describes in the available abstract an association of TAM 
infiltration in ovarian carcinoma with poor prognosis, but the complete article is not 
available in english and it is therefore not possible to verify the authors’ conclusions 
(Wan et al., 2009). 
IL-10 is being debated to bear prognostic value in ovarian carcinoma, since IL-10 
levels correlate negatively with the differentiation grade of the malignant tumour, i.e. 
patients with poorly differentiated ovarian carcinoma present with higher levels of 
IL-10 in both ascites and serum (Mustea et al., 2009). Apart from TAM, which are 
potent producers of IL-10 and an important source of this cytokine in the ovarian 
carcinoma environment, the ovarian carcinoma epithelium itself also produces 
considerable amounts of IL-10. Although this has not been specifically addressed in 
the study by Mustea et al. or any other studies to date, it would be interesting to 
explore whether there is, in fact, a direct link between IL-10 production by cancerous 
epithelium and its grade of differentiation. In any case, the contribution of the cells of 
tumour mass to IL-10 production in ovarian carcinoma patients is considerable, and 
this is reflected by the fact that IL-10 serum levels drop significantly after de-bulking 
surgery (Mustea et al., 2009). 
In our study, selective neutralization of IL-10 alleviated suppressive effects of ovarian 
carcinoma associated ascites, largely restoring TLR-mediated monocyte-derived DC 
activation. We could further show that the effects of malignant ascites on DC extended 
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beyond their activation, impairing the cells’ T cell stimulatory capacity. However, 
once DC activation was recovered by IL-10 blockade, the ability of monocyte-derived 
DC to induce T cell proliferation equally returned. In consideration of this data, 
reducing levels of IL-10 in the ovarian carcinoma environment could potentially be a 
desirable strategy to enhance immunotherapeutic concepts, especially those intending 
to activate DC in situ. The decline in local and systemic levels of IL-10 as observed 
after de-bulking surgery presents an elegant window of opportunity which should be 
considered when designing timeframes for DC vaccination trials. 
Due to its many immunoregulatory functions in the body, a systemic blockade of 
IL-10 bears significant risk of uncontrolled immune activation. The importance of this 
cytokine in preventing chronic inflammation was demonstrated in murine IL-10 
knock-out (KO) models, which have shown that in absence of IL-10, mice develop 
chronic enterocolitis due to a failure to control an immune response to physiological 
enteric antigens. When challenged with pathogens, IL-10 KO mice mounted acute 
immune responses of significantly higher magnitude and duration than wildtype mice 
(Kuhn et al., 1993;Rennick et al., 1995). Despite these substantial consequences of 
IL-10 absence, in a small clinical study in patients suffering from systemic lupus 
erythematosus (SLE), selective IL-10 blocking antibodies were administered 
systemically, and this was surprisingly well tolerated (Llorente et al., 2000). It is 
important to note, however, that these patients were concomitantly receiving 
glucocorticoids, methotrexate and/or other immunosuppressive agents in line with 
their regular treatment regime for SLE, and side effects of excessive immune 
activation may therefore have been masked. Systemic IL-10 blockade therefore 
remains a precarious strategy which should be approached with caution, and clinical 
trials in larger cohorts may not be feasible. However, due to the limitation of ovarian 
carcinoma metastases to the peritoneal cavity even at late clinical stages, an 
intraperitoneal administration of selective IL-10 blocking agents may present an 
attractive option to lower local IL-10 levels with the aim of enhancing 
Chapter 4 Results 
 151 
immunotherapeutic strategies in situ. It may be worthwhile exploring this rationale in 
in vivo models of murine ovarian carcinoma where IL-10 signaling has also been 
shown to be of central importance to the regulation of immune responses within the 
tumour environment (Hart et al., 2011).  
While IL-10 was the main factor impairing TLR-mediated activation of monocyte-
derived DC in our study, we observed a residual suppression of activation upon IL-10 
blockade in presence of malignant ascites as compared to samples without ascites. This 
suggested that at least one additional factor suppressing DC activation other than IL-10 
was present in ovarian carcinoma ascites. Interestingly, in an identical experimental 
setup using benign peritoneal fluid, we saw no further suppression exerted by the fluid 
once the influence of IL-10 was neutralized. These findings pointed towards the 
existence of one or several soluble factors exclusively present in the malignant ovarian 
tumour environment and absent from benign conditions. A further indication that 
certain components distiguish the malignant environment from the benign was the 
observation (presented and discussed in chapter 3) that TLR-mediated TNFα induction 
remained unaffected by benign peritoneal fluid, but was potently suppressed in 
presence of malignant ascites. Additionally, while we detected a positive correlation 
between IL-10 levels in malignant ascites samples and the magnitude of suppression of 
the cytokines IL-6 and IL-12 as well as the surface marker CD86, TNFα suppression 
showed no such correlation with IL-10 levels. This led us to believe that while IL-10 
was of central importance to the suppression of IL-6, IL-12 and CD86, TNFα 
suppression may additionally be driven by one or more further factors which are only 
present in malignant ascites. 
Further experiments with neutralizing antibodies revealed that PGE2 selectively 
impairs TLR-mediated TNFα induction while leaving the other activation markers 
unaffected. PGE2 is an inflammatory mediator with known immunosuppressive 
function and has been shown to be crucial for DC migration and to influence cytokine 
release in response to TLR activation (Legler et al., 2006;Kalinski, 2012;Poloso et al., 
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2013). The study by Legler et al. suggests that varying concentrations of PGE2 may 
exert opposing influence on cytokine production by monocyte-derived DC upon TLR 
stimulation, and that this is in part due to differential use of the two functionally 
expressed PGE2 receptors on DC, EP2 and EP4. In our study, relatively low 
concentrations of PGE2 (≤ 0.75 ng/ml) were measured in ascites samples, and it is 
feasible that while this concentration may have been sufficient to suppress TNFα, 
higher levels may be necessary to effect other activation parameters. This speculation 
is supported by the fact that in experiments using recombinant PGE2 at considerably 
higher levels (≥ 10 ng/ml) than found in ascites, we did indeed detect a suppression of 
both IL-6, IL-12 as well as CD86. Experiments using a wide spectrum of 
concentrations of recombinant PGE2 and selective PGE2 receptor blockers would be 
necessary to elucidate in depth the precise mechanisms by which PGE2 acts upon DC 
activation. 
The selectivity of PGE2-dependent suppression of TNFα in our study is remarkable. 
Evidence from a study in trauma patients suggests that TNFα induction in monocytes 
may be regulated by PGE2, though the precise mechanism is likely to be very complex 
and not entirely understood (Laudanski et al., 2004). Similarly, it was shown in rodents 
that PGE2 can suppress the release of TNFα from macrophages after TLR-stimulation 
(Renz et al., 1988;Hubbard et al., 2010). 
The notion that PGE2 is a factor exclusive to the malignant tumour environment where 
it selectively suppresses TLR-mediated TNFα induction was further supported by the 
fact that while we detected a range of different PGE2 concentrations in the malignant 
ascites samples in our study, peritoneal fluid from patients with benign ovarian 
tumours was devoid of this protein. Reports describing PGE2 as a factor associated 
with the malignant tumour environment have emerged in the recent past (Lavoue et al., 
2012). PGE2 contributes to the establishment and maintenance of an 
immunosuppressive microenvironment by promoting development of myeloid-derived 
supressor cells (MDSC) and favouring the polarization of recruited monocytes into 
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TAM (Heusinkveld et al., 2011;Obermajer et al., 2012). As discussed above, TAM are 
major contributors of IL-10 to the tumour environment in ovarian carcinoma, and 
PGE2 may therefore, in fact, indirectly enhance IL-10 levels via TAM induction. The 
major sources of PGE2 in the course of an immune response are epithelial cells, 
fibroblasts and leukocytes infiltrating the site of inflammation (Kalinski, 2012) and 
these cells can equally be found within tumours. Compared to normal ovarian tissue 
and benign tumours, cancerous tissue in malignant ovarian tumours shows 
overexpression of cyclooxygenase-1 and -2 (COX-1 and COX-2, respectively), the key 
enzymes of PGE2 synthesis (Rask et al., 2006). Inhibitors of COX-1 and COX-2 are a 
widely used class of drugs referred to as non-steroidal anti-inflammatory drugs 
(NSAID) and are regarded as potentially powerful drugs for treatment of malignant 
conditions (Menter et al., 2010). NSAID block the synthesis of eicosanoids including 
PGE2 and are applied in a variety of medical conditions such as rheumatoid diseases. 
The use of COX inhibitors in cancer therapy and prevention is currently being 
explored and interestingly, COX inhibitors have previously been successfully used in 
murine experimental models of breast and lung tumours to enhance DC-based vaccines 
(Haas et al., 2006;Hahn et al., 2006). In light of our findings, the application of COX 
inhibitors may equally be an attractive measure to boost the efficacy of DC vaccines in 
ovarian carcinoma. 
It is important to note that PGE2 was not detected in all malignant ascites samples in 
our study, indicating that there may be two patient groups for which PGE2 either does 
or does not play a role in the tumour microenvironment. Investigating whether 
presence of PGE2 influences patient prognosis, correlates with other parameters of 
disease progression or affects susceptibility to treatment with COX inhibitors and/or 
immunotherapeutic intervention strategies would be of great interest. However, such 
hypotheses exceed the scope of our study, and much larger cohorts will be necessary to 
address these questions. 
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Chapter 5 
 
Contribution of ascites-derived versus autocrine IL-10 and 
PGE2 to suppression of TLR-mediated monocyte-derived DC 
activation 
 
Introduction 
 
As extensively shown and discussed in the previous chapters, stimulation of 
monocyte-derived DC with TLR agonists induces their activation, which is 
characterized by up-regulation of specific surface markers and production of 
pro-inflammatory cytokines. Previous reports have documented that upon TLR 
stimulation, DC equally produce the immunoregulatory protein IL-10 (Chang et al., 
2000;Jarrossay et al., 2001), and this was also confirmed in our study (chapter 3, 
Figure 3.6 A). Concomitant induction of the immunoregulatory factor IL-10 under 
inflammatory conditions is an important protective mechanism of the immune system, 
serving to prevent excessive and uncontrolled immune activation. This protein can act 
in autocrine and paracrine manner, affecting both the producing cells as well as 
surrounding cells and tissues. While these processes take place during inflammatory 
responses in vivo, they equally bear significance in experimental in vitro systems, 
where factors secreted by cells in culture inevitably influence the culture conditions. 
While studying which factors within ovarian carcinoma associated ascites impaired 
TLR-mediated activation of monocyte-derived DC in our assays, we selectively 
neutralized various immunosuppressive factors in cell cultures using specific 
antibodies. Our data have shown that neutralization of IL-10 leads to a potent 
restoration of DC activation in presence of ascites, pointing towards a central 
suppressive role of this cytokine in our experiments. However, the activation levels of 
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DC upon TLR stimulation in presence of IL-10 neutralizing antibody were 
considerably higher than those induced by TLR agonists alone. This observation 
revealed that autocrine IL-10 produced by monocyte-derived DC in cell cultures was 
contributing to the observed suppression, and prompted us to explore the relative 
importance of ascites-derived versus autocrine IL-10 in our experimental system. 
We also identified PGE2 as a factor present in ovarian carcinoma associated ascites 
which selectively impaired TNFα induction upon R848 stimulation. Previous reports 
indicate that different leukocyte populations produce PGE2 in the course of an immune 
response (Kalinski, 2012). However, our data, albeit limited, did not necessarily 
suggest that production of PGE2 by monocyte-derived DC played a role in our 
experiments (chapter 4, Figure 4.12 D). Our primary focus was therefore on the 
understanding of the roles of autocrine and ascites-derived IL-10, and in order to 
address this question, we designed an approach to selectively eliminate IL-10 from 
ascites samples used in our activation assays, while leaving autocrine IL-10 
unaffected. To achieve this, we depleted IL-10 from ascites and used such depleted 
fluid in cell cultures without further addition of IL-10 neutralizing antibodies. Our 
endeavours to perform these experiments, their outcome and the difficulties we 
encountered along the way are outlined in detail in this chapter. 
For a better understanding of the challenges we faced, it is of importance to emphasize 
that ovarian carcinoma associated ascites is a highly variable biological specimen 
containing an array of proteins, only a fraction of which we have quantified and 
addressed in our study. The pathophysiology of ascites formation has been outlined in 
chapter 1, and in malignant conditions that lead to ascites such as ovarian carcinoma, 
the fluid is particularly rich in proteins. The serum-ascites albumin gradient (SAAG) is 
a clinical parameter and diagnostic tool commonly used to distinguish between 
underlying conditions that lead to ascites formation (Chung and Kozuch, 2008): 
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Albumin is the most abundant protein in human serum, its typical concentration 
ranging between 3.5 – 5.0 g/dL. Since ascites is essentially a filtrate of serum, albumin 
is also present in ascites, but its levels vary depending on the pathophysiological cause 
that leads to ascites formation in a particular case. In peritoneal carcinomatosis, the 
reasons for retention of liquid in the peritoneal cavity include local lymph vessel 
obstruction by tumour cells, hormonal imbalances and others. The hydrostatic and 
osmotic pressure between the circulation and the extravascular compartment remain 
unchanged or are only slightly altered, leading to an albumin concentration in ascites 
similar to or only a little lower than in serum. This results in a SAAG of typically 
<1.1 g/dL (Chung and Kozuch, 2008).  
In contrast, if ascites is caused by high portal venous pressure, for example due to 
heart failure or liver cirrhosis, the hydrostatic pressure in the peritoneal venous 
circulation causes significantly more fluid to leave the blood vessels than is reabsorbed 
by osmotic pressure. Large amounts of protein-poor filtrate are accumulated in the 
peritoneal cavity while albumin is retained within the circulation. This leads to a 
relative dilution of extravascular protein leading to a considerably lower concentration 
of albumin in ascites than in serum. Consequently, in pathologies associated with high 
portal pressure, the SAAG reaches >1.1 g/dL (Kuiper et al., 2007). 
The typically high concentration of albumin in ovarian carcinoma associated ascites as 
reflected in the SAAG values in this disease can be extrapolated to other serum 
proteins such as immunoglobulins, but equally to a plethora of factors not associated 
with immunological processes, making ascites abundant with soluble proteins 
(Gortzak-Uzan et al., 2008). Regardless of whether particular ascites constituents have 
immunological function and/or direct effect on read-out parameters monitored in our 
experiments, when attempting depletion of a specific protein from ascites, all 
components of this material have to be taken into account and, as we have learned, 
reckoned with as potential agents that may interfere with the experimental design. 
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 5.1 Depletion of IL-10 from ovarian carcinoma associated ascites using 
αIL-10 antibody and Protein G agarose beads 
 
The experimental design of the first approach we took to deplete IL-10 from ascites in 
order to study the contribution of autocrine versus ascites-derived IL-10 is 
schematically illustrated in Figure 5.1. The rationale comprised addition of the 
previously used IL-10 specific neutralizing antibody to pure ascites to enable IL-10 in 
ascites to bind to this antibody, forming antibody-antigen complexes. Subsequently, 
we intended to remove such complexes by centrifugation after addition of agarose 
beads coated with Protein G, an immunoglobulin binding protein with a high affinity 
to the Fc and Fab regions of antibodies. The affinity of Protein G varies considerably 
for antibodies of different isotype and host species. Its very high affinity for mouse 
IgG2b antibody, the precise isotype of the IL-10 neutralizing antibody used for this 
depletion, made Protein G a suitable candidate for these experiments.  
In our initial pilot experiment, we incubated two malignant ascites samples from two 
ovarian carcinoma patients with IL-10 neutralizing antibody at two different 
concentrations of 5 µg/ml (identical to the concentration previously used in cell 
culture) and 20 µg/ml. The depletion was verified by measurement of IL-10 in the 
depleted samples, and indeed, IL-10 was not detectable in the samples depleted with 
the antibody concentration of 20 µg/ml (data not shown). We therefore considered this 
depletion to be successful, and conducted several monocyte-derived DC activation 
assays with these samples. We further depleted two more samples of IL-10 with this 
method, using the antibody concentration of 20 µg/ml. In the activation assays 
conducted with depleted ascites, we were interested to compare levels of activation 
induced by R848 in presence of non-depleted ascites with addition of IL-10 
neutralizing antibody versus IL-10 depleted ascites from the same patient. Our results 
showed very similar levels of CD86, IL-6, IL-12p40 and TNFα induced under both 
culture conditions (Figure 5.2 A-B). These data could be interpreted as indication of  
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Figure 5.1 Schematic depiction of rationale behind the experimental approach using α IL-10 
neutralizing antibody and Protein G coated agarose beads for depletion of IL-10 from ascites. 
(1) Neutralizing αIL-10 IgG2b antibody is added to ascites at a concentration of 20µg/ml, 
binding all IL-10 present in ascites. 
(2) Protein G coated agarose beads are added, binding to the antibody-antigen complexes with 
high affinity. 
(3) Centrifugation creates a pellet of agarose beads with bound antibody-antigen complexes; 
the pellet is clearly visible at the bottom of the centrifuge tube. 
(4) The supernatant of depleted ascites is transferred into a fresh centrifuge tube and used in 
experiments as depleted, IL-10-free ascites. The pellet containing agarose beads and 
antibody-antigen complexes is discarded. 
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autocrine IL-10 playing a negligible role in the suppression of TLR-mediated 
activation, because in the depleted samples, such autocrine IL-10 was still present but 
not neutralized, and yet the DC activation levels were comparable to samples were 
autocrine IL-10 was blocked. 
 
  
Figure 5.2 Activation assays performed in order 
to explore effects of ascites-derived versus 
autocrine IL-10 on TLR-mediated DC activation. 
(A-B) Monocyte-derived DC were stimulated with 
3µg/ml R848 in the presence or absence of 10% 
ascites as before. IL-10 neutralizing antibodies 
(5µg/ml) were added to cultures as indicated. 
Alternatively, DC cultures were treated with R848 
and ascites which had previously been depleted of 
IL-10; n=6 (DC from four different healthy volunteers 
were cultured with ascites from 3 different ovarian 
carcinoma patients. Altogether, 6 independent 
experiments were performed. Cells from two 
volunteers were cultured with only one ascites 
sample each, while cells from the remaining two 
donors were cultured with two different ascites 
samples each). CD86 expression levels were 
measured by flow-cytometry, and cytokine levels 
were measured in cell culture supernatants by 
sandwich ELISA. One-way ANOVA (Friedman test 
with Dunn post test): ns = not significant. (C) Levels 
of IL-10 neutralizing antibody in ascites samples 
after attempted depletion of IL-10 using Protein G 
coated agarose beads. The depletion was attempted 
with 5 µg/ml (lower panel) neutralizing antibody in 
two samples (n=2) and with 20 µg/ml (top panel) 
neutralizing antibody in four samples (n=4). 
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However, it is of pivotal importance to note that under both culture conditions, the 
levels detected for all activation markers were considerably higher when compared to 
‘baseline’ activation levels of R848 alone (Figure 5.2 A-B). This led us to discover a 
flaw in the design of the performed IL-10 depletion, and the pitfall we encountered is 
depicted schematically in Figure 5.3. The tumour environment in ovarian carcinoma 
harbours B lympohocytes (Nelson, 2010;Nielsen and Nelson, 2012;Nielsen et al., 
2012), and the ascites samples extracted from within this environment are therefore 
certain to contain human immunoglobulins, possibly at high concentrations. Although 
the first step of the protocol was successful and IL-10 neutralizing antibody 
specifically bound to IL-10 in ascites, the agarose beads coated with Protein G added 
in the next step not only reacted with these antibody-antigen complexes, but rather, 
either due to higher affinity and/or higher concentrations of human immunoglobulins, 
mainly formed bonds with the latter. Due to preferencial binding of human 
immunoglobulins, or, possibly, other proteins in ascites to the agarose beads, after 
centrifugation, the supernatant contained undesired IL-10 neutralizing antibody. Given 
the concentration of 20 µg/ml used in step 1, this residual antibody was most likely not 
saturated with IL-10. Hence, when this “depleted” supernatant was added to cell 
cultures, the IL-10 specific antibodies within had the capacity to also neutralize the 
autocrine IL-10 produced by monocyte-derived DC, explaining the elevated levels of 
activation in these samples when compared to ‘baseline’ levels of R848 alone.  
Since IL-10 in the “depleted” ascites was bound to the neutralizing antibody, it was 
undetectable in the IL-10 specific ELISA that had been performed to verify the 
depletion, desceptively mimicking a successful removal of IL-10. To confirm the 
hypothesis that residual IL-10 specific antibody was present in the depleted ascites, we 
performed ELISA for detection of mouse IgG2b and indeed found high levels of IL-10 
neutralizing antibody in ascites samples depleted with this method (Figure 5.2 C). The 
two samples from the pilot experiment depleted with a concentration of 5 µg/ml 
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αIL-10 antibody showed levels of approximately 4 µg/ml, indicating that 80% of the 
antibody used had not bound to Protein G beads and remained in the supernatant after 
centrifugation. Among the four samples depleted using 20 µg/ml, the IgG2b 
concentrations ranged from 13 – 17 µg/ml. It is highly unlikely that the binding 
capacity of the Protein G coated beads had been exceeded at the used concentration of 
20 µg/ml IL-10 neutralizing antibody, because the amount of beads added had a total 
binding capacity of 2 mg/ml IgG (≈ 100-fold higher).  
To summarize, these results confirmed that this approach was not successful, most 
likely due to direct competition of neutralizing antibody with proteins found in ascites, 
and a different experimental protocol had to be identified to achieve successful 
depletion of IL-10 from ascites. 
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Figure 5.3 Schematic depiction of pitfalls encountered with the experimental approach using 
α IL-10 neutralizing antibody and Protein G coated agarose beads for depletion of IL-10 from 
ascites. 
(1) Ascites from ovarian carcinoma patients contains a high concentration of the patient’s own, 
human immunoglobulins (green). Neutralizing αIL-10 IgG2b (black) is added to ascites at a 
concentration of 20µg/ml, successfully binding all IL-10 present in ascites.  
(2) Protein G coated agarose beads are added. For reasons of either higher affinity and/or 
higher concentration of human immunoglobulins in ascites, the antibody-antigen complexes 
consisting of mouse IgG2b and IL-10 are outcompeted by human immunoglobulins, which 
readily bind to the Protein G coated agarose beads. 
(3) Centrifugation creates a pellet of agarose beads with bound human immunoglobulins, 
leaving complexes of mouse IgG2b and IL-10 behind in suspension in the supernatant; the 
pellet is clearly visible at the bottom of the centrifuge tube. 
(4) The supernatant containing mouse IgG2b and IL-10 complexes is transferred into a fresh 
centrifuge tube. IL-10 cannot be detected by ELISA and this sample appears “depleted”, 
because IL-10 is neutralized by its specific antibody. The αIL-10 antibody is, however, 
present at high concentrations and when this “depleted” ascites is added to cultures, 
autocrine IL-10 is neutralized. 
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5.2 Alternative methods for IL-10 depletion from ovarian carcinoma ascites 
and their drawbacks 
 
The problems we encountered with our first approach to deplete IL-10 from ascites 
highlighted the difficulties one faces when working with a biological fluid containing 
an array of components that may affect experimental assays. Since no problems 
occurred with regards to the binding of IL-10 to the neutralizing antibody we used in 
the previous approach, we were content to use this same antibody in our next attempts. 
However, it had become clear that the removal of antibody-IL-10 complexes from 
ascites must be designed such that allows for specific elimination of these complexes 
only. If these attempts were high in their specificity, we would avoid competition with 
intrinsic components of ascites, making the chance of successful removal more likely. 
At the same time, such specific removal of antibody-IL-10 complexes would leave the 
other proteins in ascites unaffected, which was also highly desirable. With these aims 
in mind, we designed several approaches, the rationales and drawbacks of which are 
described in detail in the following sections. 
 
5.2.1 Depletion of IL-10 from ascites using streptavidin beads and magnetic 
column separation 
 
A schematic illustration of this experimental approach is shown in Figure 5.4. In order 
to achieve a specific removal of complexes formed between IL-10 and its neutralizing 
antibody (mouse IgG2b), we attempted to use a secondary anti-mouse IgG2b 
biotinylated antibody to target these complexes within the ascites sample. A 
subsequent addition of magnetic streptavidin beads would lead to a reaction with the 
biotinylated secondary antibody, leading to the formation of complexes between 
magnetic beads, secondary antibody and primary αIL-10 antibody with its bound 
ligand IL-10. By passing the sample over a magnetic column, we expected the  
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Figure 5.4 Schematic illustration of the experimental approach using streptavidin beads and 
magnetic column separation for depletion of IL-10 from ascites. 
(1) Neutralizing αIL-10 IgG2b (black) is added to ascites at a concentration of 10µg/ml, binding 
all IL-10 present in ascites, forming antibody-antigen complexes 
(2) A secondary biotinylated α-mouse IgG2b antibody is added and binds to all complexes of 
αIL-10 antibody and αIL-10. The naturally occurring human Ig remain unaffected. 
(3) Streptavidin magnetic beads are added to the mixture, reacting with the biotin on the 
secondary α-mouse IgG2b antibody. Complexes consisting of streptavidin beads, 
biotinylated secondary antibody, and αIL-10 antibody bound to IL-10 are formed. 
(4) The sample is loaded onto a magnetic column, where magnetic streptavidin beads are 
retained together with both secondary antibody and primary αIL-10 antibody and its ligand 
IL-10. 
(5) The flow-through, now depleted of IL-10 but still containing its other components is collected 
in a fresh centrifuge tube. 
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magnetic streptavidin beads to be retained within the column together with its bound 
antibody-antibody-antigen complexes. The collected flow-through after passage over 
the column would now be depleted of IL-10 as well as the neutralizing antibody. 
The concentration of αIL-10 antibody used in step 1 of this protocol was 10 µg/ml. We 
chose this concentration because previous titration experiments as well as the technical 
data sheet for this antibody indicated that this concentration is abundantly sufficient to 
neutralize the levels of IL-10 found in the used ascites sample. Although 20 µg/ml had 
been used previously (see above, section 5.1), this was considered unnecessary and the 
concentration was therefore adjusted to 10 µg/ml in this experiment. To ensure binding 
of all primary antibody in step 2 of this protocol, we added the secondary biotinylated 
antibody at a concentration of 20 µg/ml. Generous incubation times were provided in 
all steps of this protocol to allow the individual components to bind successfully. The 
streptavidin beads used (Miltenyi Biotec) are typically used for cell separation, and the 
amount required is therefore usually calibrated to the cell number processed. The 
amount we used in this experiment therefore had to be estimated but was rather 
generous in order to ensure binding of all secondary antibody, since this was crucial 
for the retention of antibody-antibody-antigen complexes within the magnetic column. 
We repeated step 4 of the protocol 3 times, i.e. the sample was passed over three fresh 
magnetic columns to ensure complete removal of complexes. 
Although after each column passage the levels of αIL-10 antibody as detected by 
IgG2b ELISA decreased, residual antibody of 0.2 µg/ml was present even after the last 
passage (Figure 5.5 A). Importantly, the secondary biotinylated antibody must have 
also been present, because the biotin interferred with the sandwich ELISA used to 
detect IL-10 levels in the depleted sample, creating an artifact of several-fold higher 
levels of IL-10 in the depleted samples compared to a non-depleted control 
(Figure 5.5 B). We therefore could not verify whether IL-10 was still present or not. A 
further pitfall of this protocol arose from the need to pre-moisten the magnetic 
columns used with PBS before loading of the sample. This led to a dilution of the 
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ascites sample, which could be observed as a fading of its natural yellowish colour, 
becoming increasingly less intense after each of the three column passages. This 
dilution could not be precisely quantified, and it would therefore be impossible to 
account for in future experiments when comparing with non-depleted ascites. The 
dilution phenomenon also led us to believe that the gradual decrease in αIL-10 
antibody concentration (Figure 5.5 A) after each column passage may, in fact, not be 
the sign of successful removal of the antibody-antibody-antigen complexes, but may 
be in part an artefact caused by the dilution of the ascites samples with PBS. 
For all these explained reasons, we deemed this approach not suitable for depletion of 
IL-10 from ascites samples and had to resort to alternative protocols. 
  
Figure 5.5 Attempted depletion of IL-10 from ascites using streptavidin magnetic beads and 
magnetic columns.  
(A) Levels of IL-10 neutralizing antibody in ascites samples after attempted depletion of IL-10 using 
the protocol described in section 5.2.1. IgG2b levels were measured by ELISA either before 
passage of the ascites sample through magnetic columns (‘pre column’) or after one, two or three 
passages. (B) Results of IL-10 specific sandwich ELISA performed on ascites from this attempted 
depletion assay. IL-10 levels were measured after addition of IL-10 neutralizing antibody, secondary 
biotinylated antibody and streptavidin beads, and either before passage through magnetic columns 
(‘pre column’) or after one, two or three passages. In all samples, the levels of IL-10 appear 
considerably higher than in an undepleted control. This is due to an artefact of interferrence of 
biotinylated secondary antibody and/or streptavidin beads with our IL-10 ELISA. With increasing 
passages over magnetic columns, the measured values drop, indicating gradual removal of 
biotinylated antibody and/or streptavidin beads.  
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5.2.2 Depletion of IL-10 from ascites using magnetic Protein G beads pre-coated 
with IL-10 specific neutralizing antibody 
 
Despite the problems we encountered with the use of Protein G coated agarose beads 
(see above, section 5.1), Protein G remained an agent worth considering for our 
purposes because of its very high affinity to immunoglobulins and its frequent use in 
antibody purification and immobilization protocols. We hypothesized that it had been 
the competition with other proteins present in ascites that led to unsatisfactory binding 
of neutralizing antibody to the beads, and therefore to its residue in the IL-10 depleted 
samples. 
To avoid the direct competition for binding sites between neutralizing antibody and 
ascites-intrinsic proteins, in our next approach (Figure 5.6) we pre-coated magnetic 
Protein G beads with the neutralizing antibody before addition of such complexes to 
ascites samples. We expected that binding sites on Protein G beads that were already 
occupied by IL-10 neutralizing antibodies when encountering proteins in ascites would 
not be subject to competition. We hoped to achieve a binding of IL-10 to its 
neutralizing antibody that had been immobilized on the magnetic Protein G coated 
bead, and a subsequent removal of bead-antibody-antigen complexes by magnetic 
separation. The binding capacity of the used magnetic beads coated with Protein G 
was very high, and it was not feasible to saturate the beads using the IL-10 neutralizing 
antibody. However, we wanted to ensure that binding sites that remained vacant did 
not attract proteins from ascites, thereby altering its composition beyond IL-10 
depletion. Therefore, after successful coating of beads with the neutralizing antibody 
(Figure 5.6, after step 1) and before addition to ascites (Figure 5.6, before step 2), we 
saturated the bead binding capacity using chromatographically purified unspecific 
mouse IgG (this step is not depicted in Figure 5.6). 
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Figure 5.6 Schematic depiction of the rationale behind the experimental approach using 
magnetic Protein G beads pre-coated with neutralizing IL-10 antibody for depletion of IL-10 
from ascites. 
(1) Protein G magnetic beads are incubated with IL-10 neutralizing antibody. The antibody binds 
to Protein G beads with high affinity. 
(2) The beads pre-coated with IL-10 neutralizing antibody are added to ascites and incubated to 
allow binding of IL-10 to its neutralizing antibody. The incubation times chosen were 1 hour 
or 16 hours overnight. 
(3) A powerful block magnet is used to remove complexes of beads, neutralizing antibody and 
IL-10 by retaining them at the wall of the centrifuge tube while…  
(4) the remaining, IL-10 depleted fluid is carefully transferred into a fresh centrifuge tube by 
pipetting. 
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In our first depletion attempt with this method, we incubated the ascites samples with 
the pre-coated beads overnight with continuous mixing (after step 2, before step 3). 
After removal of bead complexes (after step 4), we measured IgG2b levels in the 
depleted samples. The amount of neutralizing IL-10 antibody used to pre-coat the 
magnetic beads had been 10 µg. Disappointingly, the detected levels of IL-10 
neutralizing antibody in this sample reached the considerable level of 2 µg 
(Figure 5.7), indicating that 20% of the starting amount of antibody must have 
detached itself from the beads during incubation. We suspected that this may have 
been due to the long overnight incubation time, and hence repeated the experiment, 
reducing the incubation to 1 hour. However, after this time, the levels of IgG detected 
in the ascites sample were even higher, reaching a level close to 10 µg, which was 
almost 100% of the starting amount of neutralizing antibody. (Figure 5.7).  
  
Figure 5.7 IgG2b levels in ascites samples 
after attempted depletion of IL-10 using 
magnetic Protein G beads pre-coated with 
IL-10 neutralizing antibody. 
In two independent experiments, two different 
incubation times (16 hours overnight or 1 hour) 
were chosen. After both attempts, IgG2b was 
detected in high levels in ascites. 
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We concluded that evidently, even after pre-coating of Protein G beads with IL-10 
neutralizing antibody before addition to ascites, the binding sites on the beads remain 
subject to competition. Due to higher affinity and/or concentration, neutralizing 
antibodies are outcompeted and displaced from their binding sites by proteins found in 
ascites. 
This experimental approach has shown us that despite its high affinity to mouse IgG2b 
(the isotype of the neutralizing IL-10 antibody used) Protein G is not suitable for our 
purposes because it appears to bind human immunoglobulins and possibly other 
proteins in ascites with a superior affinity. 
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5.3 Successful depletion of IL-10 and PGE2 from ascites using neutralizing 
antibodies covalently bound to NHS ester coated magnetic beads 
 
After several failed attempts, we have identified a successful method for specific 
depletion of cytokines from ascites, using magnetic beads coated with NHS ester 
groups which have the ability to covalently bind antibodies. These beads are 
commercially available (Millipore), and the technical details of this method are 
described in Chapter 2 Material and Methods, section 2.11.4. The rationale closely 
resembles that of the aforementioned protocol which uses Protein G magnetic beads 
pre-coated with cytokine-specific neutralizing antibody (see above, section 5.2.2). 
However, an important difference is the nature of the bond formed between the 
magnetic bead and the neutralizing antibody. While the antibody binds to Protein G in 
a reversible way which can be easily disrupted e.g. in presence of another 
immunoglobulin with higher affinity to Protein G, the bond formed between NHS ester 
groups on the magnetic beads used in this protocol and free amine groups of the 
neutralizing antibody is covalent (Figure 5.8). 
We first tested this method to deplete IL-10 from one ascites sample. When 
performing an IgG2b specific ELISA on the depleted sample, we could detect a 
concentration of 0.0013 µg/ml IL-10 neutralizing antibody (data not shown). The data 
sheet of this antibody provides titration guidelines suggesting that this concentration of 
antibody has no neutralizing ability. Additionally, if using this sample in cell culture in 
our usual protocol, it would only be added at 10% of the final well volume, and 
therefore further diluted by a factor of 10. We were therefore confident that this 
amount of neutralizing antibody would not neutralize autocrine IL-10 and was 
therefore negligible. The success of the depletion of IL-10 was further verified by 
IL-10 specific ELISA. The depleted sample showed IL-10 levels below the assay's 
sensitivity, while a mock-depleted control sample, using unspecific mouse IgG2b  
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Figure 5.8 Schematic depiction of the experimental approach using magnetic NHS ester 
coated beads with neutralizing IL-10 antibody for depletion of IL-10 from ascites. 
(1) Magnetic NHS ester beads are coated with IL-10 neutralizing antibody. The bonds between 
the NHS ester group on the beads and free amines of the antibody are covalent. The 
covalent binding is achieved by following a carefully optimized protocol using specific buffers 
of defined composition and pH values. 
(2) Such pre-coated beads are added to ascites and incubated overnight to allow binding of 
IL-10 to its neutralizing antibody. 
(3) A powerful block magnet is used to remove complexes of beads, neutralizing antibody and 
IL-10 by retaining them at the wall of the centrifuge tube. 
(4) The remaining, IL-10 depleted fluid is carefully transferred into a fresh centrifuge tube by 
pipetting. 
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isotype control antibody, contained IL-10 at levels identical to the undepleted ascites 
(Figure 5.9). 
Following this protocol, we depleted three further ascites samples from different 
patients of IL-10, verifying the success of this method by measuring IgG2b and IL-10 
levels in the depleted samples each time. IgG2b levels were below 0.001 µg/ml and 
IL-10 was not detectable in all depleted samples (data not shown). 
As described in Chapter 4, we had identified PGE2 as a further suppressive factor in 
ovarian carcinoma associated ascites acting alongside IL-10, specifically impairing 
TNFα production by monocyte-derived DC upon R848 stimulation. Although initial 
experiments did not suggest a contribution of autocrine PGE2 to this suppression (see 
Chapter 4, Figure 4.7 D), PGE2 can be produced by all cells of the body and we 
wanted to exclude the role of autocrine PGE2 more robustly. Comparison of activation 
in cultures using ascites depleted of PGE2 versus PGE2 neutralizing antibody presented 
an elegant method to test this, and we therefore used the same depletion protocol as 
described above for IL-10 to deplete 2 ascites samples from ovarian carcinoma patients 
of PGE2. As with the IL-10 depletion, levels of PGE2 specific neutralizing antibody in 
the depleted samples were in the range of 0.001 – 0.0013 µg/ml and therefore 
negligible (data not shown).  
  
Figure 5.9 IL-10 levels in ascites after 
depletion using NHS magnetic beads. 
IL-10 was measured by sandwich ELISA. While 
levels in the IL-10 depleted sample (middle) 
were below the sensitivity of the assay, levels in 
a mock depleted sample (right bar) using 
unspecific IgG2b isotype control antibody 
remained unaffected by the depletion procedure 
and were identical to the undepleted control (left 
bar). 
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PGE2 removal from depleted samples was verified by PGE2 specific ELISA. We saw a 
considerable decrease in PGE2 levels in one of the depleted samples (Figure 5.10 A), 
indicating an almost complete removal of PGE2 from ascites. The second ascites 
sample contained an approximately three-fold higher starting concentration of PGE2, 
and here we observed PGE2 levels reduced by 60% upon depletion (Figure 5.10 B). 
Importantly, in both samples, PGE2 remained unaffected by mock depletion. In 
principle, the method was therefore successful and specific, but it appears that the 
antibody reached its saturation and could not bind all PGE2 present. The protocol for 
depletion of PGE2 therefore requires optimization in terms of the amount of αPGE2 
coated NHS beads used, or rounds of depletion that are necessary for complete protein 
removal. 
 
  
Figure 5.10 PGE2 levels in ascites after depletion using NHS magnetic beads. 
PGE2 was measured by sandwich ELISA. Levels of PGE2 were determined in undepleted, PGE2 
depleted and mock depleted ascites samples. One ascites sample is shown in A and B, 
respectively.  
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5.4 Initial experiments with IL-10 or PGE2 depleted ovarian carcinoma ascites 
 
Having at last succeeded in identifying a method which allowed us to specifically 
deplete either IL-10 or PGE2 from ovarian carcinoma associated ascites, we conducted 
first experiments using these samples in order to elucidate the contribution of autocrine 
production of these two proteins to the observed suppresion of TLR-mediated 
activation of monocyte-derived DC. It is important to note that this work is ongoing at 
present and the data shown in this section are therefore very preliminary. 
We performed an activation assay using R848 as TLR stimulant, adding IL-10 
depleted ascites from three patients to cell cultures at a final concentration of 10%. We 
included control samples using undepleted ascites from the same patients, also at a 
concentration of 10% with or without addition of IL-10 neutralizing antibody (5 µg/ml 
as previously). We observed no alleviation of suppression for CD86, IL-6 or IL-12 
where IL-10 depleted ascites was added to cultures (Figure 5.11). This was also not 
observed for TNFα induction, but it is important to note that surprisingly, we did not 
see a suppression of TNFα in presence of ascites in this experiment (Figure 5.11, 
graph on the far right), and it is therefore not possible to conclusively interpret the 
influence of undepleted versus depleted ascites on TNFα in this instance. However, 
what is very clear in this assay is the striking impact that neutralization of autocrine 
IL-10 has on activation levels of monocyte-derived DC upon R848 stimulation. This is 
in accordance with our previous sets of data in this study using neutralizing IL-10 
antibodies. 
This assay was conducted before PGE2 depletion could be verified by PGE2-specific 
ELISA, and we were therefore not aware that removal of PGE2 may have been 
incomplete. PGE2 depleted samples had therefore also been included in this assay with 
their respective controls of undepleted ascites plus PGE2 specific neutralizing 
antibody. However, because of the lack of suppression of TNFα in this experiment, 
these data were inconclusive (data not shown). 
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Further experiments with depleted ascites are necessary to elucidate the impact of 
autocrine IL-10 and PGE2 on monocyte-derived DC activation in our experimental 
system. Having established a reliable method of specific depletion of the desired 
proteins from ascites, we hope to avoid further technical pitfalls while these important 
experiments are underway. The first experiment shown in Figure 5.11 points towards 
an overriding role of autocrine IL-10 in comparison to ascites-derived IL-10. However, 
these data require verification, and additional controls as well as further experimental 
procedures may in fact reveal more complex and intricate pathways regulating 
monocyte-derived DC activation in presence of ovarian carcinoma associated ascites. 
Our ongoing work and its rationale for dissecting the role of autocrine versus ascites-
derived factors in our experimental scenario are put forward in more detail in the 
discussion to this chapter.  
Figure 5.11 Initial activation assays performed with ascites that had been successfully 
depleted of IL-10 in order to explore effects of ascites-derived versus autocrine IL-10 on 
TLR-mediated DC activation. 
Monocyte-derived DC were stimulated with 3µg/ml R848 in the presence or absence of 10% ascites. 
IL-10 neutralizing antibody (5 µg/ml) was added to cultures as indicated. Alternatively, DC cultures 
were treated with R848 and ascites which had previously been depleted of IL-10; For R848 n=1, for 
the other samples n=3 (1 experiment using monocyte-derived DC from one healthy control which 
were treated with ascites from three different ovarian carcinoma patients). CD86 expression levels 
were measured by flow-cytometry, and cytokine levels were measured in cell culture supernatants by 
sandwich ELISA.  
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Discussion 
 
Ascites from ovarian carcinoma patients lends itself to research studies exploring the 
tumour environment in this disease, because its cellular composition as well as soluble 
factors within reflect to a great extent the constitution of the solid tumour mass. Its 
liquid form makes it a convenient material to study, since, if required, the soluble 
components can be separated from the cellular fraction by simple methods such as 
centrifugation and filtration, allowing for studies of its specific constituents. The 
experimental data presented in this chapter outline the difficulties we encountered 
when working with cell-free ascites and attempting its depletion of specific soluble 
factors. 
Ascites is a biological fluid abundant with proteins, and their characterization has been 
the focus of several studies in the past, mostly with the aim to single out candidates 
that bear potential for clinical use as tumour biomarkers for diagnostic and disease 
monitoring purposes. A proteomic study of ovarian carcinoma associated ascites has 
identified more than 2500 proteins, 229 of which were found in the cell-free 
supernatant obtained after centrifugation, material identical to that used in our study 
(Gortzak-Uzan et al., 2008). These 229 proteins are likely to represent only the most 
abundant candidates, because the authors disclose the lack of detection of certain 
growth factors such as VEGFα and TGFβ which are well documented as components 
of ovarian carcinoma ascites, and explain that these proteins were most likely missed 
in the proteomics analysis due to their relatively low abundance. Hence, it is only 
natural that the myriad of soluble factors in our ascites samples made a selective 
depletion of a particular protein very challenging, and as we have shown, in the 
protocol that finally led to the successful depletion of IL-10 and PGE2, we had to take 
the composition of ascites into careful consideration. 
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The difficulties we encountered in our depletion attempts using protein G coated beads 
suggested the presence of ascites-associated proteins that competed for protein G 
binding sites with the αIL-10 neutralizing antibody used. Protein G is a streptococcal 
cell wall protein featuring binding domains for Fc and Fab fragments of 
immunoglobulins (Grubb et al., 1982;Kraulis et al., 1996). Because of this property, it 
is widely used for purification and immobilization of immunoglobulins for various 
applications. While IgG of numerous species including mouse and human IgG show 
high affinity for protein G, other human immunoglobulin subclasses such as IgA, IgD 
and IgM do not bind to protein G (Bjorck and Kronvall, 1984). The native molecule of 
protein G also features an albumin binding domain (Kraulis et al., 1996). The 
physiological concentration range of serum albumin is 3.5 – 5.0 g/dL, and as explained 
in the introduction to this chapter, its ascitic concentration in ovarian carcinoma is 
typically only slightly lower than in serum, resulting in considerable levels of albumin 
within the ascites. Due to its small size of 67 kilodalton (kDa), albumin easily passes 
through the filters used for filtration of our ascites samples and it was therefore present 
during depletion. However, interference of albumin with protein G was not a concern 
in our protocols, because the recombinant protein G used in our study has been 
modified such that it is devoid of its albumin binding domain. This modification is 
typically implemented on commercially available protein G with precisely this aim to 
circumvent undesired interference with albumin and ensure undisturbed binding of 
immunoglobulins (Akerstrom et al., 1987;Goward et al., 1990). 
Given the adaptation of recombinant protein G as described above, the most likely 
components responsible for the difficulties we ran into in our protocols were human 
IgG molecules present in ascites. Human immunoglobulins are produced by plasma 
cells which arise from B lymphocytes after encountering antigens, receiving activation 
signals from helper T cells and being subjected to differentiation, enabling them to 
exert their effector function (Murphy et al., 2008). Circulating IgG levels in plasma are 
influenced by multiple factors such as age, gender and antigens encountered to date, 
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with values within the approximate range of 0.75 – 2 g/dL considered physiological 
(Stoop et al., 1969;Gonzalez-Quintela et al., 2008). IgG molecules migrate from the 
blood and diffuse into extravascular sites, and IgG has been detected in ascites of 
patients suffering from various pathologies, such as ovarian hyperstimulation 
syndrome (Abramov et al., 1999), peritoneal tuberculosis, bacterial peritonitis and 
different peritoneal malignancies including ovarian carcinoma (Abramov et al., 
1999;Yildirim et al., 2002). 
While diffusion from plasma is likely to be the most important source of IgG in 
ascites, it cannot be entirely excluded that more local processes of B cell activation and 
differentiation into plasma cells take place. Among the leukocyte populations 
infiltrating the tumour microenvironment of ovarian carcinoma, B lymphocytes are 
poorly studied. There is evidence suggesting their presence in ascites, although they 
are described as rather sparse in comparison with T cells, only constituting 
approximately 5-8% of the cellular infiltrate (Merogi et al., 1997;Melichar et al., 
2001). However, rather than in suspension in ascitic fluid, B cells are likely to be 
present in surrounding tissue, in particular in the greater omentum, which in conditions 
of peritoneal carcinomatosis is typically abundant with immune aggregates, commonly 
referred to as ‘milky spots’. Perspectives on the importance of ‘milky spots’ in 
intraperitoneal immunity are controversial, with some reports regarding them as a 
dynamic form of secondary lymphoid tissue, referred to as omentum associated 
lymphoid tissue (OALT) (Shimotsuma et al., 1991;Heel and Hall, 1996). In this 
scenario, B cell differentiation into plasma cells and local immunoglobulin production 
is thought to take place in the omentum. Others support the notion that despite 
presence of immune cells including B  and T lymphocytes in omental ‘milky spots’, 
these structures should not be classified as secondary lymphoid organs (Van Vugt et 
al., 1996;Yildirim et al., 2010). Several reports suggest that with their composition of 
adipose tissue, collagen, and abundant vasculature, ‘milky spots’ are likely to play an 
important role in metastasis formation due to the inclination of malignant cells to 
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adhere to these areas (Van Vugt et al., 1996;Gerber et al., 2006;Sorensen et al., 
2009;Khan et al., 2010;Clark et al., 2013). Given the abundance of conflicting reports, 
the exact role of these omental aggregates remains somewhat enigmatic, and with 
particular regard to our study, it is impossible to assess the potential contribution of 
intraperitoneal B lymphocytes to IgG concentration within ascites in ovarian 
carcinoma. 
As explained above, a limited number of studies have examined IgG levels in ascites 
in patients with various pathologies, but the data available is very sparse, and does not 
distinguish between peritoneal malignancies according to organ origin (Yildirim et al., 
2002). In this regard, it is, however, important to note that even within a uniform 
patient group comprising only patients suffering from ovarian carcinoma, each 
patient’s tumour tissue composition and immunological constitution is unique, and the 
concentration of IgG in different ascites samples is likely to be subject to large 
variations. 
Despite no conclusive indication to date of exact IgG concentrations that might be 
expected to be found in our samples, we hypothesize that human IgG molecules in 
ascites were the deterrant in our attempts to deplete IL-10 with the use of protein G 
coated beads. It is likely that ascites derived IgG outcompeted the αIL-10 neutralizing 
antibody used for depletion in our study, occupying the majority of protein G binding 
sites and leaving the neutralizing antibody unbound and thus leading to residual 
αIL-10 antibody in depleted samples. This was the case both when αIL-10 antibody 
was added to ascites first and protein G coated agarose beads were added 
subsequently, as well as when protein G magnetic beads were pre-coated with the 
αIL-10 antibody before encountering the ascites components. The reasons for this 
outcompetition may have been either a considerably higher concentration of human 
IgG within ascites than mouse IgG used, or superior affinity of human IgG to 
protein G binding sites, or both. 
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The concentration of human IgG can be simply determined by ELISA, and in order to 
gain a better understanding of the difficulties we encountered, we plan to perform 
these measurements on undepleted samples and further on samples obtained from the 
attempts of IL-10 depletion by protein G coated beads. The concentration of human 
IgG in undepleted ascites samples will give us an indication of its ratio to the 
concentration of mouse αIL-10 IgG that we used. Assuming our hypothesis is correct 
and protein G binding sites during depletion were largely occupied by human IgG, a 
decrease of human IgG concentration in ascites samples after depletion should become 
apparent. Given the large binding capacity of the beads used in both attempts, this 
decrease may indeed be detectable by ELISA. Clarifying the reason for the failure of 
the depletion protocols using protein G coated beads will enable us to better 
understand the ascites composition and inform future studies using this material. 
The attempt of cytokine depletion using streptavidin beads and magnetic columns 
posed many difficulties and was for a number of reasons not suitable for our purposes. 
Issues such as the necessity to calibrate magnetic columns with PBS leading to a 
dilution of ascites samples originated from the fact that magnetic column separation is 
typically used for cell enrichment where dilution of soluble components is of no 
concern. While it is often necessary to employ creativity in the laboratory when 
establishing new protocols, caution should be taken when straying far from the well 
established use of certain reagents and material for new applications. 
Our initially unsuccessful attempts to deplete IL-10 from ascites finally led us to resort 
to the use of magnetic beads coated with NHS ester groups which form covalent bonds 
with free amine groups on the depleting αIL-10 antibody. With this protocol, we 
achieved successful removal of IL-10 from four ascites samples, and have shown that 
only negligible concentrations of residual neutralizing antibody are found in the 
depleted samples. We further extended this method to the use of specific αPGE2 
antibody, and have equally successfully shown that PGE2 can be selectively depleted 
from ascites samples, although PGE2 depletion was not complete where higher 
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concentrations were present, and further optimization regarding amount of 
antibody-coated beads and/or rounds of depletion is necessary. The established 
depletion protocol is likely to be applicable for the selective removal of a multitude of 
other ascites proteins for which specific antibodies are available.  
Our preliminary data from experiments conducted with ascites depleted of IL-10 or 
PGE2 need further confirmation and exploration. In the first experiment with depleted 
ascites samples as presented in this chapter, we did not observe a suppression of TNFα 
induction with malignant, non-depleted ascites. Comparison to samples with PGE2 
depleted ascites in this experiment was therefore to no avail, because these data could 
not inform about the contribution of autocrine versus ascites-derived PGE2 to TNFα 
suppression which had been seen in our previous experiments. The remaining markers 
of activation were, however, suppressed in presence of ovarian carcinoma associated 
ascites, and we could therefore assess whether or not IL-10 depletion from the fluid 
alleviated this suppression. We used IL-10 depleted versus non-depleted ascites 
samples from three different ovarian carcinoma patients and tested their influence on 
R848-mediated activation of monocyte-derived DC from one donor only, hence these 
data are very limited and preliminary. However, they point towards a strongly 
overriding effect of autocrine IL-10 in the suppression of TLR-mediated up-regulation 
of CD86, and production of IL-6, IL-12p40 and even TNFα, because, as seen 
previously, addition of neutralizing αIL-10 antibody elevated the levels of all these 
markers far beyond the levels of samples cultured in presence of R848 only. 
Surprisingly, it appears that ascites-derived IL-10 does not have an impact on DC 
activation, since its depletion does not change levels of any activation markers. This is 
puzzling, because in our previous experiments as outlined in chapter 4, we saw a 
strong positive correlation between IL-10 levels in ascites and suppression of 
activation. It is unlikely that this correlation was entirely coincidental, but equally, 
given that depletion of ascites-derived IL-10 showed no relevance in our last 
experiments, it appears that IL-10 in ascites does not suppress TLR-mediated DC 
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activation in a direct manner. Studies of monocyte-derived DC in the field of 
autoimmunity and rheumatology have shown that presence of particular cytokines 
including IL-10 and IL-6 during DC maturation is necessary for the subsequent 
production of substantial amounts of autocrine IL-10 upon TLR activation (Torres-
Aguilar et al., 2010;Hilkens and Isaacs, 2013). It is therefore feasible that 
ascites-derived IL-10 together with other factors found in ascites exert their 
suppressive function indirectly by leading to increased autocrine IL-10 production, and 
that such autocrine IL-10 is, in fact, the main agent directly responsible for the 
suppression of DC activation. However, we could not detect increased IL-10 
production upon TLR activation in presence of ascites in our study (see chapter 3, 
Figure 3.6 C). These assumptions are therefore highly speculative, and nevertheless 
question the importance and contribution of ascites-derived IL-10 towards the 
observed ascites-induced suppression of DC activation. The regulation of cytokine 
production by DC is complex and comprises an intricate network of factors and 
receptors. The exact mechanisms behind the suppression of TLR-mediated activation 
of monocyte-derived DC as observed in our study remain unclear and require further 
clarification. 
Regardless of the outcome of these further investigations, dissecting the role of 
autocrine versus ascites derived IL-10 and PGE2 will provide a much more thorough 
insight into the mechanisms underlying the suppression of TLR-mediated activation of 
monocyte-derived DC than the use of neutralizing antibodies in cell cultures alone can 
contribute. This also applies to future studies of this kind where it may be of interest to 
elucidate autocrine immunoregulatory or –stimulatory cytokine networks. 
Distinguishing the differential influences of tumour-derived versus autocrine factors 
on DC and their activation with TLR agonists may constitute an important step 
towards a more thorough and profound understanding of the complex interactions 
within the tumour environment and may inspire more elaborate immunotherapeutic 
concepts in ovarian carcinoma. 
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Chapter 6 
 
Discussion 
 
 
In this study, we have investigated the influence of soluble factors within the ovarian 
carcinoma microenvironment on activation of DC by TLR agonists. Our findings have 
shown that the presence of ascites from patients suffering from advanced stage high-
grade serous ovarian carcinoma impairs TLR-mediated activation of monocyte-derived 
DC, as observed by reduced up-regulation of the co-stimulatory molecule CD86 on the 
surface of DC, as well as decreased production of the cytokines IL-6, IL-12p40 and 
TNFα. Other markers of activation, such as surface molecules CD40, HLA-DR or 
PD-L1 and cytokines IL-1β and IL-10 remained unaffected by ascites, pointing 
towards the selective alteration of certain pathways in monocyte-derived DC by factors 
within the ovarian carcinoma environment. Peritoneal fluid from patients with benign 
tumours of the ovary equally suppressed the TLR-mediated up-regulation of CD86 and 
production of IL-6 and IL-12p40. Intriguingly, TNFα levels remained unaltered in 
presence of benign fluid, suggesting that one or several factors present in ovarian 
carcinoma associated ascites with selective effect on TLR-mediated TNFα induction 
distinguish the malignant tumour environment from benign conditions. 
With the use of specific neutralizing antibodies, we could identify the 
immunosuppressive cytokine IL-10 as an agent central to the observed suppression. 
Upon addition of αIL-10 antibody to cultures of monocyte-derived DC in presence of 
malignant ascites, activation by TLR7/8 agonist R848 and TLR4 agonist LPS was 
once more restored, and notably, the activation levels exceeded those achieved in 
presence of the respective TLR agonist alone. We further identified PGE2 as a protein 
present in malignant ascites, and its selective neutralization alleviated the suppression 
of TNFα production by DC upon R848 stimulation. The specificity of TNFα 
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suppression by PGE2 in ovarian carcinoma associated ascites was striking, with other 
activation markers remaining unchanged upon PGE2 neutralization. PGE2 was absent 
from peritoneal fluid of patients with benign ovarian tumours in our study, and given 
the increasingly suggested importance of eicosanoids and COX inhibitors in cancer 
immunology and immunotherapy, this protein may represent an intriguing candidate 
for further study in the context of ovarian carcinoma. 
It is important to note, however, that even in the case of TNFα suppression, IL-10 was 
the central suppressive agent. The production of immunoregulatory factors including 
IL-10 by DC in order to prevent excessive immune activation is an important 
component of TLR stimulation. The fact that neutralization of IL-10 in cell cultures 
induced DC activation levels far beyond those promoted by TLR activation alone was 
a clear indication that such autocrine IL-10 was taking influence on DC and 
contributing to suppression of their activation. We felt prompted to explore the 
respective importance of ascites-derived and autocrine IL-10 in our experimental 
culture system. In pursuit of this scientific question, we have established an elegant 
method for selective depletion of IL-10 from ascites samples, using specific αIL-10 
antibody covalently ligated to magnetic beads. As shown with the subsequent 
depletion of PGE2 from ascites, this method is further applicable for removal of other 
proteins. 
Our preliminary data with ascites devoid of IL-10 indicate that, in fact, depletion of 
this cytokine from ascites does not restore monocyte-derived DC activation by TLR7/8 
agonist R848. These findings point towards an important role of autocrine IL-10 in our 
experimental system, however, as discussed in chapter 5, these results require further 
confirmation and clarification. 
The need to understand the composition of the tumour environment and its effects on 
immunotherapeutic interventions is evident. In this regard, IL-10 represents a factor 
well documented in ovarian carcinoma by several previous studies, attributed an 
important role as a component of the immunosuppressive milieu with potential 
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correlation to disease stage and prognosis. Selective depletion of IL-10 as performed in 
our study may, however, reveal that despite its indisputable immunosuppressive 
properties, IL-10 in ovarian carcinoma ascites may not hinder future DC based 
vaccination strategies. In particular, data from pilot experiments with primary mDC in 
our study indicate that TLR-mediated activation of these cells may not be effected by 
ovarian carcinoma associated ascites. This suggests that IL-10 in the malignant tumour 
environment may not pose problems for immunotherapeutic strategies in terms of DC 
activation, but it is important to bear in mind that it may well effect other leukocyte 
subsets and nevertheless impede anti-tumour responses. A considerable decrease in 
systemic and peritoneal IL-10 levels after de-bulking surgery offers an attractive time 
frame for immunotherapeutic interventions while the potential effects of IL-10 are 
minimized. 
Further experiments with IL-10 depleted ascites will elucidate the importance of 
autocrine and ascites-derived IL-10 produced upon TLR activation in more detail. 
Specifically, we are currently in the process of utilizing the molecular method of 
microarray analysis to gain insight into the signaling pathways that are affected in 
monocyte-derived DC upon TLR-activation in presence of IL-10 depleted versus non-
depleted ovarian carcinoma associated ascites. Equally, fluid devoid of PGE2 will be 
included in these sample cohorts, allowing for a better understanding of the 
mechanisms underlying the suppression of TNFα and showing whether other factors 
that had not been tested in our assays are effected by PGE2. These experiments 
compliment the presented study excellently, because due to the wide scope of 
microarray analysis, gene expression patterns of a large range of activation parameters 
can be examined. In this regard, our study to date was certainly limited and it is well 
conceivable that many more aspects of TLR-mediated activation than those that we 
have analyzed are altered by presence of malignant ascites, and more specifically by 
IL-10 and/or other factors within. Not only the breadth of parameters examined will 
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provide unprecedented insights, the depth of gene expression pattern analysis can 
contribute substantially to a new understanding of our existing data.  
A further line of work towards the completion of this study includes the verification of 
biological activity of the selective neutralizing antibodies used in our experiments. 
Specifically, assays to test the functionality of antibodies against IL-6, LIF, VEGFα 
and TGFβ which showed no effect in our assays will be carried out, and the details of 
the experimental design for each of the used antibodies are in planning. Collectively, 
these additional experiments will refine the findings of our study, and allow for 
conclusive interpretation of our results thus far. 
In light of unsatisfactory results achieved with currently available measures applied in 
the management and treatment of ovarian carcinoma, immunotherapy represents an 
exciting, relevant and promising approach to complement and enhance current 
therapeutic protocols. Within the field, DC vaccination strategies present an attractive 
line of work, pursued in many laboratories worldwide. Despite promising findings in 
preclinical studies, the translation of basic concepts into applied, clinical settings 
remains challenging. A major obstacle is posed by immunosuppressive factors within 
the tumour microenvironment, which can hinder anti-tumour immune responses by 
impairing DC activation. Findings presented in this study elucidate the processes that 
take effect when attempting to activate DC within the environment of ovarian 
carcinoma ascites. Further experiments with primary myeloid DC will be an important 
step towards the translation of our findings into more physiological settings. Equally, 
in vivo DC targeting studies in murine models of ovarian carcinoma represent an 
attractive option to expedite the field of DC immunotherapy and inform about the 
challenges posed by the microenvironment of malignant ovarian tumours in its entity 
and elucidate important new aspects that may require consideration in future design 
and application of vaccines relying on TLR-activation of DC subsets. 
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